Moderna, Inc. (Form: 10-Q, Received: 10/30/2020 08:29:35)

EXHIBIT 10.1 Contract No. 75A50120C00034 Development of an mRNA Vaccine for SARS-CoV-2 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH "[***]". SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. Table of Contents PART I - THE SCHEDULE ........................................................................................................ 2 B. SUPPLIES/SERVICES AND COST/PRICE ................................................................................... 2 C. DESCRIPTION/ SPECIFICATIONS / WORK STATEMENT ................................................... 7 D. PACKAGING AND MARKING (if applicable) ............................................................................ 14 E. INSPECTION AND ACCEPTANCE ............................................................................................. 14 F. DELIVERABLES/ PERFORMANCE .......................................................................................... 15 G. CONTRACT ADMINISTRATION .................................................................................. 34 H. SPECIAL CONTRACT REQUIREMENTS ................................................................... 39 PART II - CONTRACT CLAUSES ......................................................................................... 47 I. CONTRACT CLAUSES .................................................................................................................. 47 PART III - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS ......... 51 J. LIST OF ATTACHMENTS ............................................................................................................ 51 Page 1 of51 ACTIVE/I 04412070.3

Contract No. 75A50120C00034 Development of an mRNA Vaccine for SARS-CoV-2 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH "[***]". SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. C. DESCRIPTION I SPECIFICATIONS I WORK STATEMENT C.1 Background Coronaviruses are potential epidemic threats and have been recognized on the World Health Organization's list of top emerging diseases likely to cause major epidemics and Coalition for Epidemic Preparedness Innovations priority pathogens list. No vaccines to prevent Coronavirus infection are currently available. The emergence of the SARS-CoV-2 virus creates an urgent need to rapidly develop vaccines to prevent COVID-19 disease. Developing and delivering a vaccine for highly transmissible, emerging diseases such as the SAR-CoV-2 virus requires breaking from traditional approaches. It requires parallel development activities, aggressive manufacturing scale-up, risk management and implementation ofregulatory flexibilities. Many of these requirements are met by manufacturing 'platforms' that are capable of producing vaccines against different agents using essentially the same manufacturing systems. Suitable platforms are constituted by defined product production processes that allow significant planning for manufacturing scale and time to vaccine availability and will be supported by human safety and immunogenicity data targeting an one or more infectious agents. To meet the purposes of this contract, it is critical that the vaccine be produced in the United States. Domestic production of the vaccine is the only assurance that Americans will have access to the finished product. Modema's mRNA-based vaccine platform has been used to rapidly prepare vaccine candidates against Cytomegalovirus, Zika, Respiratory Syncytial Virus, Influenza, Human Metapneumovirus and Parainfluenza virus. Four of these candidates have been evaluated in Phase 1 clinical studies and shown to be safe and immunogenic. Modema collaborated with the Vaccine Research Center, NIAID ("VRC/NIAID") to design a lead SARS-CoV-2 vaccine candidate encoding a stabilized pre-fusion, SARS-CoV-2 Spike protein, which is more immunogenic than wild-type or subunit proteins. Modema's mRNA vaccine is currently being evaluated in pre-clinical studies and Phase 1 trials sponsored by the NIAID. For the purposes of this contract, Modema will perform all work required to support the advanced development, scale-up manufacturing and FDA licensure of their lead SARS CoV-2 vaccine candidate(s). This work includes preclinical development ofmRNA vaccines to demonstrate safety and efficacy against COVID-19, mRNA vaccine process and manufacturing scale-up development, product lot release assay development and process validation, production of clinical material and consistency lots clinical evaluation studies for safety, immunogenicity and efficacy; and fill/finish capacity evaluation, expansion, and validation. The Governments has determined a bona fide need for each non-severable discrete work segment which will conclude upon the completion of a defined task(s) that provides independent merit and value to the Government. The Contractor must achieve a defined end-point required in each discrete work segment, as outlined in Section F of this contract, before the Government will consider exercising any of the follow-on option segment(s). The Contractor's success in completing the required tasks under each work segment must be demonstrated through the Deliverables and Milestones specified under Section Band F of this contract. Those deliverables will support the GO/NO GO Contract Milestones and Decision Gates specified therein. The GO/NO GO Contract Milestones and Decision Gates will constitute the basis for the Government's decision, at its sole discretion, to exercise any follow-on option segment(s). The base and option segments under Contract Line Items (CLINs) 0001 through 0003 are event driven work segments rather than time driven CLINs. The funds for each independent, non-severable discrete work segment (requirement), regardless of duration, are separated by CLIN, and shall only be used for the scope of work covered in each discrete work segment. The periods of performance listed under each of the CLINs under Article B.2 and Article B.3 are estimated time periods. Those individual time periods may be extended by mutual agreement of the parties to complete the tasks required under each work segment. It is possible that more than one independent, non-severable discrete work segment (requirement), may be awarded at one time and that individual CLINs may overlap and/or proceed concurrently C.2 Statement of Work Independently, and not as an agent of the United States Government, the contractor shall furnish all necessary services, qualified professional, technical, and administrative personnel, material, equipment and facilities, not otherwise provided by the Government under the terms of this contract, as needed to perform the tasks set forth below. mRNA Vaccine Development (WBS 1.0) The Contractor, Modema, Inc. ("Modema") shall execute the preclinical, clinical, and chemistry, manufacturing and controls (CMC) activities required to license a vaccine against the SARS-CoV-2 virus (herein referred to as "mRNA vaccine"). Building upon early clinical development already underway, this proposal will support the late stage development, including the demonstration of clinical efficacy and generation of a dataset supportive of licensure. Modema will additionally evaluate the platform manufacturing capabilities relative to the needs for supply in response to a pandemic. Program Management (WBS 1.1) mRNA Program Management (WBS 1.1.1) Modema's mRNA program team is composed ofa multidisciplinary, highly matrixed, group of functional leads with experience in, and responsibility for, integrating plans and operationalizing strategies across Research, Toxicology, CMC, Regulatory Affairs, Page 7 of51 ACTIVE/I 04412070.3

Contract No. 75A50120C00034 Development of an mRNA Vaccine for SARS-CoV-2 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH "[***]". SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. F. DELIVERABLES/ PERFORMANCE F.l Federal Acquisition Regulation Clauses Incorporated by Reference This contract incorporates one or more clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. Also, the full text of a clause may be accessed electronically at this address: http://acguisition.gov/far/ The following FAR clause, pertinent to Section F, is hereby incorporated by reference: FAR Clause Title Date 52.242-15 Stop-Work Order, Alternate I (Apr 1984) Aug 1989 F.1.1 A pandemic facility and/or operational management plan including change procedures from normal to pandemic operations. Prepare an operational plan to continue operations in the event of a declared pandemic emergency (Draft within 15 days of award, Final within 30 days of award). F.1.2 Data Management Plan The Contractor shall develop and implement data management and quality control systems/procedures, including transmission, storage, confidentiality, and retrieval of all contract data; provide for the statistical design and analysis of data resulting from the research; provide raw data or specific analyses of data generated with contract funding to the Project Officer, upon request. F.1.3 Standard Operating Procedures The Contractor shall make internal and, to the extent possible, Subcontractor Standard Operating Procedures (SOPs) available for review by the Government on-site at Contractor's facility, upon request from the COR or CO. At Contractor's election, SOPs may be provided electronically. F.1.4 Evaluation of Fill Finish Alternatives The Contractor shall submit a Draft Final and Final Report describing the fill finish alternatives evaluated, the evaluation method and criteria used, cost comparison, and recommendation for which fill finish alternative to move forward. The draft report shall be due within thirty (30) days after completion of analysis. Subcontractor-prepared reports, on behalf of the Contractor, shall be submitted to the COR and CO for review and comment, no later than five (5) business days after receipt by the Contractor. BARDA shall provide written comments to the Draft Final Report within fifteen (15) days after the submission. The Final Report shall be due thirty (30) days after receiving comments on the Draft Final Report from BARDA. If corrective action is recommended, the Contractor must address, in written, all concerns raised by the Government. F.1.5 Supply Chain Resiliency Plan The partner contractor shall have a comprehensive Supply Chain Resiliency Program that provides for identification and reporting of critical components associated with the secure supply of drug substance, drug product, and work-in-process through to finished goods. A critical component is any material that is essential to the product or the manufacturing process associated with that product. Included in the definition are consumables and disposables associated with manufacturing. NOT included in the definition are facility and capital equipment. Consideration of critical components includes the evaluation and potential impact ofraw materials, excipients, active ingredients, substances, pieces, parts, software, firmware, labeling, assembly, testing, analytical and environmental componentry, reagents, or utility materials which are used in the manufacturing of a drug, cell banks, seed stocks, devices and key processing components and equipment. A clear example of a critical component is one where a sole supplier is utilized. Identification of key equipment suppliers and their locations, local resources and the associated planning and control processes at the time of award is important to the security of the medical countermeasure supply chain. These processes shall address planning and scheduling for active pharmaceutical ingredients, upstream, downstream, component assembly, finished drug product and delivery events as necessary for the delivery of product. Where multi-site manufacturing is integral to the delivery of contractual materials, it should be included as part of the planning and scheduling process. Communication for these requirements shall be updated as part of an annual review, or as necessary, as part of regular contractual communications. Page 12 of51 ACTIVE/I 04412070.3

Contract No. 75A50120C00034 Development of an mRNA Vaccine for SARS-CoV-2 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH "[***]". SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. date under the contract. The report shall include a description of problems encountered and proposed corrective action; differences between planned and actual progress, why the differences have occurred and what corrective actions are planned; preliminary conclusions resulting from analysis and scientific evaluation of data accumulated to date under the project. • SECTION II Part D: PROPOSED WORK - A summary of work proposed related to Gantt chart for the next reporting period and preprints/reprints of papers and abstracts. • SECTION III: Estimated and Actual Expenses. a. This section of the report shall contain a narrative or table detailing whether there is a significant discrepancy(> 10%) at this time between the% of work completed and the cumulative costs incurred to date. Monthly and actual expenses should be broken down to the appropriate WBS level. b. This section of the report should also contain estimates for the Subcontractors' expenses from the previous month if the Subcontractor did not submit a bill in the previous month. If the subcontractor(s) was not working or did not incur any costs in the previous month, then a statement to this effect should be included in this report for those respective subcontractors. A Monthly Progress Report will not be required in the same month that the Annual Progress Report is submitted. ii. Annual Progress Report This report shall include a summation of the results of the entire contract work for the period covered. Monthly Progress Reports shall not be submitted in the same month when an Annual Progress Report is due. Furthermore, an Annual Progress Report will not be required for the period when the Final Report is due. The first Annual Progress Report shall be submitted in accordance with the date set forth in the table ("Summary of Contract Deliverables") under ARTICLE F.2. of this contract. The progress report shall conform to the requirements set forth in the DELIVERIES Article in SECTION F of this contract. Each Annual Progress Report shall include: • A Cover page that includes the contract number and title; the type of report and period that it covers; the Contractor's name, address, telephone number, fax number, and email address; and the date of submission; • SECTION I: EXECUTIVE SUMMARY -A brief overview of the work completed, and the major accomplishments achieved during the reporting period. • SECTION II: PROGRESS • SECTION II Part A: OVERALL PROGRESS - A description of overall progress. • SECTION II Part B: MANAGEMENT AND ADMINISTRATIVE UPDATE - A high level summary of critical meetings, etc. that have taken place during the reporting period. Include progress on administration and management to critical factors of the project (e .g. regulatory compliance audits and key personnel changes). • SECTION II Part C: TECHNICAL PROGRESS - A detailed description of the work performed structured to follow the activities and decision gates outlined at the Integrated Baseline Review and as described in the Integrated Master Plan. The Report should include a description of any problems (technical or financial) that occurred or were identified during the reporting period, and how these problems were resolved. • SECTION II Part D: PROPOSED WORK- A summary of work proposed for the next year period to include an updated Gantt Chart. • SECTION III: Estimated and Actual Expenses. a. This section of the report shall contain a narrative or table detailing whether there were discrepancies between estimated and actual expenses over the past year. Actual expenses should be broken down to the appropriate WBS level. This section of the report should also contain estimates for outstanding costs for the previous year which may have been incurred, but not yet billed. Contractor also should include the following in the Annual Progress Report: I. Copies of manuscripts (published and unpublished), abstracts, and any protocols or methods developed specifically under the contract during the reporting period; and 2. A summary of any Subject Inventions per the requirements under FAR Clause 52.227-11 . iii. Draft Final Report and Final Report These reports are to include a summation of the work performed and results obtained for the entire contract period of performance. This report shall be in sufficient detail to describe comprehensively the results achieved. The Draft Final Report and Final Report shall be submitted in accordance with the DELIVERIES Article in SECTION F of the contract. An Annual Progress Report will not be required for the period when the Final Report is due. The Draft Final Page 23 of51 ACTIVE/I 04412070.3

Contract No. 75A50120C00034 Development of an mRNA Vaccine for SARS-CoV-2 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH "[***]". SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. Report and the Final Report shall be submitted in accordance with the dates set forth in the table ("Summary of Contract Deliverables") under ARTICLE F.2. of this contract. The report shall conform to the following format: 1. Cover page to include the contract number, contract title, performance period covered, Contractor's name and address, telephone number, fax number, email address and submission date. 2. SECTION I: EXECUTIVE SUMMARY - Summarize the purpose and scope of the contract effort including a summary of the major accomplishments relative to the specific activities set forth in the Statement of Work. 3. SECTION II: RESULTS - A detailed description of the work performed related to WBS and Ganttchart, the results obtained, and the impact of the results on the scientific and/or public health community including a listing of all manuscripts (published and in preparation) and abstracts presented during the entire period of performance and a summary of all inventions. Draft Final Report: The Contractor is required to submit the Draft Final Report to the Contracting Officer's Representative and Contracting Officer. The Contracting Officer's Representative and Contracting Officer will review the Draft Final Report and provide the Contractor with comments in accordance with the dates set forth in ARTICLE F.2. of this contract. Final Report: The Contractor will deliver the final version of the Final Report on or before the completion date of the contract. The final version shall include or address the COR's and CO's written comments on the draft report. Final Report shall be submitted on or before the completion date of the contract. iv. Summary of Salient Results The Contractor shall submit, with the Final Report, a summary (not to exceed 200 words) of salient results achieved during the performance of the contract. v. Audit Reports Within thirty (30) calendar days of an audit related to conformance to FDA regulations and guidance, including adherence to GLP, GMP, GCP guidelines, the Contractor shall provide copies of the audit report (so long as received from the FDA) and a plan for addressing areas ofnonconformance to FDA regulations and guidelines for GLP, GMP, or GCP guidelines as identified in the final audit report. vi. Other Technical Reports 1. Draft Report for Clinical and Non-Clinical Studies and Final Report for Clinical and Non-Clinical Studies • The clinical trial reports shall follow the format of International Conference on Harmonization documentICH E3 "Guideline for Industry on Structure and Content of Clinical Study Reports" • Draft Final Report for Clinical and Non-Clinical Studies funded by this contract will be submitted to the Contracting Officer's Representative and Contracting Officer (CO) for review and comment within the time frames set forth in the table ("Summary of Contract Deliverables") under ARTICLEF.2. • Subcontractor prepared reports received by the Contractor shall be submitted to the Contracting Officer's Representative and Contracting Officer (CO) for review and comment as set forth by the table in this Article. Contractor shall consider revising reports to address BARDA's recommendations prior to FDA submission. • The Government shall provide written comments to the Draft Final Report for Clinical and Non-Clinical Studies in accordance with the dates set forth by the table in this Article. • The comprehensive Final Report for Clinical and Non-Clinical Studies will be submitted to the Contracting Officer and the Contracting Officer's Representative set forth by the table in this Article. 2. Supplemental Technical Documents Upon request, Contractor shall provide CO and COR with the following contract funded documents as specified below but not limited to: Process Development Reports; Assay Qualification Plan/Report, Assay Validation Plan/Report, Assay Technology Transfer Report, Batch Records, Contractor/Subcontractor Standard Operating Procedures (SOP's), Master Production Records, Certificate of Analysis, Clinical Studies Data or Reports. The CO and COR reserve the right to request within the Period of Performance a non proprietary technical document for distribution within the USG. Contractor shall provide technical document within 10 business days of CO or COR request. Contractor can request additional time on an as needed basis. If edits are recommended, the Contractor must address, in writing, concerns raised by BARDA. Page 24 of51 ACTIVE/I 04412070.3

Contract No. 75A50120C00034 Development of an mRNA Vaccine for SARS-CoV-2 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH "[***]". SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. the Contractor after I. award). a. Contractor invoices/financial reports shall conform to the form, format, and content requirements ofthe instructions for Invoice/Financing requests and Contract Financial Reporting. b. Monthly invoices must include the cumulative total expenses to date, adjusted (as applicable) to show any amounts suspended by the Government. c. The Contractor agrees to immediately notify the CO in writing if there is an anticipated overrun (any amount) or unexpended balance (greater than 10%) of the estimated costs for the base period or any option period(s) (See estimated costs under Section B) and the reasons for the variance. These requirements are in addition to the specified requirements of FAR 52.232-20, Limitation of Cost that is incorporated by reference under Section I. I which states; Limitation of Cost (Apr 1984) The parties estimate that performance of this contract, exclusive of any fee, will not cost the Government more than (I) the estimated cost specified in the Schedule or, (2) if this is a cost-sharing contract, the Government's share of the estimated cost specified in the Schedule. The Contractor agrees to use its best efforts to perform the work specified in the Schedule and all obligations under this contract within the estimated cost, which, if this is a cost-sharing contract, includes both the Government's and the Contractor's share of the cost. The Contractor shall notify the Contracting Officer in writing whenever it has reason to believe that- The costs the Contractor expects to incur under this contract in the next 60 days, when added to all costs previously incurred, will exceed 75 percent of the estimated cost specified in the Schedule; or The total cost for the performance of this contract, exclusive of any fee, will be either greater or substantially less than had been previously estimated. As part of the notification, the Contractor shall provide the Contracting Officer a revised estimate of the total cost of performing this contract. Except as required by other provisions of this contract, specifically citing and stated to be an exception to this clause- The Government is not obligated to reimburse the Contractor for costs incurred in excess of(i) the estimated cost specified in the Schedule or, (ii) if this is a cost-sharing contract, the estimated cost to the Government specified in the Schedule;and The Contractor is not obligated to continue performance under this contract (including actions under the Termination clause of this contract) or otherwise incur costs in excess of the estimated cost specified in the Schedule, until the Contracting Officer (i) notifies the Contractor in writing that the estimated cost has been increased and (ii) provides a revised estimated total cost of performing this contract. If this is a cost-sharing contract, the increase shall be allocated in accordance with the formula specified in the Schedule. No notice, communication, or representation in any form other than that specified in paragraph ( d)(2) of this clause, or from any person other than the Contracting Officer, shall affect this contract's estimated cost to the Government. In the absence of the specified notice, the Government is not obligated to reimburse the Contractor for any costs in excess of the estimated cost or, if this is a cost-sharing contract, for any costs in excess of the estimated cost to the Government specified in the Schedule, whether those excess costs were incurred during the course of the contract or as a result of termination. Ifthe estimated cost specified in the Schedule is increased, any costs the Contractor incurs before the increase that are in excess of the previously estimated cost shall be allowable to the same extent as if incurred afterward, unless the Contracting Officer issues a termination or other notice directing that the increase is solely to cover termination or other specified expenses. Change orders shall not be considered an authorization to exceed the estimated cost to the Government specified in the Schedule, unless they contain a statement increasing the estimated cost. If this contract is terminated or the estimated cost is not increased, the Government and the Contractor shall negotiate an equitable distribution of all property produced or purchased under the contract, based upon the share of costs incurred by each. d. The Contractor shall submit an electronic copy of the payment request to the approving official instead of a paper copy. The payment request shall be transmitted as an attachment via e-mail to the address listed above in one of the following formats: MSWord, MS Excel, or Adobe Portable Document Format (PDF). Only one payment request shall be submitted per e-mail and the subject line of the e-mail shall include the Contractor's name, contract number, and unique invoice number. e. An electronic copy of the payment request shall be uploaded into the designated eRoom (as defined in Section F.3 Page 32 of51 ACTIVE/I 04412070.3

Contract No. 75A50120C00034 Development of an mRNA Vaccine for SARS-CoV-2 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH "[***]". SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. Electronic Submission) and an e-mail notification of the upload will be provided to the CO and COR. f. All invoice submissions shall be in accordance with FAR 52.232-25, Prompt Payment (Oct 2008). g. Invoices - Cost and Personnel Reporting, and Variances from the Negotiated Budget. h . Invoices - Cost and Personnel Reporting, and Variances from the Negotiated Budget. The Contractor agrees to provide a detailed breakdown on invoices of the following cost categories: 1. Direct Labor - List individuals by name, title/position, hourly/annual rate, level of effort (actual hours or% of effort), and amount claimed. 2. Fringe Benefits - Cite rate and amount 3. Overhead - Cite rate and amount 4. Materials & Supplies - Include detailed breakdown when total amount is over $100,000 5. Travel - Identify travelers, dates, destination, purpose of trip, and total breaking out amounts for transportation (plane, car, etc.), lodging, M&IE. Cite COA, if appropriate. List separately, domestic travel, general scientific meeting travel, and foreign travel. 6. Consultant Fees - Identify individuals, amounts and activities. Cite appropriate COA 7. Subcontracts - Attach subcontractor invoice(s). Cite appropriate COA 8. Equipment - Cite authorization and amount. Cite appropriate COA 9. Other Direct Costs - Include detailed breakdown when total amount is over $100,000. 10. G&A- Cite rate and amount. 11. Total Cost (and applicable cost-shared ratio) 12. Fixed Fee (if applicable) 13. Total Cost Plus Fixed Fee Monthly invoices must include the cumulative total expenses to date, adjusted (as applicable) to show any amounts suspended by the USG.Nothing inthis section discharges the contractor's responsibility to comply with any applicable FAR Parts 30 or 31 clauses' relating to cost reimbursement subcontracts. In order to verify allowability, further breakdown of costs may be requested at the USG's discretion. The Contractor shall subcontract with Firm Fixed Price Contracts to the maximum extent practicable. Additional instructions and an invoice template are provided in Section J-List of Attachments, Invoice/Financing Request Instructions and Contract Financial Reporting Instructions for Cost- Reimbursement Contracts. All invoices must be signed by a representative of the contractor authorized to certify listed charges are accurate and comply with government regulations. Invoices shall be signed and submitted electronically (in accordance with Section F.3 Electronic Submission). If applicable, the Contractor shall convert any foreign currency amount(s) in the monthly invoice to U.S. dollars each month, on the 151 of the month, using the foreign exchange rate index published on www.federalreserve. gov. Payment of invoices is subject to the U.S. dollar limits within the Total Costs ofCLIN 0001 and 0002 in Section B of the contract. The Government shall use electronic funds transfer to the maximum extent possible when making payments under this contract. FAR 52.232-33, Payment by Electronic Funds Transfer-System for Award Management, in Section I requires the Contractor to designate in writing a financial institution for receipt of electronic funds transfer payments. The electronic version of the invoice can be submitted via e-mail or uploaded through HHS' eRoom (shared access may be provided to the Contractor after award). The Government may request additional information (timecards, receipts, etc.) to support costs claimed in the Contractor's invoices. Incomplete invoices may be suspended by the Contracting Officer if the Contractor's claimed costs cannot be substantiated. G.5 REIMBURSEMENT OF COST The Government shall reimburse the Contractor the cost determined by the Contracting Officer to be allowable (hereinafter referred to as allowable cost) in accordance with FAR 52.216-7, Allowable Cost and Payment incorporated by reference in Section I, Contract Clauses, of this contract, and FAR Subpart 31 .2. Examples of allowable costs include, but are not limited to, the following: a) All direct materials and supplies that are used in performing the work provided for under the contract, including those purchased for subcontracts and purchase orders. b) All direct labor, including supervisory, that is properly chargeable directly to the contract, plus fringe benefits. Page 33 of51 ACTIVE/I 04412070.3

Contract No. 75A50120C00034 Development of an mRNA Vaccine for SARS-CoV-2 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH "[***]". SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. H. SPECIAL CONTRACT REQUIREMENTS H.1 Access and Disposition of Data The Government shall have physical and electronic access to all documentation and data generated under this contract, including: all Contractor efforts; Subcontractor efforts; communications and correspondence with regulatory agencies and bodies to include all audit observations, inspection reports, meeting minutes, and all Contractor commitments and responses. H.2 Interactions with the Food and Drug Administration (FDA) The Contractor shall memorialize any interactions between the Contractor and the FDA, and submit documentation to the COR and CO. All documents shall be duly marked as either "Draft" or "Final." H.2.1 FDA Correspondence Contractor shall provide written summary of any FDA correspondence within five (5) business days of correspondence. H.2.2 FDA Meetings The Contractor shall forward the dates and times of any meeting with the FDA to the COR and CO, and make arrangements for appropriate BARDA staff to attend the FDA meetings. BARDA staff shall include up to a maximum of four people (COR, CO and up to 2 subject matter experts). (1) Contractor shall notify the COR and CO of upcoming FDA meeting within 24 hours of scheduling Type A, B or C meetings, or within 24 hours of meeting occurrence for ad hoc meetings. (2) The Contractor shall forward initial Contractor and FDA-issued draft and final minutes of any meeting with the FDA, to the COR and CO, within 2 business days of receipt. All documents shall be duly marked as either "Draft" or "Final." H.2.3 FDA Pre-Submissions, Submissions, and Other Related Correspondence The Contractor shall provide the COR and CO the opportunity to review and comment upon all draft submissions directly related to this contract before submission to the FDA. Contractor shall provide the COR and CO with an electronic copy of the final FDA submission. All documents shall be duly marked as either "Draft" or "Final". (1) Contractor shall submit draft FDA submissions to the COR and CO at least 15 business days prior to FDA submission. (2) The COR and CO will provide feedback to Contractor within 5 business days ofreceipt. (3) If corrective action is recommended, the Contractor must address, in writing, its consideration of all concerns raised by the COR and CO. (4) The Contractor shall consider revising their documents to address the COR and CO's concerns and/or recommendations prior to FDA submission. (5) Final FDA submissions shall be submitted to the COR and CO concurrently or no later than 1 calendar day of its submission to FDA H.2.4 FDA Audits In the event of an FDA inspection which occurs as a result of this contract and for the product, or for any other FDA inspection that has the reasonable potential to impact the performance of this contract, the Contractor shall provide the USG with an exact copy (non-redacted) of the FDA Form 483 and the Establishment Inspection Report (EIR). The Contractor shall provide the COR and CO with copies of the plan for addressing areas of non-conformance to FDA regulations for GLP, GMP, or GCP guidelines as identified in the audit report, status updates during the plans execution and a copy of all final responses to the FDA. The Contractor shall also provide redacted copies of any FDA audits received from subcontractors that occur as a result of this contract or for this product. The Contractor shall make arrangements for BARDA representative(s) to be present during the final debrief by the regulatory inspector. (1) Contractor shall notify CO and COR within 10 business days of a scheduled FDA audit or within24 hours of an ad hoc site visit/audit if the FDA does not provide advanced notice. (2) Contractor shall provide copies of any FDA audit report received from subcontractors that occur as a result of this contract or for this product within 5 business days of receiving correspondence from the FDA or third party. (3) Within 10 business days of audit report, Contractor shall provide CO and COR with a plan for addressing areas of nonconformance, if any are identified. H.3 Key Personnel Pursuant to HHSAR 352.23 7-75 (Dec 2015), Key Personnel, any key personnel specified in this contract are considered to be essential to work performance. At least thirty (30) calendar days prior to the Contractor voluntarily diverting any of the specified individuals to other programs or contracts the Contractor shall notify the Contracting Officer and shall submit a justification for the diversion or replacement and a request to replace the individual. The request must identify the proposed replacement and provide an explanation of how the Page 36 of51 ACTIVE/I 04412070.3

Contract No. 75A50120C00034 Development of an mRNA Vaccine for SARS-CoV-2 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH "[***]". SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. H.6 No Personal Services or Inherently Governmental Function Pursuant to FAR 37.1, no personal services shall be performed under this contract. All work requirements shall flow only from the COR to the Contractor's Project Manager. No Contractor employee will be directly supervised by the Government. All employee assignments, and daily work direction, shall be given by the applicable Contractor supervisor. If the Contractor believes any Government action or communication has been given that would create a personal services relationship between the Government and any Contractor employee, the Contractor shall promptly notify the Contracting Officer of this communication or action. Pursuant to FAR 7.5, the Contractor shall not perform any inherently governmental actions under this contract. No Contractor employee shall hold him or herself out to be a Government employee, agent, or representative. No Contractor employee shall state orally or in writing at any time that he or she is acting on behalf of the Government. In all communications with third parties in connection with this contract, Contractor employees shall identify themselves as Contractor employees and specify the name of the company for which they work. In all communications with other Government Contractors in connection with this contract, the Contractor employee shall state that they have no authority to in any way change this contract and that if the other Contractor believes this communication to be a direction to change their contract, they shall notify the Contracting Officer for that contract and not carry out the direction until a clarification has been issued by the Contracting Officer. The Contractor shall ensure that all of its employees working on this contract are informed of the substance of this article. Nothing in this article shall limit the Government's rights in any way under the other provisions of this contract, including those related to the Government's right to inspect and accept the services to be performed under this contract. The substance of this article shall be included in all subcontracts at any tier. H.7 Acknowledgement of Federal Funding-Publication and Publicity The Contractor shall acknowledge the support of the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority whenever publicizing the work under this contract in any media by including an acknowledgment substantially as follows: "This project has been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract No. 75A50120C00034." Press Releases: The Contractor shall clearly state, when issuing statements, press releases, requests for proposals, bid solicitations and other documents describing projects or programs funded in whole or in part with Federal money: (1) the percentage of the total costs of the program or project which will be financed with Federal money; (2) the dollar amount of Federal funds for the project or program; and (3) the percentage and dollar amount of the total costs of the project or program that will be financed by nongovernmental sources. H.8 352.270-4b, Protection of Human Subjects (Dec 2015) (a) The Contractor agrees that the rights and welfare of human subjects involved in research under this contract shall be protected in accordance with 45 CPR part 46 and with the Contractor's current Federal-wide Assurance (FWA) on file with the Office for Human Research Protections (OHRP), Department of Health and Human Services. The Contractor further agrees to provide certification at least annually that the Institutional Review Board has reviewed and approved the procedures, which involve human subjects in accordance with 45 CPR part 46 and the Assurance of Compliance. (b) The Contractor shall bear full responsibility for the performance of all work and services involving the use of human subjects under this contract and shall ensure that work is conducted in a proper manner and as safely as is feasible. The parties hereto agree that the Contractor retains the right to control and direct the performance of all work under this contract. Nothing in this contract shall create an agency or employee relationship between the Government and the Contractor, or any subcontractor, agent or employee of the Contractor, or any other person, organization, institution, or group of any kind whatsoever. The Contractor agrees that it has entered into this contract and will discharge its obligations, duties, and undertakings and the work pursuant thereto, whether requiring professional judgment or otherwise, as an independent Contractor without creating liability on the part of the Government for the acts of the Contractor or its employees. (c) Contractors involving other agencies or institutions in activities considered to be engaged in research involving human subjects must ensure that such other agencies or institutions obtain their own FWA if they are routinely engaged in research involving human subjects or ensure that such agencies or institutions are covered by the Contractors' FWA via designation as agents of the institution or via individual investigator agreements (see OHRP website at: http://www.hhs.gov/ohrp/policy/guidanceonalternativetofwa.pdf). ( d) If at any time during the performance of this contract the Contractor is not in compliance with any of the requirements and or standards stated in paragraphs (a) and (b) above, the Contracting Officer may immediately suspend, in whole or in part, work and further payments under this contract until the Contractor corrects the noncompliance. The Contracting Officer may communicate the notice of suspension by telephone with confirmation in writing. If the Contractor fails to complete corrective action within the period of time designated in the Contracting Officer's written notice of suspension, the Contracting Officer may, after consultation with OHRP, terminate this contract in whole or in part. (End of clause) Page 38 of51 ACTIVE/I 04412070.3

Contract No. 75A50120C00034 Development of an mRNA Vaccine for SARS-CoV-2 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH "[***]". SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. H.9 HHSAR 352.270-5a, Notice to Offerors of Requirement for Compliance with the Public Health Service Policy on Humane Care and Use of Laboratory Animals (Dec 2015) The Public Health Service (PHS) Policy on Humane Care and Use of Laboratory Animals (PHS Policy) establishes a number of requirements for research activities involving animals. Before awarding a contract to an offeror, the organization shall file, with the Office of Laboratory Animal Welfare (OLA W), National Institutes of Health (NIH), a written Animal Welfare Assurance (Assurance) which commits the organization to comply with the provisions of the PHS Policy, the Animal Welfare Act, and the Guide for the Care and Use of Laboratory Animals (National Academy Press, Washington, DC). In accordance with the PHS Policy, offerors must establish an Institutional Animal Care and Use Committee (IACUC), qualified through the experience and expertise of its members, to oversee the institution's animal program, facilities, and procedures. Offerors must provide verification ofIACUC approval prior to receiving an award involving live vertebrate animals. No award involving the use of animals shall be made unless OLAW approves the Assurance and verification ofIACUC approval for the proposed animal activities has been provided to the Contracting Officer. Prior to award, the Contracting Officer will notify Contractor(s) selected for projects involving live vertebrate animals of the Assurance and verification ofIACUC approval requirement. The Contracting Officer will request that OLAW negotiate an acceptable Assurance with those Contractor(s) and request verification ofIACUC approval. For further information, contact OLAW at NIH, 6705 Rockledge Drive, RKLI, Suite 360, MSC 7982 Bethesda, Maryland 20892-7982 (E-mail: olaw@od.nih.gov; Phone: 301-496--7163). (End of provision) H.10 HHSAR 352.270-5b, Care of Life Vertebrate Animals (Dec 2015) (a) Before undertaking performance of any contract involving animal-related activities where the species is regulated by the United Sates Department of Agriculture (USDA), the Contractor shall register with the Secretary of Agriculture of the United States in accordance with 7 U.S.C. 2136 and 9 CPR 2.25 through 2.28. The Contractor shall furnish evidence of the registration to the Contracting Officer. (b) The Contractor shall acquire vertebrate animals used in research from a dealer licensed by the Secretary of Agriculture under 7 U.S.C. 2133 and 9 CPR 2.1 2.11, or from a source that is exempt from licensing under those sections. (c) The Contractor agrees that the care, use, and intended use of any live vertebrate animals in the performance of this contract shall conform with the Public Health Service (PHS) Policy on Humane Care of Use of Laboratory Animals (PHS Policy), the current Animal Welfare Assurance (Assurance), the Guide for the Care and Use of Laboratory Animals (National Academy Press, Washington, DC) and the pertinent laws and regulations of the United States Department of Agriculture (see 7 U.S.C. 2131 et seq. and 9 CPR subchapter A, Parts 1-4). In case of conflict between standards, the more stringent standard shall govern. ( d) If at any time during performance of this contract, the Contracting Officer determines, in consultation with the Office of Laboratory Animal Welfare (OLAW), National Institutes of Health (NIH), that the Contractor is not in compliance with any of the requirements and standards stated in paragraphs (a) through ( c) above, the Contracting Officer may immediately suspend, in whole or in part, work and further payments under this contract until the Contractor corrects the noncompliance. Notice of the suspension may be communicated by telephone and confirmed in writing. If the Contractor fails to complete corrective action within the period of time designated in the Contracting Officer's written notice of suspension, the Contracting Officer may, in consultation with OLA W, NIH, terminate this contract in whole or in part, and the Contractor's name may be removed from the list of those contractors with Animal Welfare Assurances. Note: The Contractor may request registration of its facility and a current listing of licensed dealers from the Regional Office of the Animal and Plant Health Inspection Service (APHIS), USDA, for the region in which its research facility is located. The location of the appropriate APHIS Regional Office, as well as information concerning this program may be obtained by contacting the Animal Care Staff, USDA/APHIS, 4700 River Road, Riverdale, Maryland 20737 (Email: ace@aphis.usda.gov; Web site: http://www.aphis. usda. gov /wps/portal/aphis/ourfocus/animalwelfare) (End of clause) H.11 Animal Welfare All research involving live, vertebrate animals shall be conducted in accordance with the Public Health Service Policy on Humane Care and Use of Laboratory Animals (PHS Policy). The PHS Policy can be accessed at: http:// grants l .nih. gov /grants/olaw /references/phspol.htm H.12 Dissemination of False or Deliberately Misleading Information The Contractor shall not use contract funds to disseminate information that is deliberately false or misleading. Page 39 of51 ACTIVE/I 04412070.3

Contract No. 75A50120C00034 Development of an mRNA Vaccine for SARS-CoV-2 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH "[***]". SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. H.13 Electronic Information and Technology Accessibility Notice a. Section 508 of the Rehabilitation Act of 1973 (29 U.S.C. 794d), as amended by the Workforce Investment Act of 1998 and the Architectural and Transportation Barriers Compliance Board Electronic and Information (EIT) Accessibility Standards (36 CPR part 1194), require that when Federal agencies develop, procure, maintain, or use electronic and information technology, Federal employees with disabilities have access to and use of information and data that is comparable to the access and use by Federal employees who are not individuals with disabilities, unless an undue burden would be imposed on the agency. Section 508 also requires that individuals with disabilities, who are members of the public seeking information or services from a Federal agency, have access to and use of information and data that is comparable to that provided to the public who are not individuals with disabilities, unless an undue burden would be imposed on the agency. b. Accordingly, any Offeror responding to this solicitation must comply with established HHS EIT accessibility standards. Information about Section 508 is available at http://www.hhs.gov/web/508. The complete text of the Section 508 Final Provisions can be accessed at http://www.access-board.gov/sec508/standards.htm. c. The Section 508 accessibility standards applicable to this solicitation are stated in the clause at 352.239-74, Electronic and Information Technology Accessibility. In order to facilitate the Government's determination whether proposed EIT supplies meet applicable Section 508 accessibility standards, Offerors must submit an HHS Section 508 Product Assessment Template, in accordance with its completion instructions. The purpose of the template is to assist HHS acquisition and program officials in determining whether proposed EIT supplies conform to applicable Section 508 accessibility standards. The template allows Offerors or developers to self-evaluate their supplies and document--in detail--whether they conform to a specific Section 508 accessibility standard, and any underway remediation efforts addressing conformance issues. Instructions for preparing the HHS Section 508 Evaluation Template are available under Section 508 policy on the HHS Web site http://hhs.gov/web/508. In order to facilitate the Government's determination whether proposed EIT services meet applicable Section 508 accessibility standards, Offerors must provide enough information to assist the Government in determining that the EIT services conform to Section 508 accessibility standards, including any underway remediation efforts addressing conformance issues. d. Respondents to this solicitation must identify any exception to Section 508 requirements. If a Offeror claims its supplies or services meet applicable Section 508 accessibility standards, and it is later determined by the Government, i.e., after award of a contract or order, that supplies or services delivered do not conform to the described accessibility standards, remediation of the supplies or services to the level of conformance specified in the contract will be the responsibility of the Contractor at its expense. (End of provision) H.14 Confidentiality oflnformation a Confidential information, as used in this article, means information or data of a personal nature about an individual, or proprietary information or data submitted by or pertaining to an institution or organization. b. The Contracting Officer and the Contractor may, by mutual consent, identify elsewhere in this contract specific information and/or categories of information which the Government will furnish to the Contractor or that the Contractor is expected to generate which is confidential. Similarly, the Contracting Officer and the Contractor may, by mutual consent, identify such confidential information from time to time during the performance of the contract. Failure to agree will be settled pursuant to the "Disputes" clause. c. If it is established elsewhere in this contract that information to be utilized under this contract, or a portion thereof, is subject to the Privacy Act, the Contractor will follow the rules and procedures of disclosure set forth in the Privacy Act of 1974, 5 U.S.C. 552a, and implementing regulations and policies, with respect to systems of records determined to be subject to the Privacy Act. d. Confidential information, as defined in paragraph (a) of this article, shall not be disclosed without the prior written consent of the individual, institution, or organization. e. Whenever the Contractor is uncertain with regard to the proper handling of material under the contract, or if the material in question is subject to the Privacy Act or is confidential information subject to the provisions of this article, the Contractor shall obtain a written determination from the Contracting Officer prior to any release, disclosure, dissemination, or publication. f Contracting Officer Determinations will reflect the result of internal coordination with appropriate program and legal officials. g. The provisions of paragraph (d) of this article shall not apply to conflicting or overlapping provisions in other Federal, State or local laws. H.15 Institutional Responsibility Regarding Investigator Conflicts of Interest The Institution (includes any Contractor, public or private, excluding a Federal agency) shall comply with the requirements of 45 CPR Part 94, Responsible Prospective Contractors, which promotes objectivity in research by establishing standards to ensure that Investigators ( defined as the project director or principal Investigator and any other person, regardless of title or position, Page 40 of51 ACTIVE/I 04412070.3

Contract No. 75A50120C00034 Development of an mRNA Vaccine for SARS-CoV-2 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH "[***]". SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. who is responsible for the design, conduct, or reporting of research funded under BARDA contracts, or proposed for such funding, which may include, for example, collaborators or consultants) will not be biased by any Investigator financial conflicts of interest. 45 CPR Part 94 is available at the following Web site: http://www.ecfr.gov/cgi bin/textidx?c=ecfr&SID=Oaf84ca649a74846f102aaf664dal 623&rgn=div5&view=text&node=45: l .0. l. l .5 l&idno=45 As required by 45 CPR Part 94, the Institution shall, at a minimum: a. Maintain an up-to-date, written, enforceable policy on financial conflicts of interest that complies with 45 CPR Part 94, inform each Investigator of the policy, the Investigator's reporting responsibilities regarding disclosure of significant financial interests, and the applicable regulation, and make such policy available via a publicly accessible Web site, or if none currently exist, available to any requestor within five business days of a request. A significant financial interest means a financial interest consisting of one or more of the following interests of the Investigator (and those of the Investigator's spouse and dependent children) that reasonably appears to be related to the Investigator's institutional responsibilities: I. With regard to any publicly traded entity, a significant financial interest exists if the value of any remuneration received from the entity in the twelve months preceding the disclosure and the value of any equity interest in the entity as of the date of disclosure, when aggregated, exceeds $5,000. Included are payments and equity interests; 2. With regard to any non-publicly traded entity, a significant financial interest exists if the value of any remuneration received from the entity in the twelve months preceding the disclosure, when aggregated, exceeds $5,000, or when the Investigator (or the Investigator's spouse or dependent children) holds any equity interest; or 3. Intellectual property rights and interests, upon receipt of income related to such rights and interest. Significant financial interests do not include the following: I. Income from seminars, lectures, or teaching, and service on advisory or review panels for G agencies, Institutions of higher education, academic teaching hospitals, medical centers, or research institutes with an Institution of higher learning; and 2. Income from investment vehicles, such as mutual funds and retirement accounts, as long as the Investigator does not directly control the investment decisions made in these vehicles. b. Require each Investigator to complete training regarding the Institution's financial conflicts of interest policy prior to engaging in research related to any BARDA funded contract and at least every four years. The Institution must take reasonable steps [see Part 94.4(c)] to ensure that investigators working as collaborators, consultants or subcontractors comply with the regulations. C. Designate an official(s) to solicit and review disclosures of significant financial interests from each Investigator who is planning to participate in, or is participating in, the BARDA funded research. d. Require that each Investigator who is planning to participate in the BARDA funded research disclose to the Institution's designated official(s) the Investigator's significant financial interest (and those of the Investigator's spouse and dependent children) no later than the date of submission of the Institution's proposal for BARDA funded research. Require that each Investigator who is participating in the BARDA funded research to submit an updated disclosure of significant financial interests at least annually, in accordance with the specific time period prescribed by the Institution during the period of the award as well as within thirty days of discovering or acquiring a new significant financial interest. e. Provide guidelines consistent with the regulations for the designated official(s) to determine whether an Investigator's significant financial interest is related to BARDA funded research and, if so related, whether the significant financial interest is a financial conflict of interest. An Investigator's significant financial interest is related to BARDA funded research when the Institution, thorough its designated official(s), reasonably determines that the significant financial interest: Could be affected by the BARDA funded research; or is in an entity whose financial interest could be affected by the research. A financial conflict of interest exists when the Institution, through its designated official(s), reasonably determines that the significant financial interest could directly and significantly affect the design, conduct, or reporting of the BARDA funded research. f. Take such actions as necessary to manage financial conflicts of interest, including any financial conflicts of a subcontractor Investigator. Management of an identified financial conflict of interest requires development and implementation of a management plan and, if necessary, a retrospective review and mitigation report pursuant to Part 94.5(a). g. Provide initial and ongoing PCOI reports to the Contracting Officer pursuant to Part 94.5(b ). Page 41 of51 ACTIVE/I 04412070.3

Contract No. 75A50120C00034 Development of an mRNA Vaccine for SARS-CoV-2 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH "[***]". SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. h. Maintain records relating to all Investigator disclosures of financial interests and the Institution's review of, and response to, such disclosures, and all actions under the Institution's policy or retrospective review, if applicable, for at least 3 years from the date of final payment or, where applicable, for the other time periods specified in 48 CFR Part 4, subpart 4.7, Contract Records Retention. i. Establish adequate enforcement mechanisms and provide for employee sanctions or other administrative actions to ensure Investigator compliance as appropriate. j. Complete the certification in Section K - Representations, Certifications, and Other Statements of Contractors titled "Certification of Institutional Policy on Financial Conflicts oflnterest". If the failure of an Institution to comply with an Institution's financial conflicts of interest policy or a financial conflict of interest management plan appears to have biased the design, conduct, or reporting of the BARDA funded research, the Institution must promptly notify the Contracting Officer of the corrective action taken or to be taken. The Contracting Officer will consider the situation and, as necessary, take appropriate action or refer the matter to the Institution for further action, which may include directions to the Institution on how to maintain appropriate objectivity in the BARDA funded research project. The Contracting Officer and/or HHS may inquire at any time before, during, or after award into any Investigator disclosure of financial interests, and the Institution's review of, and response to, such disclosure, regardless of whether the disclosure resulted in the Institution's determination of a financial conflict of interests. The Contracting Officer may require submission of the records or review them on site. On the basis of this review of records or other information that may be available, the Contracting Officer may decide that a particular financial conflict of interest will bias the objectivity of the BARDA funded research to such an extent that further corrective action is needed or that the Institution has not managed the financial conflict of interest in accordance with Part 94.6(b ). The issuance of a Stop Work Order by the Contracting Officer may be necessary until the matter is resolved. If the Contracting Officer determines that BARDA funded clinical research, whose purpose is to evaluate the safety or effectiveness of a drug, medical device, or treatment, has been designed, conducted, or reported by an Investigator with a financial conflict of interest that was not managed or reported by the Institution, the Institution shall require the Investigator involved to disclose the financial conflict of interest in each public presentation of the results of the research and to request an addendum to previously published presentations. H.16 Reporting Matters Involving Fraud, Waste and Abuse Anyone who becomes aware of the existence or apparent existence of fraud, waste and abuse in BARDA funded programs is encouraged to report such matters to the HHS Inspector General's Office in writing or on the Inspector General's Hotline. The toll free number is 1-800-HHS-TIPS (1-800-447-8477). All telephone calls will be handled confidentially. The e-mail address is Htips@os.dhhs.gov and the mailing address is: Office of Inspector General Department of Health and Human Services TIPS HOTLINE P.O. Box 23489 Washington, D.C. 20026 H.17 Prohibition on Contractor Involvement with Terrorist Activities The Contractor acknowledges that U.S. Executive Orders and Laws, including but not limited to E.O. 13224 and Pub. L. 107-56, prohibit transactions with, and the provision ofresources and support to, individuals and organizations associated with terrorism. It is the legal responsibility of the Contractor to ensure compliance with these Executive Orders and Laws. This clause must be included in all subcontracts issued under this contract. H.18 FAR 52.227-14, Rights in Data - General (May 2014), Alternate II (December 2007) As prescribed in FAR 27.409(b)(3), the following paragraph is inserted into (g)(3) of the basic clause: (g)(3) Notwithstanding paragraph (g)(l) of this clause, the contract may identify and specify the delivery of limited rights data, or the Contracting Officer may require by written request the delivery of limited rights data that has been withheld or would otherwise be entitled to be withheld. If delivery of that data is required, the Contractor shall affix the following "Limited Rights Notice" to the data and the Government will treat the data, subject to the provisions of paragraphs (e) and (f) of this clause, in accordance with the notice: Limited Rights Notice (Dec 2007) (a) These data are submitted with limited rights under Government Contract No. 75A50120C00034 and subcontracts. These data may be reproduced and used by the Government with the express limitation that they will not, without written permission of the Contractor, be used for purposes of manufacture nor disclosed outside the Government; except that the Government may disclose Page 42 of51 ACTIVE/I 04412070.3

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. OS259279 ASPR-BARDA02 8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code) (x) 75A50120C00034 11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers is extended, is not extended. Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended , by one of the following methods: (a) By completing Items 8 and 15, and returning copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted ; or (c) By separate letter or electronic communication which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted , such change may be made by letter or electronic communication, provided each letter or electronic communication makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified. 12. ACCOUNTING AND APPROPRIATION DATA (If required) 2020.199c001.25103 Net Increase: $53,000,000.00 13. THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14. CHECK ONE A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A. B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation data, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b). C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF: D. OTHER (Specify type of modification and authority) X FAR 43.103(a) E. IMPORTANT: Contractor is not is required to sign this document and return 1 copies to the issuing office. 14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.) Tax ID Number: 27-0226313 DUNS Number: 069723520 The purpose of this modification is to exercise the Government s right to exercise an Option 1 CLIN 0003 - Domestic Manufacturing Scale-Out domestic manufacturing in accordance with the contract's clause FAR 52.217-9, Option to Extend the Term of the Contract. 1. The Government hereby exercises Option 1 CLIN 0003 as priced in Section B.3.2 of the Contract at a Total Price of $53,000,000. 2. Funding and Contract Total Summary: The total funded amount on the contract is hereby increased by $53,000,000 from $430,298,520 to $483,298,520 and that the total contract amount is hereby increased by $53,000,000 from $430,298,520 to $483,298,520. 3. Reference SOW Attached for Option 1 CLIN 0003 Continued ... Except as provided herein, all terms and conditions of the document referenced in Item 9 A or 10A, as heretofore changed, remains unchanged and in full force and effect . 15A. NAME AND TITLE OF SIGNER (Type or print) 16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print) Stephane Bancel, Chief Executive Officer WENDELL CONYERS

15B. CONTRACTOR/OFFEROR 15C. DATE SIGNED 16B. UNITED STATES OF AMERICA 16C. DATE SIGNED /s/ Wendell Conyers 05/24/2020 /s/ Stephane Bancel (Signature of person authorized to sign) (Signature of Contracting Officer)

REFERENCE NO. OF DOCUMENT BEING CONTINUED PAGE OF CONTINUATION SHEET 75A50120C00034/P00001 2 30 NAME OF THE OFFEROR OR CONTRACTOR MODERNATX, INC 1492235 ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT (A) (B) (C) (D) (E) (F) Appr. Yr.: 2020 CAN: 199C001 Object Class: 25103 Change Item 3 to read as follows(amount shown is the obligated amount): 3 Option 1 Kit Build-Out 53,000,000.00 Obligated Amount: $53,000,000.00

Contract Number: 75A50120C00034 Development of an mRNA Vaccine for SARS-CoV-2 Request to Award Option 1 Revised 8 May 2020 Moderna Therapeutics, Inc. Prime Contract 200 Technology Square Cambridge, MA 02139-3578 [***] Point of Contact CONFIDENTIAL

200 Tech Square • Cambridge, MA 02139 phone 617-714-6500 • fax 617-583-1998 1- Objective: This document outlines the current plans to enable a second node of domestic mRNA-1273 supply at Lonza’s New Hampshire facility [***]. 2- Approach & Estimated cost [***]

Statement of Work Nr. 2 This Statement of Work (“SOW”) is effective as of [May 8, 2020] (the “Effective Date”) by and between ModernaTX, Inc., with an address at 200 Technology Square, Cambridge, MA 02139 USA (“Moderna”) on the one part; and [***] [***]

[***] [***] IN WITNESS WHEREOF, each Party hereto has caused this Statement of Work to be executed on its behalf by its duly authorized representative. MODERNATX, INC [***] By: ____________________________ By: _____________________________ (Signature) (Signature) Print Name: Print Name: ______________________ Title: Title: ____________________________ SOW2 30 of 30

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED ASPR-BARDA02 8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code) (x) 75A50120C00034 15. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers is extended, is not extended. Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended , by one of the following methods: (a) By completing Items 8 and 15, and returning copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted ; or (c) By separate letter or electronic communication which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted , such change may be made by letter or electronic communication, provided each letter or electronic communication makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified. 16. ACCOUNTING AND APPROPRIATION DATA (If required) See Schedule 17. THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14. CHECK ONE A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A. B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation data, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b). C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF: D. OTHER (Specify type of modification and authority) X FAR 43.103(a) E. IMPORTANT: Contractor is not is required to sign this document and return 1 copies to the issuing office. 18. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.) Tax ID Number: 27-0226313 DUNS Number: 069723520 The purpose of this modification is to add the revised Statement of Work (SOW) dated June 3, 2020 to the Option CLIN 0003. The CLIN value remains unchanged at $53,000,000. All other contract terms and conditions remain unchanged. Except as provided herein, all terms and conditions of the document referenced in Item 9 A or 10A, as heretofore changed, remains unchanged and in full force and effect . 15A. NAME AND TITLE OF SIGNER (Type or print) 16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print) Stephane Bancel, Chief Executive Officer WENDELL CONYERS 15B. CONTRACTOR/OFFEROR 15C. DATE SIGNED 16B. UNITED STATES OF AMERICA 16C. DATE SIGNED /s/ Wendell Conyers 6/16/2020 /s/ Stephane Bancel (Signature of person authorized to sign) 6/4/2020 (Signature of Contracting Officer)

Continuation Page Contract Number: 75A50120C00034 Development of an mRNA Vaccine for SARS-CoV-2 Option 1 Statement of Work Dated June 3, 2020 Moderna Therapeutics, Inc. Prime Contract 200 Technology Square Cambridge, MA 02139-3578 [***] Point of Contact CONFIDENTIAL

1- Objective: This document outlines the current plans to enable a second node of domestic mRNA-1273 supply at Lonza’s New Hampshire facility [***] 2- Approach & Estimated cost: [***]

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED ASPR-BARDA02 8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code) (x) 75A50120C00034 19. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers is extended, is not extended. Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended , by one of the following methods: (a) By completing Items 8 and 15, and returning copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted ; or (c) By separate letter or electronic communication which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted , such change may be made by letter or electronic communication, provided each letter or electronic communication makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified. 20. ACCOUNTING AND APPROPRIATION DATA (If required) Net Increase: $471,596,459.00 See Schedule 21. THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14. CHECK ONE A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A. B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation data, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b). C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF: D. OTHER (Specify type of modification and authority) X FAR 43.103(a) E. IMPORTANT: Contractor is not is required to sign this document and return 1 copies to the issuing office. 22. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.) Tax ID Number: 27-0226313 DUNS Number: 069723520 The purpose of this modification is to support the additional scope of the Clinical Development Plan including direct increases to the clinical subcontractors on the P201 (Work Breakdown Structure 1.4.2.1) and P301 (Work Breakdown Structure 1.4.3.1) clinical studies, and forecasted overruns across the remaining WBS elements. This modification with Moderna to develop a mRNA vaccine for SARS-CoV-2 is part of the USG effort to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics (medical countermeasures) in the midst of a global novel coronavirus pandemic. As a result of the additional scope, the following was updated in this modification.

Continued ... Except as provided herein, all terms and conditions of the document referenced in Item 9 A or 10A, as heretofore changed, remains unchanged and in full force and effect . 15A. NAME AND TITLE OF SIGNER (Type or print) 16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print) Stephane Bancel, Chief Executive Officer WENDELL CONYERS 15B. CONTRACTOR/OFFEROR 15C. DATE SIGNED 16B. UNITED STATES OF AMERICA 16C. DATE SIGNED /s/ Stephane Bancel (Signature of person authorized to sign) 7-25-20 (Signature of Contracting Officer)

REFERENCE NO. OF DOCUMENT BEING CONTINUED PAGE OF CONTINUATION SHEET 75A50120C00034/P00003 2 39 NAME OF OFFEROR OR CONTRACTOR MODERNATX, INC 1492235 ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT (A) (B) (C) (D) (E) (F) - Increase in total contract value from $483,298,520 to $954,894,979; - Section B.4.14 Enrollment Chart - Section C.2 Statement of Work - Section C.2.1 Development Approach - Section F.1.6. Organizational Chart - Section F.1.7. Contractor Provided Facilities, Infrastructure and Other Resources - Section F.2 Deliverables - Section F.3 Contract WBS Milestones/Deliverables and Technical Deliverables - Section H.3 Key Personnel - Section H.9 Security - Section H.20 Organizational Conflicts of Interest - Section H.21 Disclosure of Information - Section H.22 Publication and Publicity - Section H.23 Vetting Period of Performance: [***] Change Item 2 to read as follows(amount shown is the obligated amount): 2 Base CLIN 0002 - Development of mRNA vaccine to 471,596,459.00 BLA [***] [***] [***] Funded: $471,596,459.00

Contract No. 75A50120C00034 Mod P00003 Moderna - Development of an mRNA Vaccine for SARS-CoV-2 CONTINUATION PAGE 1. Modification Purpose The purpose of this modification is to support the additional scope of the Clinical Development Plan including direct increases to the clinical subcontractors on the P201 (Work Breakdown Structure 1.4.2.1) and P301 (Work Breakdown Structure 1.4.3.1) clinical studies, and forecasted overruns across the remaining WBS elements. This modification with Moderna to develop a mRNA vaccine for SARS-CoV-2 is part of the USG effort to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics (medical countermeasures) in the midst of a global novel coronavirus pandemic. As a result of the additional scope, the following was updated in this modification. - Increase in total contract value from $483,298,520 to $954,894,979; - Section B.4.14 Enrollment Chart - Section C.2 Statement of Work - Section C.2.1 Development Approach - Section F.1.6. Organizational Chart - Section F.1.7. Contractor Provided Facilities, Infrastructure and Other Resources - Section F.2 Deliverables - Section F.3 Contract WBS Milestones/Deliverables and Technical Deliverables - Section H.3 Key Personnel - Section H.9 Security - Section H.20 Organizational Conflicts of Interest - Section H.21 Disclosure of Information - Section H.22 Publication and Publicity - Section H.23 Vetting 2. Modification to Contract This modification adds $471,596,459 to CLIN 0002 and increases the total contract value from $483,298,520 to $954,894,979. [***] CLIN 0003 POP extends to [***] at no additional cost. Awarded Additional Total Period CLIN 4/16/2020 Scope Contract Pre Award CLIN 0001 [***] [***] [***] Base CLIN 0002 [***] [***] [***] Option 1 CLIN 0003 [***] [***] [***] Total $483,298,520 $471,596,459 $954,894,979 The period of performance changes [***]

Contract No. 75A50120C00034 Mod P00003 Moderna - Development of an mRNA Vaccine for SARS-CoV-2 B.4.14 Enrollment Chart [***] Unit Qty Total Unit Price [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] Page 4 of 39

Contract No. 75A50120C00034 Mod P00003 Moderna - Development of an mRNA Vaccine for SARS-CoV-2 C.2 Statement of Work (Revised 7-14-2020) Updates to WBS 1.4.2.1 and 1.4.3.1 Only Independently, and not as an agent of the United States Government, the contractor shall furnish all necessary services, qualified professional, technical, and administrative personnel, material, equipment and facilities, not otherwise provided by the Government under the terms of this contract, as needed to perform the tasks set forth below. mRNA-1273 Vaccine Development (WBS 1.0) The Contractor, ModernaTX, Inc. (“Moderna”) shall execute the preclinical, clinical, and chemistry, manufacturing and controls (CMC) activities required to license a vaccine against the SARS-CoV-2 virus (hereafter referred to as “mRNA-1273”). Building upon early clinical development already underway, this proposal will support the late stage development, including the demonstration of clinical efficacy and generation of a dataset supportive of licensure. Moderna will additionally evaluate the platform manufacturing capabilities relative to the needs for supply in response to a pandemic. Program Management (WBS 1.1) mRNA-1273 Program Management (WBS 1.1.1) Moderna’s mRNA-1273 program team is composed of a multidisciplinary, highly matrixed, group of functional leads with experience in, and responsibility for, integrating plans and operationalizing strategies across Research, Toxicology, CMC, Regulatory Affairs, Clinical Development and Quality. Collectively, the team has advanced ten programs to first-in-human studies within five years. The group will be led by a program lead (PL) who will oversee and coordinate the activities necessary to meet program objectives. The PL will be the point of accountability for the development of mRNA-1273. [***] A program management office (PMO) will be responsible for managing the cost and schedule constraints of the contract via an integrated master schedule and corresponding budget, identifying and managing program risk, and ensuring contract compliance. With the input from the mRNA-1273 project team, the PMO will be responsible for coordinating the drafting of and management to an integrated development plan. Upon execution of the contract, weekly meetings with BARDA will be held to monitor program performance and monthly and annual reports will be will delivered to BARDA for the record. Nonclinical Toxicology (WBS 1.2) Development and Reproductive Toxicology of mRNA-1273 (WBS 1.2.2.1) To assess the risk of administering the vaccine to pregnant women, a complete GLP rat developmental and reproductive toxicology (DART) study is planned. Female Sprague Dawley rats will be dosed at the highest anticipated clinical dose level and include a control arm of phosphate-buffered saline (PBS). As is typical for DART evaluations for vaccines, the animals will be immunized three times prior to mating and two times during gestation. Each group will have two cohorts (one group will undergo Cesarean section with examination of the uteri and embryos; the other group will have natural delivery and will be terminated at weaning). Nonclinical (WBS 1.3) For the purposes of this proposal it is assumed that the VRC continues to support nonclinical activities to develop murine and non-human primate efficacy studies, and animal models to assess the potential of vaccine-enhanced disease. The scope of work below will execute additional robustness experiments in these developed models. Page 5 of 39

Contract No. 75A50120C00034 Mod P00003 Moderna - Development of an mRNA Vaccine for SARS-CoV-2 Assess Disease Enhancement (WBS 1.3.3.1) [***] We plan to perform studies in mouse and NHPs to assess the theoretical risk of vaccine induced disease enhancement triggered by CoV infection following vaccination with imRNA-1273. [***] Establish a Surrogate of Protection (WBS 1.3.3.2) The primary endpoint for accelerated approval of a SARS-CoV-2 vaccine would be a neutralization assay. This endpoint must be supported with a body of pre-clinical work that demonstrates a correlation between neutralizing titers and efficacy and that quantifies a protective serologic threshold titer using the same neutralization assay. Murine and NHP efficacy models are being developed in parallel to the Phase 1 Page 6 of 39

Contract No. 75A50120C00034 Mod P00003 Moderna - Development of an mRNA Vaccine for SARS-CoV-2 clinical study. Building on data from these preliminary models and studies, Moderna will conduct NHP efficacy and murine passive transfer studies to confirm and refine the surrogate of protection. Clinical (WBS 1.4) [***] Phase 2 Safety and Immunogenicity Study (WBS 1.4.2.1) - Updated [***] Phase 3 Pivotal Study:(WBS 1.4.3.1) - Updated Phase 3 Pivotal Study (WBS 1.4.3.1). The Phase 3 mRNA-1273-P301 study will confirm the trends observed during the Phase 1 and 2 trials, evaluating safety and efficacy in a larger number of subjects aged 18 and above. Approximately 30,000 subjects will be enrolled according to 1:1 randomization (active: placebo). Primary objectives will be 1) to demonstrate the efficacy of mRNA-1273 to prevent COVID-19 Page 7 of 39

Contract No. 75A50120C00034 Mod P00003 Moderna - Development of an mRNA Vaccine for SARS-CoV-2 and 2) to evaluate the safety and reactogenicity of 2 injections of the mRNA-1273 vaccine given 28 days apart. [***] Lot to Lot Consistency (WBS 1.4.3.2) [***] Pediatrics (WBS 1.4.3.3) [***] Regulatory (WBS 1.5) IND Preparation and Filing (WBS 1.5.1.1) Moderna’s Regulatory Affairs group, in close collaboration with BARDA, will work to draft a comprehensive regulatory master plan to guide the preclinical, CMC and clinical development of mRNA- 1273 within the first 90 days of the contract. An original investigational new drug application (IND) will Page 8 of 39

Contract No. 75A50120C00034 Mod P00003 Moderna - Development of an mRNA Vaccine for SARS-CoV-2 be filed with the United States Food and Drug Administration (FDA) to support the clinical development of the Moderna product from Phase 2 onwards. IND Maintenance (WBS 1.5.1.2) The Moderna-owned IND will be maintained to support the desired clinical development plan. As needed, meetings will be conducted to receive feedback and gain concurrence on the specifics of the development activities with the FDA. BLA Submission (WBS 1.5.2.1) Moderna will submit a Biologics License Application (BLA) and seek approval for the mRNA-1273 vaccine. CMC (WBS 1.6) CTM Manufacture for Phase 2 (WBS 1.6.3.2) [***] Process Development for Late Stage Clinical Supply (WBS 1.6.3.3) mRNA Process Development Technical Development will confirm and optimize the process parameters for mRNA manufacture. [***] Page 9 of 39

Contract No. 75A50120C00034 Mod P00003 Moderna - Development of an mRNA Vaccine for SARS-CoV-2 BLA Readiness (WBS 1.6.3.8) In support of the Biologics License Application (BLA) due to the nature of the proposed timeline, it is likely that Moderna will need to complete some of process validation activities, primarily process characterization, after the completion of process performance qualification and before BLA filing. Moderna intends to rapidly develop a robust process for clinical manufacturing and PPQ, and then fully describe the acceptable design space for the process prior to BLA filing. Other activities to support this BLA filing, such as completing raw material qualification activities; if not included in the BLA submission, will require a supplement to the initial BLA. In the initial BLA filing Moderna will describe its control strategy to cover the gap between initial BLA filing and the BLA supplement. Process Development for Full Commercial Scale (WBS 1.6.4.1) The following section outlines the process development activities [***]. The goal of this work is to demonstrate the capability to produce mRNA- 1273 at a scale that can support clinical demand. [***] Page 11 of 39

[***] Stability Studies (WBS 1.6.5.4) Throughout the program, many studies will be undertaken [***]. This includes studies using development bench scale material, engineering lot material, and GMP material. This body of data will be used to apply interim and long-term shelf life to the drug product and process intermediates. C.2.1. Development Approach [***] Page 12 of 39

F.3 Contract WBS Milestones/Deliverables and Technical Deliverables Work Breakdown Structure (WBS), Go/No Go Program Stage Gates Gantt Chart, Integrated Master Schedule (IMS) Work Breakdown Structure and Option Periods [***] Page 25 of 39

F.3. Deliverables The primary deliverable of this proposal is a licensed mRNA-1273 vaccine. In addition, the team, in partnership with BARDA, will also design a plan to enhance Moderna’s ability to rapidly respond to a Coronavirus pandemic by leveraging our mRNA platform. Interim deliverables are presented below. WBS Title Deliverable Timing 1 mRNA-1273 Vaccine Development 1.1 Program Management Program and Alliance Management -Management Plans; Routine Reporting [***] 1.1.1 Deliverables 1.2 Nonclinical Toxicology 1.2.2 Safety 1.2.2.1 Development and Reproductive Toxicology - Final Study Report [***] 1.3 Nonclinical 1.3.1 Model Development (reserved) 1.3.1.2 NHP Efficacy Study - Final Study Report [***] 1.3.1.3 Mouse Efficacy Study - Final Study Report [***] 1.4 Clinical 1.4.2 Phase 2 Phase 2 Safety and Immunogenicity Study - Clinical Study Protocol [***] 1.4.2.1 - Final Clinical Study Report [***] 1.4.3 Phase 3 1.4.3.1 Phase 3 Efficacy or Safety and Immunogenicity - Clinical Study Protocol [***] - Final Clinical Study Report [***] Phase 3 Lot-to-Lot - Clinical Study Protocol [***] 1.4.3.2 - Final Clinical Study Report [***] Phase 3 Adolescents - Clinical Study Protocol [***] 1.4.3.3 - Final Clinical Study Report [***] Regulatory 1.5.1 IND 1.5.1.1 IND Filing - NA 1.5.1.2 IND Maintenance - Record of FDA Communications [***] 1.5.2 BLA [***] 1.5.2.1 BLA Submission - NA 1.6 CMC 1.6.3 Pilot Scale Manufacturing 1.6.3.2 CTM Manufacture for P201 - CoA for Clinical Lots [***] 1.6.3.4 CTM Manufacture for P301 - CoA for Clinical Lots [***] 1.6.3.6 CTM Manufacture for P302/P303 - CoA for Clinical Lots [***] Page 27 of 39

H.3 Key Personnel [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] Page 28 of 39

F.1.6. Organizational Chart The organizational chart depicts the project team reporting structure of the key personnel for the scope of work for this proposal. [***] [***] Page 29 of 39

ARTICLE F.2. DELIVERABLES SCHEDULE ARTICLE F.2. DELIVERABLES Successful performance of the final contract shall be deemed to occur upon performance of the work set forth in the Statement of Work attached to this contract as Attachment 1 (SECTION J-List of Attachments), and upon delivery and acceptance, as required by the Statement of Work, by the Contracting Officer, or the duly authorized representative pursuant to SECTION E-Inspection and Acceptance, of the following items listed below under heading 1 “Summary of Contract Deliverables” in accordance with the stated delivery schedule. The items specified below under heading 1 “Summary of Contract Deliverables”, as described in the Statement of Work which is Attachment 1 to this contract will be required to be delivered by the date(s) specified below and in accordance with any specifications stated in SECTION D- PACKAGING, MARKING AND SHIPPING, of this contract. All reports identified below relate solely to the development activity funded under this contract: 1. Summary of Contract Deliverables Unless otherwise stated, each deliverable in the table below shall be provided as one (1) electronic copy to the contracting officer representative (COR), contract specialist (CS), and contracting officer (CO) as set forth in SECTION D. In addition to or in replacement of electronic copies, the CO may direct the Contractor to submit the below deliverables via BARDA Digital Resources Portal in machine-readable format. CDRL# Deliverable Deliverable Description Reporting Procedures and Due Dates 01 Meetings Upon request of the Government, the Contractor shall participate in a daily check-in update with the project staff (via teleconference or email).  No agenda will be required for the meeting Daily check in  No meeting minutes with project The updates will address key cost, are required 01.6 staff for COVID- schedule and technical updates.  Contractor will provide 19 Daily updates may be shared with bulleted email updates following any Contract senior Government leaders call or in lieu of a call by 2PM for that during the COVID- 19 response day and should be provided on a non- confidential basis, unless the update includes confidential information in which case Page 33 of 39

CDRL# Deliverable Deliverable Description Reporting Procedures and Due Dates Contractor shall provide the update in both confidential and non-confidential formats. Daily check-ins may occur on weekdays, excluding federal holidays. Upon request of the Government, check-ins may also occur on weekends and on federal holidays, provided at least 24 hours’ notice. Technical 02 Reporting  Contractor will submit The Contractor shall submit a Product Development Source Material detailed spreadsheet regarding Report critical project materials that are o Within month of contract award o Within 30 days of sourced from a location other substantive changes are than the United States, sources, made to sources and/or and manufacturing sites, materials including but not limited to: o Or on the 6th month physical locations of sources of contract anniversary. raw and processed material by type of material; location and  Contractor will update the nature of work performed at Product Dose Tracking Template weekly, during manufacturing sites; and location Development manufacturing campaigns and COVID and nature of non- clinical and Source Material response, with the first deliverable clinical study sites. and submission within 15 days of 02.8 Manufacturing award/modification. Updates to be Reports and provided weekly. Projections The Contractor will provide  The Government will provide manufacturing reports and written comments to the Product manufacturing dose tracking Development Source Material and projections/actuals utilizing the Manufacturing Report within 15 “COVID-19 Dose Tracking business days after the submission Templates”, on any  If corrective action is contract/agreement that is recommended, Contractor must manufacturing product for the address all concerns raised by BARDA USG in writing Contractor The contractor shall submit Contractor will submit Work Locations 02.9 Locations detailed data regarding locations Report: where work will be performed Page 34 of 39

CDRL# Deliverable Deliverable Description Reporting Procedures and Due Dates under this contract, including  Within 5 business days of addresses, points of contact, and contract award work performed per location, to  Within 30 business days after include sub-contractors. a substantive location or capabilities change  Within 2 business days of a substantive change if the work performed supports medical countermeasure development that addresses a threat that has been declared a Public Health Emergency by the HHS Secretary or a Public Health Emergency of International Concern (PHEIC) by the WHO 09 Advanced R&D Products Page 35 of 39

CDRL# Deliverable Deliverable Description Reporting Procedures and Due Dates The Contractor and Government are committed to transparent and timely publication of clinical trial data to ensure rapid distribution of information during the COVID- 19 Pandemic. Within 30 days of the primary analysis, results from clinical  Contractor shall notify CO and studies funded in whole or in part within 30 of primary analysis results under this contract and consistent and study end date [last subject last with Good Publications Practices. visit] if they plan not to publish data. Sponsor must publish the primary endpoint analysis.  Within 10 calendar days of a request for clinical data from the CO, Contractor the Contractor shall provide CO with 09.5 Publication Within 90 days of the of study end requested data, information and Timeline and date [last subject last visit] for materials in the form(s) requested by USG Right to studies funded in part or whole the government, to support the Publish Data under this contract and consistent government publication of the clinical with Good Publication Practices trial data funded in part or whole sponsor shall publish clinical trial under this contract data. If the contractor does not elect to publish data, Contractor shall provide CO and COR with clinical trial data to support the government publication of data as deemed appropriate by the government, without the contractor involvement. Contractor shall provide read-only access to clinical trials management system [***] Additional Contractor shall provide for Contractor shall provide upon request of 09.6 Clinical Trial review for all study operational Deliverables the CO or COR. Page 36 of 39

CDRL# Deliverable Deliverable Description Reporting Procedures and Due Dates plans prior to finalization including but not limited: 1. Global communication plan 2. Project management plan 3. Study subject recruitment/retention plan 4. Clinical monitoring plan 5. Medical monitoring plan 6. Safety management plan 7. Laboratory manual 8. Study procedures manual 9. Sample management plan 10. Clinical supply management plan 11. Quality management plan 12. Data management plan 13. Statistical analysis plan C.4 Target Product Profile [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] Page 37 of 39

H.19 Security BARDA Security Requirements: All COVID-19 contracts are required to address security requirements. In the event that Moderna does not have another contract in place with the USG within 45 days of execution of this contract modification that incorporates the security requirement, Moderna will submit a cost estimate for implementing security requirements for this contract. Moderna will be entitled to an equitable upward adjustment in the value of this contract to cover all additional costs associated with additional security requirements imposed by the Government. H.20 Organizational Conflicts of Interest Performance under this contract may create an actual or potential organizational conflict of interest such as are contemplated by FAR Part 9.505-General Rules. The Contractor shall not engage in any other contractual or other activities which could create an organizational conflict of interest (OCI). This provision shall apply to the prime Contractor and all sub-Contractors. This provision shall have effect throughout the period of performance of this contract, any extensions thereto by change order or supplemental agreement, and for two (2) years thereafter. The Government may pursue such remedies as may be permitted by law or this contract, upon determination that an OCI has occurred. The work performed under this contract may create a significant potential for certain conflicts of interest, as set forth in FAR Parts 9.505-1, 9.505-2, 9.505-3, and 9.505-4. It is the intention of the parties hereto to prevent both the potential for bias in connection with the Contractor's performance of this contract, as well as the creation of any unfair competitive advantage as a result of knowledge gained through access to any non• public data or third party proprietary information. The Contractor shall notify the Contracting Officer immediately whenever it becomes aware that such access or participation may result in any actual or potential OCI. Furthermore, the Contractor shall promptly submit a plan to the Contracting Officer to either avoid or mitigate any such OCI. The Contracting Officer will have sole discretion in accepting the Contractor's mitigation plan. In the event the Contracting Officer unilaterally determines that any such OCI cannot be satisfactorily avoided or mitigated, other remedies may be taken to prohibit the Contractor from participating in contract requirements related to OCI. Whenever performance of this contract provides access to another Contractor's proprietary information, the Contractor shall: (1) enter into a written agreement with the other entities involved, as appropriate, in order to protect such proprietary information from unauthorized use or disclosure for as long as it remains proprietary; and refrain from using such proprietary information other than as agreed to, for example to provide assistance during technical evaluation of other Contractors' offers or products under this contract. An executed copy of all proprietary information agreements by individual personnel or on a cmporate basis shall be furnished to the CO within fifteen (15) calendar days of execution Page 38 of 39

H.21 Disclosure of Information Performance under this contract may require the Contractor to access non-public data and information proprietary to a Government agency, another Government Contractor or of such nature that its dissemination or use other than as specified in the work statement would be adverse to the interests of the Government or others. Neither the Contractor, nor Contractor personnel, shall divulge nor release data nor information developed or obtained under performance pf this contract, except authorized by Government personnel or upon written approval of the CO. The Contractor shall not use, disclose, or reproduce proprietary data that bears a restrictive legend, other than as specified in this contract, or any information at all regarding this agency. Consistent with HHS Directive 1139, the Contractor shall comply with HHS requirements for protection of non-public information. Unauthorized disclosure of nonpublic information is prohibited by the HHS's rules. Unauthorized disclosure may result in termination of the contract, replacement of a Contractor employee, or other appropriate redress. Neither the Contractor nor the Contractor's employees shall disclose or cause to be disseminated, any information concerning the operations of the activity, which could result in, or increase the likelihood of, the possibility of a breach of the activity's security or interrupt the continuity of its operations. No information related to data obtained under this contract shall be released or publicized without the prior written consent of the COR, whose approval shall not be unreasonably withheld, conditioned, or delayed, provided that no such consent is required to comply with any law, rule, regulation, court ruling or similar order; for submission to any government entity' for submission to any securities exchange on which the Contractor's (or its parent corporation's) securities may be listed for trading; or to third parties relating to securing, seeking, establishing or maintaining regulatory or other legal approvals or compliance, financing and capital raising activities, or mergers, acquisitions, or other business transactions. H. 22 PUBLICATION AND PUBLICITY The contractor shall not release any reports, manuscripts, press releases, or abstracts about the work being performed under this contract without written notice in advance to the Government, for additional information see HHSAR 352.227-70. Publications and Publicity (Dec 2015). (a) Unless otherwise specified in this contract, the contractor may publish the results of its work under this contract. The contractor shall promptly send a copy of each submission to the COR for security review prior to submission. The contractor shall also inform the COR when the abstract article or other publication is published, and furnish a copy of it as finally published. Page 39 of 39

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED ASPR-BARDA02 8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code) (x) 75A50120C00034 11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers is extended, is not extended. Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended , by one of the following methods: (a) By completing Items 8 and 15, and returning copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted ; or (c) By separate letter or electronic communication which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted , such change may be made by letter or electronic communication, provided each letter or electronic communication makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified. 12. ACCOUNTING AND APPROPRIATION DATA (If required) See Schedule 13. THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14. CHECK ONE A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A. B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation data, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b). C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF: D. OTHER (Specify type of modification and authority) X FAR 43.103(a) E. IMPORTANT: Contractor is not is required to sign this document and return 1 copies to the issuing office. 14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.) Tax ID Number: 27-0226313 DUNS Number: 069723520 The purpose of this modification is to add the Defense Priorities and Allocations System (DPAS) priority rating language to the contract. The modification changes the contract from unrated to a DO-H5 rating at no additional cost. Section B.4.14 DPAS PRIORITY RATING has been added to the contract. Reference the Continuation Page for detail. All other contract terms and conditions remain unchanged. Continued…

Except as provided herein, all terms and conditions of the document referenced in Item 9 A or 10A, as heretofore changed, remains unchanged and in full force and effect . 15A. NAME AND TITLE OF SIGNER (Type or print) 16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print) Stephane Bancel, Chief Executive Officer WENDELL CONYERS 15B. CONTRACTOR/OFFEROR 15C. DATE SIGNED 16B. UNITED STATES OF AMERICA 16C. DATE SIGNED /s/ Wendell Conyers 8/31/2020 /s/ Stephane Bancel (Signature of person authorized to sign) 8/31/2020 (Signature of Contracting Officer)

REFERENCE NO. OF DOCUMENTS BEING CONTINUED PAG CONTINUATION SHEET 75A50120C00034/P00004 2 4 NAME OF OFFEROR OR CONTRACTOR MODERNATX, INC 1492235 ITEM NO. SUPPLIES/SERVICES QUANTITY UN T UNIT PRICE AMOUNT (A) (B) (C) (D) (E) (F) Period of Performance: [***]

Contract #75A50120C00034 Modification P00004 Page 3 of 4 CONTINUATION PAGE B.4 Advanced Understandings B.4.14 DPAS PRIORITY RATING This is a DO rated order for the purpose of emergency preparedness and the Contractor shall follow all the provisions of the Defense Priorities and Allocations System regulation (15 CFR Part700). If the contractor needs to utilize industrial resources to fulfill this rated order for capacity and industrial expansion, it is authorized pursuant to 15 CFR §700.16(b) to place the same priority rating and program identification symbol on its orders for industrial resources with its suppliers. DPAS PRIORITY RATING LANGUAGE: The purpose of this no cost bilateral modification is to provide notice that this is a priority DO-H5 rated Contract #75A50120C00034. The Contractor and its subcontractors at all tiers are required to follow all of the provisions of the Defense Priorities and Allocations System regulation (15 C.F.R. part 700) as this contract is certified for national defense and emergency preparedness use. The authority for this rating is attached (Attachment A). The priority rating issued pursuant to the authorization is subject to the restrictions in the authorization. The Parties agree that this change from an unrated contract to a DO-H5 priority rated is a no-cost change. Upon execution of this modification, the Contractor and its subcontractors must give the appropriate preferential treatment to the contract as of the date of the modification. The Contractor shall accept, perform, and prioritize this contract. The Parties agree that this modification to rate this contract does not significantly alter the production or delivery schedule already in existence under this contract. This contract shall take precedence over any and all other contracts and orders that do not have a priority rating and shall take precedence over orders or contracts that have the same level of priority rating but were received later in time. This priority rating allows the Contractor to priority rate orders to its subcontractors and suppliers for purpose of fulfilling the priority-rated order expediently. This priority rating automatically expires at the end of the contract’s period of performance. The parties agree that the U.S. Government (USG) may withdraw or extend this authorization at any time prior to the expiration of the contract’s period of performance at no cost to the USG. If the Contractor and/or its subcontractors are unable to comply fully with the terms of this rated order Clause, the Contractor must immediately notify the Assistant Secretary for Preparedness and Response (ASPR) in writing and explain the extent to which compliance is possible and provide reasons why full compliance is not possible. The contractor understands that use of this DO-rating can only be used for the procurement of raw materials, consumables, equipment, etc. necessary for the work covered under the scope of this contract. The Contractor agrees that the Government's right to exercise priorities and allocations authority with respect to this contract to include the use of directives constitutes a no-cost change to this contract. The written signature on a manually placed order, or the digital signature or name on an electronically placed order, of an individual authorized to sign rated orders for the person placing the order is

Contract #75A50120C00034 Modification P00004 Page 4 of 4 provided. The signature, manual or digital, certifies that the rated contract is authorized under this regulation and that the requirements of this regulation are being followed. This language shall be added to the contract or task order by modification, if previously awarded. This is a rated order certified for national defense use and you are required to follow all provisions of the Defense Priorities and Allocations System regulations (15 CFR part 700). This rated order is placed for the purpose of emergency preparedness. The Parties agree that this modification includes the following documents: Attachment Title Date Number Authorization to issue Defense Priorities and August 30, Allocations System Rating for Operation Warp 2020 Speed Contract – ModernaTx, Inc.

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. ASPR-BARDA02 8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code) (x) 75A50120C00034 23. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers is extended, is not extended. Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended , by one of the following methods: (a) By completing Items 8 and 15, and returning copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted ; or (c) By separate letter or electronic communication which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted , such change may be made by letter or electronic communication, provided each letter or electronic communication makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified. 24. ACCOUNTING AND APPROPRIATION DATA (If required) See Schedule 25. THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14. CHECK ONE A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A. B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation data, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b). C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF: D. OTHER (Specify type of modification and authority) X FAR 43.103(a) E. IMPORTANT: Contractor is not is required to sign this document and return 1 copies to the issuing office. 26. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.) Tax ID Number: 27-0226313 DUNS Number: 069723520 The purpose of this modification is to revise the Statement of Work (SOW) to reflect recent feedback from the FDA and OWS on the clinical development plan, and to reallocate the resulting funding to the ongoing mRNA-1273-P301 clinical study. As a result of the additional scope, the following was updated in this modification. - Section B.4.14 Enrollment Chart - Section C.2 Statement of Work - This modification reallocates up to $48,137,292 within CLIN 0002 Continued ...

Except as provided herein, all terms and conditions of the document referenced in Item 9 A or 10A, as heretofore changed, remains unchanged and in full force and effect . 15A. NAME AND TITLE OF SIGNER (Type or print) 16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print) Stephane Bancel, Chief Executive Officer WENDELL CONYERS 15B. CONTRACTOR/OFFEROR 15C. DATE SIGNED 16B. UNITED STATES OF AMERICA 16C. DATE SIGNED /s/ Wendell Conyers Sept. 5, 2020 /s/ Stephane Bancel (Signature of person authorized to sign) 9/15/2020 (Signature of Contracting Officer)

REFERENCE NO. OF DOCUMENT BEING CONTINUED PAGE OF CONTINUATION SHEET 75A50120C00034/P00005 2 11 NAME OF OFFEROR OR CONTRACTOR MODERNATX, INC 1492235 ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT (A) (B) (C) (D) (E) (F) All other contract terms and conditions remain unchanged. Period of Performance: [***]

Contract #75A50120C00034 Modification P00005 CONTINUATION PAGE B.4.14 Enrollment Chart [***] Page 3 of 11

Contract #75A50120C00034 Modification P00005 C. Statement of Work – Dated 9-14-2020 Independently, and not as an agent of the United States Government, the contractor shall furnish all necessary services, qualified professional, technical, and administrative personnel, material, equipment and facilities, not otherwise provided by the Government under the terms of this contract, as needed to perform the tasks set forth below. mRNA-1273 Vaccine Development (WBS 1.0) The Contractor, Moderna, Inc. (“Moderna”) shall execute the preclinical, clinical, and chemistry, manufacturing and controls (CMC) activities required to license a vaccine against the SARS-CoV-2 virus (hereafter referred to as “mRNA-1273”). Building upon early clinical development already underway, this proposal will support the late stage development, including the demonstration of clinical efficacy and generation of a dataset supportive of licensure. Moderna will additionally evaluate the platform manufacturing capabilities relative to the needs for supply in response to a pandemic. Program Management (WBS 1.1) mRNA-1273 Program Management (WBS 1.1.1) Moderna’s mRNA-1273 program team is composed of a multidisciplinary, highly matrixed, group of functional leads with experience in, and responsibility for, integrating plans and operationalizing strategies across Research, Toxicology, CMC, Regulatory Affairs, Clinical Development and Quality. Collectively, the team has advanced ten programs to first-in-human studies within five years. The group will be led by a program lead (PL) who will oversee and coordinate the activities necessary to meet program objectives. The PL will be the point of accountability for the development of mRNA-1273. [***]. A program management office (PMO) will be responsible for managing the cost and schedule constraints of the contract via an integrated master schedule and corresponding budget, identifying and managing program risk, and ensuring contract compliance. With the input from the mRNA-1273 project team, the PMO will be responsible for coordinating the drafting of and management to an integrated development plan. Upon execution of the contract, weekly meetings with BARDA will be held to monitor program performance and monthly and annual reports will be will delivered to BARDA for the record. Nonclinical Toxicology (WBS 1.2) Development and Reproductive Toxicology of mRNA-1273 (WBS 1.2.2.1) To assess the risk of administering the vaccine to pregnant women, a complete GLP rat developmental and reproductive toxicology (DART) study is planned. Female Sprague Dawley rats will be dosed at the highest anticipated clinical dose level and include a control arm of phosphate-buffered saline (PBS). As is typical for DART evaluations for vaccines, the animals will be immunized three times prior to mating and two times during gestation. Each group will have two cohorts (one group will undergo Cesarean section with examination of the uteri and embryos; the other group will have natural delivery and will be terminated at weaning). Page 4 of 11

Contract #75A50120C00034 Modification P00005 Nonclinical (WBS 1.3) For the purposes of this proposal it is assumed that the VRC continues to support nonclinical activities to develop murine and non-human primate efficacy studies, and animal models to assess the potential of vaccine-enhanced disease. The scope of work below will execute additional robustness experiments in these developed models. Assess Disease Enhancement (WBS 1.3.3.1) [***] We plan to perform studies in mouse and NHPs to assess the theoretical risk of vaccine induced disease enhancement triggered by CoV infection following vaccination with imRNA-1273. [***] [***] Page 5 of 11

Contract #75A50120C00034 Modification P00005 Establish a Surrogate of Protection (WBS 1.3.3.2) The primary endpoint for accelerated approval of a SARS-CoV-2 vaccine would be a neutralization assay. This endpoint must be supported with a body of pre-clinical work that demonstrates a correlation between neutralizing titers and efficacy and that quantifies a protective serologic threshold titer using the same neutralization assay. Murine and NHP efficacy models are being developed in parallel to the Phase 1 clinical study. Building on data from these preliminary models and studies, Moderna will conduct NHP efficacy and murine passive transfer studies to confirm and refine the surrogate of protection. Clinical (WBS 1.4) [***] Page 6 of 11

Contract #75A50120C00034 Modification P00005 [***] Phase 3 Pivotal Study (WBS 1.4.3.1) Phase 3 Pivotal Study (WBS 1.4.3.1). The Phase 3 mRNA-1273-P301 study will confirm the trends observed during the Phase 1 and 2 trials, evaluating safety and efficacy in a larger number of subjects aged 18 and above. Approximately 30,000 subjects will be enrolled according to 1:1 randomization (active: placebo). Primary objectives will be 1) to demonstrate the efficacy of mRNA-1273 to prevent COVID-19 and 2) to evaluate the safety and reactogenicity of 2 injections of the mRNA-1273 vaccine given 28 days apart. [***] [***] Page 7 of 11

Contract #75A50120C00034 Modification P00005 Lot to Lot Consistency (WBS 1.4.3.2) Based on FDA feedback received on 27 Aug this study is no longer required for licensure. Pediatrics (WBS 1.4.3.3) [***] Regulatory (WBS 1.5) IND Preparation and Filing (WBS 1.5.1.1) Moderna’s Regulatory Affairs group, in close collaboration with BARDA, will work to draft a comprehensive regulatory master plan to guide the preclinical, CMC and clinical development of mRNA- 1273 within the first 90 days of the contract. An original investigational new drug application (IND) will be filed with the United States Food and Drug Administration (FDA) to support the clinical development of the Moderna product from Phase 2 onwards. IND Maintenance (WBS 1.5.1.2) The Moderna-owned IND will be maintained to support the desired clinical development plan. As needed, meetings will be conducted to receive feedback and gain concurrence on the specifics of the development activities with the FDA. BLA Submission (WBS 1.5.2.1) Moderna will submit a Biologics License Application (BLA) and seek approval for the mRNA-1273 vaccine. CMC (WBS 1.6) CTM Manufacture for Phase 2 (WBS 1.6.3.2) [***] Process Development for Late Stage Clinical Supply (WBS 1.6.3.3) mRNA Process Development Technical Development will confirm and optimize the process parameters for mRNA manufacture. [***]\ Page 8 of 11

Contract #75A50120C00034 Modification P00005 [***] BLA Readiness (WBS 1.6.3.8) In support of the Biologics License Application (BLA) due to the nature of the proposed timeline, it is likely that Moderna will need to complete some of process validation activities, primarily process characterization, after the completion of process performance qualification and before BLA filing. Moderna intends to rapidly develop a robust process for clinical manufacturing and PPQ, and then fully describe the acceptable design space for the process prior to BLA filing. Other activities to support this BLA filing, such as completing raw material qualification activities; if not included in the BLA submission, will require a supplement to the initial BLA. In the initial BLA filing Moderna will describe its control strategy to cover the gap between initial BLA filing and the BLA supplement. Process Development for Full Commercial Scale (WBS 1.6.4.1) The following section outlines the process development activities [***]. The goal of this work is to demonstrate the capability to produce mRNA-1273 at a scale that can support clinical demand. Page 10 of 11

Contract #75A50120C00034 Modification P00005 [***] Stability Studies (WBS 1.6.5.4) Throughout the program, many studies will be undertaken [***]. This includes studies using development bench scale material, engineering lot material, and GMP material. This body of data will be used to apply interim and long-term shelf life to the drug product and process intermediates. Page 11 of 11

EXHIBIT 10.3 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. 1. THIS CONTRACT IS A RATED ORDER RATING PAGE OF PAGES AWARD/CONTRACT UNDER DPAS (15 CFR 700) 1 53 2. CONTRACT (Proc. Inst. Ident.) NO. 3. EFFECTIVE DATE 4. REQUISITION/PURCHASE REQUEST/PROJECT NO. W911QY20C0100 09 Aug 2020 0011534693 5. ISSUED BY CODE W911QY 6. ADMINIST ERED BY (If other than Item 5) CODE S2206A W6QK ACC-APG NATICK DEFENSE CONTRACT MANAGEMENT AGENCY CONTRACTING DIVISION DCMA BOSTON BLDG 1 GENERAL GREENE AVENUE 495 SUMMER STREET NATICK MA 01760-5011 BOSTON MA 02210-2138 7. NAME AND ADDRESS OF CONTRACTOR (No., street, city, county, state and zip code) 8. DELIVERY MODERNATX, INC. [ ] FOB ORIGIN [ X ] OTHER (See below) [***] 9. DISCOUNT FOR PROMPT PAYMENT 200 TECHNOLOGY SQ CAMBRIDGE MA 02139-3578 10. SUBMIT INVOICES 1 ITEM (4 copies unless otherwise specified) TO THE ADDRESS Section G CODE 6RP85 FACILITY CODE SHOWN IN: 11. SHIP TO/MARK FOR CODE 12. PAYMENT WILL BE MADE BY CODE HQ0337 DEFENSE FINANCE AND ACCOUNTING SERVICE DFAS - COLUMBUS CENTER (HQ0337) NORTH ENTITLEMENT OPERATIONS P.O. BOX 182317 See Schedule COLUMBUS OH 43218-2266 13. AUTHORITY FOR USING OTHER THAN FULL AND OPEN 14. ACCOUNTING AND APPROPRIATION DATA COMPETITION: See Schedule [ X ] 10 U.S.C. 2304(c)( 2 ) [ ] 41 U.S.C. 253(c)( ) 15A. ITEM NO. 15B. SUPPLIES/ SERVICES 15C. QUANTITY 15D. UNIT 15E. UNIT PRICE 15F. AMOUNT SEE SCHEDULE 15G. TO TAL AMOUNT OF CONTRACT $1,525,000,000.00 16. TABLE OF CONTENTS (X) SEC. DESCRIPTION PAGE(S) (X) SEC. DESCRIPTION PAGE(S) PART I - THE SCHEDULE PART II - CONTRACT CLAUSES X A SOLICITATION/ CONTRACT FORM 1 - 2 X I CONTRACT CLAUSES 45 - 51 X B SUPPLIES OR SERVICES AND PRICES/ COSTS 3 - 18 PART III – LIST OF DOCUMENTS, EXHIBITS AND O THER ATTACH. X C DESCRIPTION/ SPECS./ WORK STATEMENT 19 - 27 X J LIST OF ATTACHMENTS 52 - 53 X D PACKAGING AND MARKING 28 PART IV - REPRESENTATIONS AND INSTRUCTIONS X E INSPECT ION AND ACCEPTANCE 29 - 30 REPRESENTATIONS, CERTIFICATIONS AND K X F DELIVERIES OR PERFORMANCE 31 - 33 OTHER STATEMENTS OF OFFERORS X G CONTRACT ADMINISTRATION DATA 34 - 38 L INST RS., CONDS., AND NOTICES TO OFFERORS X H SPECIAL CONTRACT REQUIREMENTS 39 - 44 M EVALUATION FACTORS FOR AWARD CONTRACTING OFFICER WILL COMPLETE ITEM 17 (SEALED-BID OR NEGOTIATED PROCUREMENT) OR 18 (SEALED-BID PROCUREMENT) AS APPLICABLE 17. [ ] CONTRACTOR'S NEGOTIATED AGREEMENT Contractor is required to sign this 18. [ ] SEALED-BID AWARD (Contractor is not required to sign this document.) document and return1 copies to issuing office.) Contractor agrees to furnish and deliver all Your bid on Solicitation Number W911QY20R0043 items or perform all the services set forth or otherwise identified above and on any continuation sheets for the consideration stated herein. The rights and obligations of the parties to this contract shall be subject to and governed by the following documents: (a) this award/contract, including the additions or changes made by you which additions or changes are set forth in full above, is hereby accepted as (b) the solicitation, if any, and (c) such provisions, representations, certifications, and specifications, to the terms listed above and on any continuation sheets. This award consummates the contract which consists of the as are attached or incorporated by reference herein. following documents: (a) the Government's solicitation and your bid, and (b) this award/contract. No further contractual (Attachments are listed herein.) document is necessary. (Block 18 should be checked only when awarding a sealed-bid contract.) 19A. NAME AND TITLE OF SIGNER ( Type or print) 20A. NAME OF CONTRACTING OFFICER CONNELL-MAGAW, CAMILLE / BRANCH CHIEF Stéphane Bancel, CEO TEL: EMAIL: [***] 19B. NAME OF CONTRACTOR 19C. DATE SIGNED 20B. UNITED STATES OF AMERICA 20C. DATE SIGNED 11-Aug-2020 BY /s/ Stéphane Bancel 8/11/2020 BY /s/ Camille B. Connell-Magaw (Signature of person authorized to sign) (Signature of Contracting Officer) AUTHORIZED FOR LOCAL REPRODUCTION STANDARD FORM 26 (REV. 5/2011) Previous edition is NOT usable Prescribed by GSA – FAR (48 CFR) 53.214(a)

W911QY20C0100 Page 2 of 53 Section A - Solicitation/Contract Form A.1 The U.S. Army Contracting Command - Aberdeen Proving Ground (ACC-APG), Natick Division has a requirement for up to 500 million SARS-CoV-2 mRNA-1273 Vaccine doses (100 μg) in support of Joint Program Executive Office - Chemical Biological Radiological Nuclear Defense (JPEO-CBRND), the Assistant Secretary for Preparedness and Response (ASPR), and Biomedical Advanced Research and Development Authority (BARDA). All doses of mRNA-1273 Vaccine referenced herein are 100 μg doses. All doses will be delivered in a multi- dose vial with a volume sufficient for 10 doses per vial.

W911QY20C0100 Page 3 of 53 Section B - Supplies or Services and Prices ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 0001 $0.00 SARS-CoV-2 mRNA-1273 Vaccine FFP The contractor shall produce and deliver 100M doses of the SARS-CoV-2 mRNA- 1273 Vaccine filled drug product (FDP), IAW Section C, Statement of Work (SOW) and CDRLs (Exhibit A) on this contract. PROJECT: Operation Warp Speed NET AMT $0.00 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 0001AA 15,000,000 Each $12.25 $183,750,000.00 15M Doses FFP FOB: Origin (Shipping Point) PURCHASE REQUEST NUMBER: 0011534693 PROJECT: Operation Warp Speed PSC CD: 6505 NET AMT $183,750,000.00 ACRN AA $183,750,000.00 CIN: GFEBS001153469300001

W911QY20C0100 Page 4 of 53 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 0001AB 22,000,000 Each $12.25 $269,500,000.00 22M Doses FFP FOB: Origin (Shipping Point) PURCHASE REQUEST NUMBER: 0011534693 PROJECT: Operation Warp Speed PSC CD: 6505 NET AMT $269,500,000.00 ACRN AB $269,500,000.00 CIN: GFEBS001153469300002 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 0001AC 30,000,000 Each $12.25 $367,500,000.00 30M Doses FFP FOB: Destination PURCHASE REQUEST NUMBER: 0011534693 PROJECT: Operation Warp Speed PSC CD: 6505 NET AMT $367,500,000.00 ACRN AA $367,500,000.00 CIN: GFEBS001153469300003

W911QY20C0100 Page 5 of 53 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 0001AD 33,000,000 Each $12.25 $404,250,000.00 33M Doses FFP FOB: Destination PURCHASE REQUEST NUMBER: 0011534693 PROJECT: Operation Warp Speed PSC CD: 6505 NET AMT $404,250,000.00 ACRN AA $404,250,000.00 CIN: GFEBS001153469300004 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 0002 1 Job $0.00 TBN Vendor Managed Inventory FFP a. The contractor shall secure, manage and maintain storage for up to 100M doses of mRNA-1273 vaccine and deliver to the designated government facility in accordance with Section F. b. [***] FOB: Destination PROJECT: Operation Warp Speed PSC CD: 6505 NET AMT $0.00

W911QY20C0100 Page 6 of 53 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 0003 $0.00 EUA or BLA Incentive FFP This is an incentive CLIN and will be earned only if an Emergency Use Authorization (EUA) or Biologics License Application (BLA) is obtained no later than 31 January 2021. PROJECT: Operation Warp Speed NET AMT $0.00 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 0003AA 15,000,000 Each $3.00 $45,000,000.00 EUA or BLA Incentive FFP If earned, this incentive shall be paid at final acceptance of subCLIN 0001AA. FOB: Destination PSC CD: 6505 NET AMT $45,000,000.00

W911QY20C0100 Page 7 of 53 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 0003AB 22,000,000 Each $3.00 $66,000,000.00 EUA or BLA Incentive FFP If earned, this incentive shall be paid at final acceptance of subCLIN 0001AB. FOB: Destination PSC CD: 6505 NET AMT $66,000,000.00 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 0003AC 30,000,000 Each $3.00 $90,000,000.00 EUA or BLA Incentive FFP If earned, this incentive shall be paid at final acceptance of subCLIN 0001AC. FOB: Destination PSC CD: 6505 NET AMT $90,000,000.00 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 0003AD 33,000,000 Each $3.00 $99,000,000.00 EUA or BLA Incentive FFP If earned, this incentive shall be paid at final acceptance of subCLIN 0001AD. FOB: Destination PSC CD: 6505 NET AMT $99,000,000.00

W911QY20C0100 Page 8 of 53 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 0004 1 Job NSP Technical Data FFP The contractor shall deliver technical Data IAW Contract Data Requirements List (CDRL) IAW deliveries in Section C.4 and Section J, Exhibit A. FOB: Destination PROJECT: Operation Warp Speed PSC CD: 6505 NET AMT ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 1001 $0.00 OPTION SARS-CoV-2 mRNA-1273 Vaccine FFP The contractor shall produce and deliver 100M doses of the SARS-CoV-2 mRNA- 1273 Vaccine filled drug product (FDP), IAW Section C, Statement of Work (SOW) and CDRLs (Exhibit A) on this contract. PROJECT: Operation Warp Speed NET AMT $0.00

W911QY20C0100 Page 9 of 53 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 1001AA 33,200,000 Each $16.50 $547,800,000.00 OPTION 33.2M Doses FFP a. If executed, the option shall be awarded upon EUA or no later than [***]. b. The government shall provide [***] notification to exercise the option. FOB: Destination PROJECT: Operation Warp Speed PSC CD: 6505 NET AMT $547,800,000.00 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 1001AB 33,400,000 Each $16.50 $551,100,000.00 OPTION 33.4M Doses FFP a. If executed, the option shall be awarded upon EUA or no later than [***]. b. The government shall provide [***] notification to exercise the option. FOB: Destination PROJECT: Operation Warp Speed PSC CD: 6505 NET AMT $551,100,000.00

W911QY20C0100 Page 10 of 53 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 1001AC 33,400,000 Each $16.50 $551,100,000.00 OPTION 33.4M Doses FFP a. If executed, the option shall be awarded upon EUA or no later than [***]. b. The government shall provide [***] notification to exercise the option. FOB: Destination PROJECT: Operation Warp Speed PSC CD: 6505 NET AMT $551,100,000.00 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 1002 1 Job $0.00 TBN OPTION Vendor Managed Inventory FFP a. The contractor shall secure, manage and maintain storage for up to 100M doses of mRNA-1273 vaccine and deliver to the designated government facility in accordance with Section F. b. [***] FOB: Destination PROJECT: Operation Warp Speed PSC CD: 6505 NET AMT $0.00

W911QY20C0100 Page 11 of 53 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 2001 $0.00 OPTION SARS-CoV-2 mRNA-1273 Vaccine FFP The contractor shall produce and deliver 100M doses of the SARS-CoV-2 mRNA- 1273 Vaccine filled drug product (FDP), IAW Section C, Statement of Work (SOW) and CDRLs (Exhibit A) on this contract. PROJECT: Operation Warp Speed NET AMT $0.00 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 2001AA 33,400,000 Each $16.50 $551,100,000.00 OPTION 33.4M Doses FFP a. If executed, the option shall be awarded upon EUA or no later than [***]. b. The government shall provide [***] notification to exercise the option. FOB: Destination PROJECT: Operation Warp Speed PSC CD: 6505 NET AMT $551,100,000.00

W911QY20C0100 Page 12 of 53 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 2001AB 33,400,000 Each $16.50 $551,100,000.00 OPTION 33.4M Doses FFP a. If executed, the option shall be awarded upon EUA or no later than [***]. b. The government shall provide [***] notification to exercise the option. FOB: Destination PROJECT: Operation Warp Speed PSC CD: 6505 NET AMT $551,100,000.00 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 2001AC 33,200,000 Each $16.50 $547,800,000.00 OPTION 33.2M Doses FFP a. If executed, the option shall be awarded upon EUA or no later than [***]. b. The government shall provide [***] notification to exercise the option. FOB: Destination PROJECT: Operation Warp Speed PSC CD: 6505 NET AMT $547,800,000.00

W911QY20C0100 Page 13 of 53 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 2002 1 Job $0.00 TBN OPTION Vendor Managed Inventory FFP a. The contractor shall secure, manage and maintain storage for up to 100M doses of mRNA-1273 vaccine and deliver to the designated government facility in accordance with Section F. b. [***] FOB: Destination PROJECT: Operation Warp Speed PSC CD: 6505 NET AMT $0.00 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 3001 $0.00 OPTION SARS-CoV-2 mRNA-1273 Vaccine FFP The contractor shall produce and deliver 100M doses of the SARS-CoV-2 mRNA- 1273 Vaccine filled drug product (FDP), IAW Section C, Statement of Work (SOW) and CDRLs (Exhibit A) on this contract. PROJECT: Operation Warp Speed NET AMT $0.00

W911QY20C0100 Page 14 of 53 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 3001AA 33,400,000 Each $16.50 $551,100,000.00 OPTION 33.4M Doses FFP a. If executed, the option shall be awarded upon EUA or no later than [***]. b. The government shall provide [***] notification to exercise the option. FOB: Destination PROJECT: Operation Warp Speed PSC CD: 6505 NET AMT $551,100,000.00 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 3001AB 33,400,000 Each $16.50 $551,100,000.00 OPTION 33.4M Doses FFP a. If executed, the option shall be awarded upon EUA or no later than [***]. b. The government shall provide [***] notification to exercise the option. FOB: Destination PROJECT: Operation Warp Speed PSC CD: 6505 NET AMT $551,100,000.00

W911QY20C0100 Page 15 of 53 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 3001AC 33,200,000 Each $16.50 $547,800,000.00 OPTION 33.2M Doses FFP a. If executed, the option shall be awarded upon EUA or no later than [***]. b. The government shall provide [***] notification to exercise the option. FOB: Destination PROJECT: Operation Warp Speed PSC CD: 6505 NET AMT $547,800,000.00 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 3002 1 Job $0.00 TBN OPTION Vendor Managed Inventory FFP The contractor shall secure, manage and maintain storage for up to 100M doses of mRNA-1273 vaccine and deliver to the designated government facility in accordance with Section F. b. [***] FOB: Destination PROJECT: Operation Warp Speed PSC CD: 6505 NET AMT $0.00

W911QY20C0100 Page 16 of 53 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 4001 $0.00 OPTION SARS-CoV-2 mRNA-1273 Vaccine FFP The contractor shall produce and deliver 100M doses of the SARS-CoV-2 mRNA- 1273 Vaccine filled drug product (FDP), IAW Section C, Statement of Work (SOW) and CDRLs (Exhibit A) on this contract. PROJECT: Operation Warp Speed NET AMT $0.00 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 4001AA 33,400,000 Each $16.50 $551,100,000.00 OPTION 33.4M Doses FFP a. If executed, the option shall be awarded upon EUA or no later than [***]. b. The government shall provide [***] notification to exercise the option. FOB: Destination PROJECT: Operation Warp Speed PSC CD: 6505 NET AMT $551,100,000.00

W911QY20C0100 Page 17 of 53 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 4001AB 33,400,000 Each $16.50 $551,100,000.00 OPTION 33.4M Doses FFP a. If executed, the option shall be awarded upon EUA or no later than [***]. b. The government shall provide [***] notification to exercise the option. FOB: Destination PROJECT: Operation Warp Speed PSC CD: 6505 NET AMT $551,100,000.00 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 4001AC 33,200,000 Each $16.50 $547,800,000.00 OPTION 33.2M Doses FFP a. If executed, the option shall be awarded upon EUA or no later than [***]. b. The government shall provide [***] notification to exercise the option. FOB: Destination PROJECT: Operation Warp Speed PSC CD: 6505 NET AMT $547,800,000.00

W911QY20C0100 Page 18 of 53 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 4002 1 Job $0.00 TBN OPTION Vendor Managed Inventory FFP The contractor shall secure, manage and maintain storage for up to 100M doses of mRNA-1273 vaccine and deliver to the designated government facility in accordance with Section F. b. [***] FOB: Destination PROJECT: Operation Warp Speed PSC CD: 6505 NET AMT $0.00

W911QY20C0100 Page 19 of 53 Section C - Descriptions and Specifications STATEMENT OF WORK LARGE SCALE PRODUCTION OF SARS-CoV-2 VACCINE C.1 SCOPE. The Department of Defense and Health and Human Services (HHS) require large scale manufacturing of vaccine doses in support of the national emergency response to the Coronavirus Disease 2019 (COVID-19) for the United States Government (USG) and the US population. C.1.1 Background. In December 2019, a novel coronavirus now known as SARS-CoV-2 was first detected in Wuhan, Hubei Province, People’s Republic of China, causing outbreaks of the coronavirus disease COVID-19 that has now spread globally. The Secretary of Health and Human Service declared a public health emergency on January 31, 2020, under section 319 of the Public Health Service Act (42 U.S.C. 247d), in response to COVID-19. On March 1, 2020, the President of the United States, pursuant to sections 01 and 301 of the National Emergencies Act (50 U.S.C. 1601 et seq.) and consistent with section 1135 of the Social Security Act (SSA), as amended (42 U.S.C. 1320b-5), proclaimed that the COVID-19 outbreak in the United States constitutes a national emergency. C.1.1.1 Under Operation Warp Speed (OWS), the Department of Defense and HHS are leading a whole of nation effort to ensure development of promising vaccine, diagnostic and therapeutic candidates and ensure that these medical countermeasures are available in the quantities required to reduce SARS-CoV-2 transmission, identify prior and/or current infection, and improve patient care, thereby mitigating the impact of COVID-19 on the nation and its people. The DoD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRD) is providing expertise and contracting support to HHS, in compliance with PL 115-92 Authorization Letter for DoD Medical Priorities, through an Interagency Agreement, signed April 23, 2020. As OWS products progress to clinical trials to evaluate the safety and efficacy of vaccines and therapeutics, it is critical that, in parallel, the USG supports large scale manufacturing so that vaccine doses or therapeutic treatment courses are immediately available for nationwide access as soon as a positive efficacy signal is obtained and the medical countermeasures are authorized for widespread use. C.1.2 Objective: The objective of this effort is to obtain the following: a. Base Period: Large scale manufacturing of 100 million vaccine doses b. Option Period 1: Large scale manufacturing of 100 million vaccine doses c. Option Period 2: Large scale manufacturing of 100 million vaccine doses d. Option Period 3: Large scale manufacturing of 100 million vaccine doses e. Option Period 4: Large scale manufacturing of 100 million vaccine doses The Base Period is 9 months, with overlapping options for a total of 20 months if all options are exercised. C.2 APPLICABLE DOCUMENTS. C.2.1 Federal Documents: C.2.1.1 Title 21 Code of Federal Regulations (CFR), Food and Drugs: Part 210, Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs; General; and, Part 211, Current Good Manufacturing Practice In Manufacturing, Processing, Packing, or Holding of Drugs; General. (https://www.ecfr.gov/cgi-bin/text- idx?SID=a95cab20f443897a400bb7e44a27cf4c&mc=true&tpl=/ecfrbrowse/Title21/21cfrv4_02.tpl#0) C.3 REQUIREMENTS. Independently, and not as an agent of the USG, in accordance with the Proposal submitted by ModernaTX, Inc. in response to Solicitation Number W911QY20R0043, Titled, “Advanced Procurement of mRNA-1273 Vaccine for Prevention of SARS-CoV-2 Coronavirus (COVID-19)”), dated July 10, 2020 (and any subsequent USG-approved revisions thereto), the contractor shall provide all necessary services,

W911QY20C0100 Page 20 of 53 qualified personnel, material, equipment and facilities (not otherwise provided by the USG under the terms of this contract) to perform the specific tasks set forth below. C.3.1 C ontract Line Item Number (CLIN) 0001 - Base Period: Large Scale Manufacturing of 100 Million V accine Doses. C.3.1.1 The contractor shall complete all scope required for the production, release and delivery use of 100 million Final Drug Product (FDP) doses of a SARS-CoV-2 mRNA-1273 vaccine. This shall include, the following tasks and other activities reasonably contemplated by such task: C.3.1.1.1 Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations. Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of 12 months. (Based on FDP stability data that supports a 12-month shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC. Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation. C.3.1.1.2 cGMP manufacturing of 100 million doses fully compliant with 21 CFR 210 and 211. C.3.1.1.3 Ensuring that vial labeling and packaging is consistent with FDA guidance for use in target populations and that labeling is updated as appropriate. C.3.1.1.4 Coordinating with FDA to establish an approved commercial vial label, carton and packaging insert (printed or electronic). C.3.1.1.5 Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 22013), including product verification, serialization, traceability and detection and response requirements, subject to any exceptions established by or the enforcement discretion of the FDA, including “Exemption from Certain Product Tracing and Product Identification Requirements Under Section 582 of the FD&C Act” (April 2020). C.3.1.1.6 In coordination with the USG, the contractor shall conduct a demonstration of the vaccine shipping process prior to the first delivery of FDP doses at a time mutually agreed to by the contractor and the USG. Moderna shall provide specifications and details associated with the shipping process and containers (IAW CDRL A005) to enable the USG to adequately plan and prepare for potential distribution of the vaccine. C.3.1.1.7 Following release of product the contractor shall, promptly deliver product to the designated delivery site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below. In the unforeseen event that a designated delivery site cannot receive product and the contractor provides storage beyond 20 days of product release, the contract will be subject to modification for acceptance purposes. C.3.1.2 Site Visits and Audits. The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract. C.3.1.2.1 BARDA Audits. If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001. C.3.1.2.2 FDA Audits. The Contractor shall notify the Contracting Officer and Contracting Officer’s Representative (COR) within [***] of a scheduled FDA audit or within [***] of an ad hoc site visit or audit if the FDA does not provide advance notice. The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within [***] of receiving correspondence from the FDA or third party in accordance with CDRL A002. The Contractor shall

W911QY20C0100 Page 21 of 53 provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within [***] of submittal of the audit report in accordance with CDRL A002. C.3.1.2.3 FDA Interactions. The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologics for the following, but not limited to: FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002. C.3.2 C LIN 1001 - Option Period 1: Large Scale Manufacturing of 100 Million Vaccine Doses. C.3.2.1 The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine. This shall include the following tasks and other activities reasonably contemplated by such tasks: C.3.2.1.1 Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations. Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of 12 months. (Based on FDP stability data that supports a 12-month shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC. Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation. C.3.2.1.2 cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA. C.3.2.1.3 Ensuring that vial labeling and packaging is consistent with FDA guidance for use in target populations and that labeling is updated. C.3.2.1.4 Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 22013), including product verification, serialization, traceability and detection and response requirements subject to any exceptions established by or the enforcement discretion of the FDA. C.3.2.1.5 Following release of the product the contractor shall deliver the product to the designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below. To the extent a natural disaster or other emergency affecting a designated delivery site restricts such site’s ability to receive product, the Contractor and the USG will promptly agree on an alternate USG delivery location, or storage as Vendor Managed Inventory (VMI) at the contractor site. C.3.2.2 Site Visits and Audits. The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract. C.3.2.2.1 BARDA Audits. If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001. C.3.2.2.2 FDA Audits. The Contractor shall notify the Contracting Officer and COR within [***] of a scheduled FDA audit or within [***] of an ad hoc site visit or audit if the FDA does not provide advance notice. The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within [***] of receiving correspondence from the FDA or third party in accordance with CDRL A015. The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within [***] of submittal of the audit report in accordance with CDRL A002. C.3.2.2.3 FDA Interactions. The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologics for the following, but

W911QY20C0100 Page 22 of 53 not limited to: FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002. C.3.3 C LIN 2001 - Option Period 2: Large Scale Manufacturing of 100 Million Vaccine Doses. C.3.3.1 The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine. This shall include the following tasks and other activities reasonably contemplated by such tasks: C.3.3.1.1 Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations. Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of 12 months. (Based on FDP stability data that supports a 12-month shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC. Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation. C.3.3.1.2 cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA. C.3.3.1.3 Ensuring that vial labeling and packaging is consistent with FDA guidance for use in target populations and that labeling is updated as appropriate. C.3.3.1.4 Ensuring that the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581- 585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements, subject to any exceptions established by or the enforcement discretion of the FDA. C.3.3.1.5 Following release the contractor shall deliver product to the nearest designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below. To the extent a natural disaster or other emergency affecting a designated delivery site restricts such site’s ability to receive product, the Contractor and the USG will promptly agree on an alternate USG delivery location, or storage as Vendor Managed Inventory (VMI) at the contractor site. C.3.3.2 Site Visits and Audits. The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract. C.3.3.2.1 BARDA Audits. If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001. C.3.3.2.2 FDA Audits. The Contractor shall notify the Contracting Officer and COR within [***] of a scheduled FDA audit or within [***] of an ad hoc site visit or audit if the FDA does not provide advance notice. The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within [***] of receiving correspondence from the FDA or third party in accordance with CDRL A002. The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within [***] of submittal of the audit report in accordance with CDRL A002. C.3.3.2.3 FDA Interactions. The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologics for the following, but not limited to: FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002. C.3.4 C LIN 3001 - Option Period 3: Large Scale Manufacturing of 100 Million Vaccine Doses.

W911QY20C0100 Page 23 of 53 C.3.4.1 The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine. This shall include the following tasks and other activities reasonably contemplated by such tasks: C.3.4.1.1 Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations. Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of 12 months. (Based on FDP stability data that supports a 12-month shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC. Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation. C.3.4.1.2 cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA. C.3.4.1.3 Ensuring that vial labeling and packaging is consistent with FDA guidance for use in target populations and that labeling is updated. C.3.4.1.4 Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 22013), including product verification, serialization, traceability and detection and response requirements subject to any exceptions established by or the enforcement discretion of the FDA. C.3.4.1.5 Following release of the product the contractor shall deliver the product to the designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below. To the extent a natural disaster or other emergency affecting a designated delivery site restricts such site’s ability to receive product, the Contractor and the USG will promptly agree on an alternate USG delivery location, or storage as Vendor Managed Inventory (VMI) at the contractor site. C.3.4.2 Site Visits and Audits. The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract. C.3.4.2.1 BARDA Audits. If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001. C.3.4.2.2 FDA Audits. The Contractor shall notify the Contracting Officer and COR within [***] of a scheduled FDA audit or within [***] of an ad hoc site visit or audit if the FDA does not provide advance notice. The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within [***] of receiving correspondence from the FDA or third party in accordance with CDRL A015. The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within [***] of submittal of the audit report in accordance with CDRL A002. C.3.4.2.3 FDA Interactions. The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding mRNA-1273 for the following, but not limited to: FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002. C.3.5 C LIN 4001 - Option Period 4: Large Scale Manufacturing of 100 Million Vaccine Doses. C.3.5.1 The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine. This shall include the following tasks and other activities reasonably contemplated by such tasks:

W911QY20C0100 Page 24 of 53 C.3.5.1.1 Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations. Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of 12 months. (Based on FDP stability data that supports a 12-month shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC. Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation. C.3.5.1.2 cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA. C.3.5.1.3 Ensuring that vial labeling and packaging is consistent with FDA guidance for use in target populations and that labeling is updated. C.3.5.1.4 Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 22013), including product verification, serialization, traceability and detection and response requirements subject to any exceptions established by or the enforcement discretion of the FDA. C.3.5.1.5 Following release of the product the contractor shall deliver the product to the designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below. To the extent a natural disaster or other emergency affecting a designated delivery site restricts such site’s ability to receive product, the Contractor and the USG will promptly agree on an alternate USG delivery location, or storage as Vendor Managed Inventory (VMI) at the contractor site. C.3.5.2 Site Visits and Audits. The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract. C.3.5.2.1 BARDA Audits. If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001. C.3.5.2.2 FDA Audits. The Contractor shall notify the Contracting Officer and COR within [***] of a scheduled FDA audit or within [***] of an ad hoc site visit or audit if the FDA does not provide advance notice. The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within [***] of receiving correspondence from the FDA or third party in accordance with CDRL A015. The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within [***] of submittal of the audit report in accordance with CDRL A002. C.3.5.2.3 FDA Interactions. The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologics for the following, but not limited to: FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002. C.4 C LIN 0002: Data Deliverables. The contractor shall provide the following in accordance with the Contract Data Requirements List (CDRL), DD Forms 1423, provided at Appendix A. C.4.1 Monthly Inventory Report (CDRL A003), detailing at a minimum, raw materials, Bulk mRNA, formulated LNPs, and the fill, finish, and released product. C.4.2 Quality Management Plan. The contractor shall provide a Quality Management Plan, in accordance with CDRL A004, describing the quality policy and objectives, management review, competencies and training, process document control, feedback, evaluation, corrective action and preventive action, process improvement, measurement, and data analysis processes. The framework is normally divided into infrastructure, senior

W911QY20C0100 Page 25 of 53 management responsibility, resource management, lifecycle management, and quality management system evaluation. C.4.3 Shipping Documentation (CDRL A005) for all Finished Drug Product (FDP) transferring from the contractor’s fill/finish facility to a USG facility. The contractor shall obtain concurrence on planned shipment protocols prior to transport. C.4.4 Expiring Items Report (CDRL A006) for all FDP in the USG’s possession. C.4.5 Key Personnel Listing (CDRL A007). C.4.6 Monthly Technical Progress Report (CDRL A008), to include an Integrated Master Schedule, identifying key activities and contract status. C.4.7 Final Technical Report (CDRL A009), documenting the work performed and results obtained for the entire contract period of performance. C.4.8 Supply Chain Resiliency Plan (SCRP). The contractor shall provide, in accordance with CDRL A010 and CDRL Attachment 0001, a comprehensive SCRP that provides for identification and reporting of critical components associated with the secure supply of drug substance, drug product, and work-in-process through to finished goods, and key equipment suppliers and their locations, including addresses, points of contact, and work performed per location, to include subcontractors. C.4.9 Risk Management Plan (RMP). The Contractor shall provide an RMP in accordance with CDRL A011 that outlines the impacts of each risk in relation to the cost, schedule, and performance objectives. The plan shall include risk mitigation strategies. Each risk mitigation strategy shall capture how the corrective action will reduce impacts on cost, schedule and performance. C.4.10 Manufacturing Reports and Dose Tracking. The Contractor shall provide, in accordance with CDRL A013, manufacturing reports and manufacturing dose tracking projections and actuals utilizing the USG-provided “COVID-19 Dose Tracking Template” (CDRL Attachment 0003). C.4.11 Product Acceptance Report (for each lot of Drug Product). The contractor shall provide, in accordance with CDRL A014, pictures of the drug product with lot number, drug product lot tree, list of associated deviations (from drug substance and product), and a Certificate of Analysis. C.4.12 Incident Report. The contractor shall communicate to BARDA and document all critical programmatic concerns, issues, or probable risks that have or are likely to significantly impact project schedule and/or cost and/or performance in accordance with CDRL A016. “Significant” is frequently defined as a 10% or greater cost or schedule variance within a control account, but should be confirmed in consultation with the COR. Incidents that present liability to the project even without cost/schedule impact, such as breach of GCP during a clinical study, shall also be reported. C.4.13 FDA Correspondence. The contractor shall provide any correspondence between Contractor and FDA relevant to the scope of this contract and submit in accordance with CDRL A017. C.4.14 Press Releases. The contractor shall accurately and factually represent the work conducted under this contract in all press releases. The contractor shall provide an advance copy of any press release in accordance with CDRL A018. C.4.15 Manufacturing Development Plan. The contractor shall provide a Manufacturing Development Plan, in accordance with CDRL A025, describing the manufacturing process for the drug/biologic product to ensure conformity with §501(a)(2)(B) of the Food, Drug, and Cosmetics Act (FD&C Act, Title 21 United States Code (USC) §351 (a)(2)(B)), regarding good manufacturing practices (GMP).

W911QY20C0100 Page 26 of 53 C.5 Administration. C.5.1 Post Award Teleconference. The contractor shall host a Post Award Teleconference within 7 calendar days after contract award. C.5.1.1 The contractor shall provide an Agenda, IAW CDRL A020, detailing the planned activities for the subsequent 30 calendar days and shall discuss agenda items for the Post Award Kickoff Meeting. C.5.1.2 The contractor shall provide Meeting Minutes IAW CDRL A021. C.5.2 Post Award Kickoff Meeting. The contracting officer may request the contractor host a contract Kick-Off Meeting within 30 calendar days after contract award via teleconference. The contracting officer shall establish the date and time of the conference and prepare the agenda to include discussion on contract activities and schedule. C.5.3 Bi-Weekly Teleconference. The contractor shall participate in bi-weekly teleconferences (or more frequent meetings required by the USG if warranted based on contract activities) to discuss performance on the contract. C.5.4 The contractor shall provide an Agenda, IAW CDRL A020; Meeting Minutes in accordance with CDRL A021; and, Presentation Material in accordance with CDRL A022 for each of the aforementioned teleconferences or meetings throughout the contract period of performance. C.5.5 Daily “Check-In”. The contractor shall participate in a daily “check-in” (via teleconference or email) to address key cost, schedule and technical updates. Daily updates may be shared with senior USG leaders during the COVID- 19 response and should be provided on a non-confidential basis, unless the update includes confidential information in which case, the contractor shall provide the update in both confidential and non-confidential formats. Daily check-ins may occur on weekdays, excluding federal holidays. Upon request of the USG, check-ins may also occur on weekends and on federal holidays, provided at least 24 hours’ notice. C.6 Security. C.6.1 Access and General Protection/Security Policy and Procedures. The contractor shall provide all information required for background checks necessary to access critical information related to OWS, and to meet USG installation access requirements to be accomplished by the installation Director of Emergency Services or Security Office. The contractor employees shall comply with all personnel identity verification requirements as directed by the USG and/or local policy. In addition to the changes otherwise authorized by the changes clause of this contract, should the security status of OWS change the USG may require changes in the contractor’s security matters or processes. In addition to the industry standards for employment background checks, the contractor shall be willing to have key individuals, in exceptionally sensitive positions, identified for additional vetting by the United States USG. C.6.2 Security Program and Plan. The contractor shall implement a comprehensive security program that provides overall protection of personnel, information, data, and facilities associated with fulfilling the USG’s requirement. The contractor’s security practices and procedures shall be detailed in a Security Plan, in accordance with CDRL A019, and shall demonstrate how the contractor shall meet and adhere to the security requirements outlined in CDRL Attachment 0002. This plan shall be delivered to the USG within 45 days of award, and the USG will review in detail and submit comments within ten (10) business days to the Contracting Officer (CO) to be forwarded to the Contractor. The Contractor shall review the Security Plan comments, and, submit a final Security Plan to the U.S. USG within thirty (30) calendar days after receipt of the comments. The Security Plan shall include a timeline for compliance of all the required security measures outlined in CDRL Attachment 0002. C.6.3 Operational Security (OPSEC). The contractor shall develop and submit an OPSEC Standard Operating Procedure (SOP)/Plan IAW CDRL A024. The contractor shall identify in the SOP/Plan critical information related to this contract, why it needs to be protected, where it is located, who is responsible for it, and how to protect it.

W911QY20C0100 Page 27 of 53 C.7 C LIN 0002 Vendor Managed Inventory (VMI). The Contractor shall provide the capability to store the vaccine for up to 52 weeks, up to 100M doses of mRNA-1273 vaccine, in accordance with product labeling. The contractor shall, in accordance with paragraph C.3.1.1.6, ensure the product storage of FDP doses for up to 12 months prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations. [***]. The contractor shall store the product to insure product quality with audible alarms and contacting. The contractor shall notify the USG within [***] of detection of an incident with the potential to impact product quality, and implement corrective actions to mitigate the incident. . BARDA/JPEO- CBRND personnel may conduct Quality Audits of the storage facility, when deemed necessary. The contractor shall notify the USG of Corrective/Preventive actions within [***] of detection of an incident with potential to impacts product quality. BARDA/JPEO-CBRND personnel may conduct Quality Audits of the storage facility, when deemed necessary. C.7.1 The USG will provide the contractor advance notice of the required delivery locations for the vaccine. The contractor shall ship mRNA-1273 vaccines to designated locations [***] in the United States. The contractor shall be responsible for shipment of all vaccine product whether acceptance is conducted at origin or destination. [***]. C.7.2 The vaccine product shall be shipped and tracked by the distribution vendor’s shipping tracking number, to the USG-designated sites within the continental United States. C.7.3 [***]. Implementation of a Vendor Managed Inventory Plan/SOP (CDRL A012) shall be provided to the USG. [***]. Notwithstanding either of the foregoing sentences, the contractor shall not be liable for loss of or damage to supplies caused by the negligence of officers, agents, or employees of the USG acting within the scope of their employment.

W911QY20C0100 Page 28 of 53 Section D - Packaging and Marking D.1 Vaccine markings and labeling will be in accordance with FDA and will be finalized through a contract modification.

W911QY20C0100 Page 29 of 53 Section E - Inspection and Acceptance INSPECTION AND ACCEPTANCE TERMS Supplies/services will be inspected/accepted at: CLIN INSPECT AT INSPECT BY ACCEPT AT ACCEPT BY 0001 N/A N/A N/A N/A 0001AA Origin Government Origin Government 0001AB Origin Government Origin Government 0001AC Destination Government Destination Government 0001AD Destination Government Destination Government 0002 Destination Government Destination Government 0003 N/A N/A N/A N/A 0003AA Destination Government Destination Government 0003AB Destination Government Destination Government 0003AC Destination Government Destination Government 0003AD Destination Government Destination Government 0004 Destination Government Destination Government 1001 N/A N/A N/A N/A 1001AA Destination Government Destination Government 1001AB Destination Government Destination Government 1001AC Destination Government Destination Government 1002 Destination Government Destination Government 2001 N/A N/A N/A N/A 2001AA Destination Government Destination Government 2001AB Destination Government Destination Government 2001AC Destination Government Destination Government 2002 Destination Government Destination Government 3001 N/A N/A N/A N/A 3001AA Destination Government Destination Government 3001AB Destination Government Destination Government 3001AC Destination Government Destination Government 3002 Destination Government Destination Government 4001 N/A N/A N/A N/A 4001AA Destination Government Destination Government 4001AB Destination Government Destination Government 4001AC Destination Government Destination Government 4002 Destination Government Destination Government CLAUSES INCORPORATED BY REFERENCE 52.246-16 Responsibility For Supplies APR 1984 E1. Inspection:

W911QY20C0100 Page 30 of 53 Initial quality inspection of Filled Drug Product (FDP) shall occur when the Contractor performs release testing to confirm that products complies with Contractor’s release specifications and criteria. Contractor will submit in WAWF to the Contracting Officer or the duly authorized representative of the Government with a Certificate of Analysis for quality inspection of all deliverables. Initial Inspection under this contract will be performed at the Contractor’s facility, or the subcontractor facility, by the BARDA Contracting Officer Technical Representative (COTR). Final inspection of product shall occur when the Government inspects each shipment of product delivered to it hereunder for visible damage and quantity within [***] of such delivery. In the event Contractor supplies any product to the Government and it is established that such Product was damaged or does not include the required quantities at the time of delivery, the Government shall promptly notify Contractor in writing within [***]. Final inspection shall be conducted at the CDC location identified as destination. In the event the USG requires storage of the FDP to a Vendor Managed Inventory (VMI) location, final quantity inspection shall be conducted by submission into WAWF of shipping or other documentation confirming quantity to VMI location. Final physical inspection of the FDP shall be conducted upon receipt of product to USG location. Inspection of all reports and Contract Data Requirement List (CDRL) under this contract will be performed at Destination by duly authorized representative of the Government. E.2 Acceptance a. Acceptance at origin shall occur at [***]. Acceptance at destination shall occur [***]. Regardless of where acceptance occurs, the contractor is responsible for final delivery of Filled Drug Product (FDP) to a government designated CDC location. b. Acceptance under this agreement will be performed by Army Contracting Command Aberdeen Proving Ground (ACC-APG) Natick Contracting Division (NCD) Contracting Officer. c. Acceptance of services under VMI SubCLINs ( List CLINS) shall occur upon satisfactory physical and quantity inspection of FDP upon delivery at USG designated CDC location. d. The parties acknowledge that acceptance may depend on the compliance with the Contractor’s product specifications. The KO and COR may prior to acceptance consult with FDA under its authority under Public Law 115-92 to determine whether the material to be delivered meets the Contractor’s product specifications. To this end, Contractor agrees to provide a letter to FDA authorizing the Government to engage in dialog with FDA about the ultimate compliance of this product with the Contractor’s product specifications prior to acceptance. BARDA/COR will accept product according to the approved Product Acceptance Procedure.

W911QY20C0100 Page 31 of 53 Section F - Deliveries or Performance DELIVERY INFORMATION CLIN DELIVERY DATE QUANTITY SHIP TO ADDRESS DODAAC / CAGE [***] [***] [***] N/A N/A [***] [***] [***] N/A Origin (Shipping Point) FOB: [***] [***] [***] N/A Origin (Shipping Point) FOB: [***] [***] [***] N/A Destination FOB: [***] [***] [***] N/A Destination FOB: [***] [***] [***] N/A Destination FOB: [***] [***] [***] N/A N/A [***] [***] [***] N/A Destination FOB: [***] [***] [***] N/A Destination FOB: [***] [***] [***] N/A Destination FOB: [***] [***] [***] N/A Destination FOB: [***] [***] [***] [***] [***] FOB: Destination [***] [***] [***] N/A N/A [***] [***] [***] N/A FOB: Destination

W911QY20C0100 Page 32 of 53 [***] [***] [***] Destination N/A FOB: [***] [***] [***] Destination N/A FOB: [***] [***] [***] Destination N/A FOB: [***] [***] [***] N/A N/A [***] [***] [***] N/A FOB: Destination [***] [***] [***] N/A FOB: Destination [***] [***] [***] N/A FOB: Destination [***] [***] [***] N/A FOB: Destination [***] [***] [***] N/A N/A [***] [***] [***] N/A FOB: Destination [***] [***] [***] N/A FOB: Destination [***] [***] [***] N/A FOB: Destination [***] [***] [***] N/A FOB: Destination [***] [***] [***] N/A N/A [***] [***] [***] N/A FOB: Destination [***] [***] [***] N/A FOB: Destination [***] [***] [***] N/A FOB: Destination [***] [***] [***] N/A FOB: Destination CLAUSES INCORPORATED BY REFERENCE

W911QY20C0100 Page 33 of 53 52.211-17 Delivery of Excess Quantities SEP 1989 52.242-15 Stop-Work Order AUG 1989 52.247-34 F.O.B. Destination NOV 1991 F.1 The contractor shall ship mRNA-1273 vaccines to designated locations [***] in the United States. The contractor shall be responsible for secure shipment of all vaccine product whether acceptance is conducted at origin or destination.

W911QY20C0100 Page 34 of 53 Section G - Contract Administration Data ACCOUNTING AND APPROPRIATION DATA AA: 0212020202120400000664643255 S.0074658.5.6 6100.9000021001 COST CODE: A5XAH AMOUNT: $955,500,000.00 AB: 0212020202120400000664643255 S.0074658.5.6.1 6100.9000021001 COST CODE: A5XAH AMOUNT: $269,500,000.00 ACRN CLIN/SLIN CIN AMOUNT AA 0001AA GFEBS001153469300001 $183,750,000.00 0001AC GFEBS001153469300003 $367,500,000.00 0001AD GFEBS001153469300004 $404,250,000.00 AB 0001AB GFEBS001153469300002 $269,500,000.00 CLAUSES INCORPORATED BY REFERENCE 252.204-7006 Billing Instructions OCT 2005 252.232-7003 Electronic Submission of Payment Requests and Receiving DEC 2018 Reports CLAUSES INCORPORATED BY FULL TEXT 252.232-7006 WIDE AREA WORKFLOW PAYMENT INSTRUCTIONS (DEC 2018) (a) Definitions. As used in this clause— “Department of Defense Activity Address Code (DoDAAC)” is a six position code that uniquely identifies a unit, activity, or organization. “Document type” means the type of payment request or receiving report available for creation in Wide Area WorkFlow (WAWF). “Local processing office (LPO)” is the office responsible for payment certification when payment certification is done external to the entitlement system. “Payment request” and “receiving report” are defined in the clause at 252.232-7003, Electronic Submission of Payment Requests and Receiving Reports. (b) Electronic invoicing. The WAWF system provides the method to electronically process vendor payment requests and receiving reports, as authorized by Defense Federal Acquisition Regulation Supplement (DFARS) 252.232- 7003, Electronic Submission of Payment Requests and Receiving Reports. (c) WAWF access. To access WAWF, the Contractor shall—

W911QY20C0100 Page 35 of 53 (1) Have a designated electronic business point of contact in the System for Award Management at https://www.sam.gov; and (2) Be registered to use WAWF at https://wawf.eb.mil/ following the step-by-step procedures for self-registration available at this web site. (d) WAWF training. The Contractor should follow the training instructions of the WAWF Web-Based Training Course and use the Practice Training Site before submitting payment requests through WAWF. Both can be accessed by selecting the “Web Based Training” link on the WAWF home page at https://wawf.eb.mil/. (e) WAWF methods of document submission. Document submissions may be via web entry, Electronic Data Interchange, or File Transfer Protocol. (f) WAWF payment instructions. The Contractor shall use the following information when submitting payment requests and receiving reports in WAWF for this contract or task or delivery order: (1) Document type. The Contractor shall submit payment requests using the following document type(s): COMBO (ii) For fixed price line items— (A) That require shipment of a deliverable, submit the invoice and receiving report specified by the Contracting Officer. Invoice and receiving report document type (B) For services that do not require shipment of a deliverable, submit either the Invoice 2in1, which meets the requirements for the invoice and receiving report, or the applicable invoice and receiving report, as specified by the Contracting Officer. N/A (iii) For customary progress payments based on costs incurred, submit a progress payment request. (iv) For performance based payments, submit a performance based payment request. (v) For commercial item financing, submit a commercial item financing request. (2) Fast Pay requests are only permitted when Federal Acquisition Regulation (FAR) 52.213-1 is included in the contract. (3) Document routing. The Contractor shall use the information in the Routing Data Table below only to fill in applicable fields in WAWF when creating payment requests and receiving reports in the system. Routing Data Table Field Name in WAWF Data to be entered in WAWF Pay Official DoDAAC HQ0337 Issue By DoDAAC W911QY Admin DoDAAC** S2206A

W911QY20C0100 Page 36 of 53 Inspect By DoDAAC S2206A / BARDA Acceptor W911QY Ship To TDB (4) Payment request. The Contractor shall ensure a payment request includes documentation appropriate to the type of payment request in accordance with the payment clause, contract financing clause, or Federal Acquisition Regulation 52.216-7, Allowable Cost and Payment, as applicable. (5) Receiving report. The Contractor shall ensure a receiving report meets the requirements of DFARS Appendix F. (g) WAWF point of contact. (1) The Contractor may obtain clarification regarding invoicing in WAWF from the following contracting activity’s WAWF point of contact. [***] / DCMA Boston-AFAW, Administrative Contracting Officer / [***] (2) Contact the WAWF helpdesk at [***], if assistance is needed. (End of clause) FOR REFERANCE: DFARS PGI 204.7108 Payment Instructions Table https://www.acq.osd.mil/dpap/dars/pgi/pgi_htm/current/PGI204_71.htm#payment_instructions G.1 GOVERNMENT CONTRACT ADMINISTRATION In no event shall any understanding or agreement, contract modification, change order, or other matter in deviation from the terms of this contract between the Contractor and a person other than the Contracting Officer be effective or binding upon the Government. All such actions must be formalized by a proper contractual document executed by the Contracting Officer. Procuring Contracting Officer: [***] Bldg. 1, General Green Avenue Natick, MA 017650-5011 Contract Specialist:

W911QY20C0100 Page 37 of 53 [***] Bldg. 1, General Green Avenue Natick, MA 017650-5011 G.2 GOVERNMENT TECHNICAL POINT OF CONTACT [***] Biologist/Project Officer 200 C Street, NW Washington, DC 20201 G.3 CONTRACTOR’S CONTRACT ADMINISTRATION [***] ModernaTX, Inc. 200 Technology SQ. Cambridge, MA 02139-3578 G.4 PLACES OF PERFORMANCE ModernaTX, Inc. 200 Technology SQ. Cambridge, MA 02139-3578 G.5 NOTIFICATION OF REVISIONS AND CHANGE Notification of revision or changes to names or email addresses will be provided by official correspondence from the PCO/ACO or office of the PCO/ACO in lieu of a contract modification. This does not apply to any such revisions or changes in the event this contract includes a key personnel clause. G.6 PERFORMANCE BASED PAYMENT Performance-based payments (PBP) are authorized under this contract in accordance with FAR 52.232-32. The contractor shall bill for the PBP upon achievement of the completion criteria identified in Attachment 0008, Performance-based Payment Milestone Table. Upon achievement of the completion criteria, the contractor shall bill for the PBP for the base and each option IAW the following schedule: CLIN PERIOD AMOUNT 0001AA BASE $ 90,210,000 0001AA BASE $ 132,308,000 0001AA BASE $ 180,420,000 0001AA BASE $ 198,462,000 TOTAL $ 601,400,000 [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]

W911QY20C0100 Page 38 of 53 [***] [***] [***] [***] [***] Delivery Invoicing: PBPs are a type of contract financing and are recouped by the Government through deductions of payments otherwise due to the contractor for the partial or complete delivery of contract items. The deductions are made by applying a liquidation rate to the price of delivered contract items. Attachment 0009, Performance- based Payment Milestone Billing Plan, identifies the contractor invoicing schedule for liquidation. The contractor shall submit all invoices IAW Attachment 0009.

W911QY20C0100 Page 39 of 53 Section H - Special Contract Requirements H.1 Key Personnel Any key personnel specified in this contract are considered to be essential to work performance. At least thirty (30) calendar days prior to the Contractor voluntarily diverting any of the specified individuals to other programs or contracts the Contractor shall notify the Contracting Officer and shall submit a justification for the diversion or replacement and a request to replace the individual. The request must identify the proposed replacement and provide an explanation of how the replacement's skills, experience, and credentials meet or exceed the requirements of the contract (including, when applicable, Human Subjects Testing requirements). If the employee of the Contractor is terminated for cause or separates from the Contractor voluntarily with less than thirty (30) calendar-day notice, the Contractor shall provide the maximum notice practicable under the circumstances. The Contractor shall not divert, replace, or announce any such change to key personnel without the written consent of the Contracting Officer. The contract will be modified to add or delete key personnel as necessary to reflect the agreement of the parties. The following individuals are determined to be key personnel: Name Title [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] H.2 Substitution of Key Personnel The Contractor agrees to assign to the contract those persons whose resumes/CVs were submitted with the proposal who are necessary to fill the requirements of the contract. No substitutions shall be made except in accordance with this clause. All requests for substitution must provide a detailed explanation of the circumstance necessitating the proposed substitution, a complete resume for the proposed substitute and any other information requested by the contracting officer to approve or disapprove the proposed substitution. All proposed substitutes must have qualifications that are equal to or higher than the qualifications of the person to be replaced. The contracting officer or authorized representative will evaluate such requests and promptly notify the contractor of his approval or disapproval thereof. H.3 Disclosure of Information: Performance under this contract may require the Contractor to access non-public data and information proprietary to a Government agency, another Government Contractor or of such nature that its dissemination or use other than as specified in the work statement would be adverse to the interests of the Government or others. Neither the Contractor, nor Contractor personnel, shall divulge nor release data nor information developed or obtained under performance of this contract, except authorized by Government personnel or upon written approval of the CO which the KO will provide in accordance with OWS or other Government policies and/or guidance. The Contractor shall not use, disclose, or reproduce proprietary data that bears a restrictive legend, other than as specified in this contract, or any information at all regarding this agency. The Contractor shall comply with all applicable Government requirements for protection of non-public information. Unauthorized disclosure of nonpublic information is prohibited by the Government’s rules. Unauthorized disclosure may result in termination of the contract, replacement of a Contractor employee, or other appropriate redress. Neither the Contractor nor the Contractor‘s employees shall disclose or cause to be disseminated, any information concerning the operations of the activity, which could result in, or increase the likelihood of, the possibility of a breach of the activity‘s security or interrupt the continuity of its operations.

W911QY20C0100 Page 40 of 53 No information related to data obtained under this contract shall be released or publicized without the prior written consent of the COR, whose approval shall not be unreasonably withheld, conditioned, or delayed, provided that no such consent is required to comply with any law, rule, regulation, court ruling or similar order; for submission to any government entity’ for submission to any securities exchange on which the Contractor’s (or its parent corporation’s) securities may be listed for trading; or to third parties relating to securing, seeking, establishing or maintaining regulatory or other legal approvals or compliance, financing and capital raising activities, or mergers, acquisitions, or other business transactions. The exceptions identified in this paragraph apply to all disclosures under this Section H.3 except to the extent that a disclosure is otherwise prohibited by law. H.4 Publication and Publicity The contractor shall not release any reports, manuscripts, press releases, or abstracts about the work being performed under this contract without written notice in advance to the Government. (a) Unless otherwise specified in this contract, the contractor may publish the results of its work under this contract. The contractor shall promptly send a copy of each submission to the COR for security review prior to submission. The contractor shall also inform the COR when the abstract article or other publication is published, and furnish a copy of it as finally published. (b) Unless authorized in writing by the CO, the contractor shall not display the DoD logo including Operating Division or Staff Division logos on any publications. (c) The contractor shall not reference the products(s) or services(s) awarded under this contract in commercial advertising, as defined in FAR 31.205-1, in any manner which states or implies DoD approval or endorsement of the product(s) or service(s) provided. (d) The contractor shall include this clause, including this section (d) in all subcontracts where the subcontractor may propose publishing the results of its work under the subcontract. The contractor shall acknowledge the support of the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority whenever publicizing the work under this contract in any media by including an acknowledgement substantially as follows: "This project has been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract Number W911QY-20-C-0100.” H.5 Confidentiality of Information a. Confidential information, as used in this article, means non-public information or data of a personal nature about an individual, or proprietary information or data submitted by or pertaining to an institution or organization. b. The Contracting Officer and the Contractor may, by mutual consent, identify elsewhere in this contract specific information and/or categories of information which the Government will furnish to the Contractor or that the Contractor is expected to generate which is confidential. Similarly, the Contracting Officer and the Contractor may, by mutual consent, identify such confidential information from time to time during the performance of the contract. Failure to agree will be settled pursuant to the "Disputes" clause. c. If it is established elsewhere in this contract that information to be utilized under this contract, or a portion thereof, is subject to the Privacy Act, the Contractor will follow the rules and procedures of disclosure set forth in the Privacy Act of 1974, 5 U.S.C. 552a, and implementing regulations and policies, with respect to systems of records determined to be subject to the Privacy Act. d. Confidential information, as defined in paragraph (a) of this article, shall not be disclosed without the prior written consent of the individual, institution, or organization.

W911QY20C0100 Page 41 of 53 e. Whenever the Contractor is uncertain with regard to the proper handling of material under the contract, or if the material in question is subject to the Privacy Act or is confidential information subject to the provisions of this article, the Contractor shall obtain a written determination from the Contracting Officer prior to any release, disclosure, dissemination, or publication. f. Contracting Officer Determinations will reflect the result of internal coordination with appropriate program and legal officials. g. The provisions of paragraph (d) of this article shall not apply to conflicting or overlapping provisions in other Federal, State or local laws. ALL REQUIREMENTS OF THIS SECTION H.5 MUST BE PASSED TO ALL SUB-CONTRACTOR. H.6 Regulatory Rights This contract involves supply of a product that requires FDA pre-market approval or clearance before commercial authorization. Contractor is seeking FDA authorization or clearance for the commercialization of mRNA-1273, Moderna vaccine for SARS-CoV-2 Coronavirus (the “Technology”). The Contractor is the Sponsor of the Regulatory Application (an investigational new drug application (IND), investigational device exemption (IDE), emergency use authorization (EUA), new drug application (NDA), biologics license application (BLA), premarket approval application (PMA), or 510(k) pre-market notification filing (510(k)) or another regulatory filing submitted to FDA) for the technology. As the Sponsor of the Regulatory Application to FDA (as the terms “sponsor” and “applicant” are defined or used in at 21 CFR §§3.2(c), 312.5, 600.3(t), 812.2(b), 812 Subpart C, or 814.20), the Contractor has certain standing before the FDA that entitles it to exclusive communications related to the Regulatory Application. Accordingly, the Contractor and the Government agree to the following: a. DoD Medical Product Priority. PL 115-92 allows the DoD to request, and FDA to provide, assistance to expedite development of products to diagnose, treat, or prevent serious or life-threatening diseases or conditions facing American military personnel. The contractor recognizes that only the DoD can utilize PL 115-92. As such, the contractor will work proactively with the Government to leverage this law to its maximum potential under this contract. The contractor shall submit Public Law 115-92 Sponsor Authorization Letter that will be delivered to the designated OWS POC(s) within 30 days of award. [***] H.7 Performance Based Payment Liquidated under Termination

W911QY20C0100 Page 42 of 53 Performance Based Payments (PBPs) have been authorized as a method of financing under this contract. In the event the Moderna’s mRNA-1273 COVID Vaccine is unsuccessful in its bid to obtain EUA or FDA approval, the Government may issue a Termination for Convenience (T4C) in whole or in part, on this contract. Upon notice of a T4C, the contractor shall submit a termination settlement proposal, IAW FAR 52.249-2, Termination for Convenience of the Government (Fixed-Price). H.8 Public Readiness and Emergency Preparedness (PREP) Act: In accordance with the Public Readiness and Emergency Preparedness Act (“PREP Act”), Pub. L. No. 109-148, Division C, Section 2, as amended (codified at 42 U.S.C. § 247d-6d and 42 U.S.C. § 247d-6e), as well as the Secretary of HHS’s Declaration Under the Public Readiness and Emergency Preparedness Act for Medical Countermeasures Against COVID-19, 85 Fed. Reg. 15198 (Mar. 17, 2020, effective Feb. 4, 2020), and amended on April 15, 2020, 85 Fed. Reg. 21012 (together, the “Prep Act Declaration”): (i) This Agreement is being entered into for purposes of facilitating the manufacture, testing, development, distribution, administration, and use of “Covered Countermeasures” for responding to the COVID-19 public health emergency, in accordance with Section VI of the PREP Act Declaration; (ii) Contractor’s performance of this Agreement falls within the scope of the “Recommended Activities” for responding to the COVID-19 public health emergency, to the extent it is in accordance with Section III of the PREP Act Declaration; and (iii) Contractor is a “Covered Person” to the extent it is a person defined in Section V of the PREP Act Declaration. Therefore, in accordance with Sections IV and VII of the PREP Act Declaration as well as the PREP Act (42 U.S.C. § 247d-6d), the Department of Defense contracting via assisted acquisition on behalf of the HHS, expressly acknowledges and agrees that the HHS Declaration cited above, specifically its language providing immunity from suit and liability is applicable to this acquisition as long as Contractors activities fall within the terms and conditions of the PREP Act and the PREP Act Declaration. The Government may not use, or authorize the use of, any products or materials provided under this contract, unless such use occurs in the United States (or a U.S. territory where U.S. law applies such as embassies, military and NATO installations) and is protected from liability under a declaration issued under the PREP Act, or a successor COVID-19 PREP Act Declaration of equal or greater scope. Any use where the application of the PREP Act is in question will be discussed with Moderna prior to use and, if the parties disagree on such use, the dispute will be resolved according to the “Disputes Clause” (52.233-1) The items and technology covered by this Contract are being developed for both civil and military applications. [***]

W911QY20C0100 Page 43 of 53 H.10 Ensuring Sufficient Supply of the Product 1. In recognition of the Government’s significant funding for the development and manufacturing of the product in this contract and the Government’s need to provide sufficient quantities of a COVID-19 vaccine to protect the United States population, the Government shall have the remedy described in this section to ensure sufficient supply of the product to meet the needs of the public health or national security. This remedy is not available to the Government unless and until both of the following conditions ((a) and (b)) are met: a. Moderna gives written notice, required to be submitted to the Government no later than [***], of: i. any formal management decision to terminate manufacturing of this product vaccine prior to delivery of any doses to USG under this contract, including all exercised options, other than as a result of clinical failure, or serious technical or safety reasons or; ii. any formal management decision to discontinue sale of this product vaccine to the Government prior to delivery of any doses to USG under this contract, including all exercised options, other than as a result of clinical failure, or serious technical or safety reasons; or iii. any filing that anticipates Federal bankruptcy protection; and b. Moderna has submitted an Emergency Use Authorization application under §564 of the FD&C Act or a biologics license application provisions of §351(a) of the Public Health Service Act (PHSA). 2. If both conditions listed in section 1 occur, Moderna, upon the request of the Government, shall provide the following items necessary for the Government to pursue manufacturing of this product vaccine with a third party for exclusive sale to the U.S. Government: a. a writing evidencing a non-exclusive, nontransferable, irrevocable (except for cause), royalty-free paid-up license to practice or have practiced for or on behalf of the U.S. Government any Moderna Background Patent, Copyright, other Moderna Intellectual Property, Moderna Know-How, Moderna Technical Data rights necessary to manufacture doses of the mRNA-1273 vaccine; b. necessary FDA regulatory filings or authorizations owned or controlled by Moderna related to this product vaccine and any confirmatory instrument pertaining thereto; and c. any outstanding Deliverables contemplated or materials purchased under this contract. 3. This remedy will remain available until the end of the contract. [***]

W911QY20C0100 Page 44 of 53 H.12 Transportation to Final Destination During the course of performance under this contract, the Government may require storage of the filled drug product (FDP) before delivery to the final government location. In these circumstances, the Government will accept FDP at the contractor facility (Origin). The contractor; however, shall continue to be responsible for secure delivery of the vaccine to its final destination as identified on this contract. [***]. H.13 Validation of IP/Data The Parties acknowledge that background intellectual property and technical data assertions have been made and evaluated by the parties. The parties agree that, should additional information relevant to these assertions become available, the parties will reevaluate said assertions as necessary in the future. H.14 Novation Upon Moderna, US, Inc.'s registration in the System for Award Management, the Government will, at the Contractor's request, complete a novation of this Contract to recognize Moderna US, Inc. as a counterparty instead of Moderna TX, Inc. This novation will be completed through a modification executed by the Government that identifies Moderna US, Inc. as the contracting party for all purposes as if it had originally executed the Contract.

W911QY20C0100 Page 45 of 53 Section I - Contract Clauses CLAUSES INCORPORATED BY REFERENCE 52.202-1 Definitions JUN 2020 52.203-3 Gratuities APR 1984 52.203-5 Covenant Against Contingent Fees MAY 2014 52.203-6 Restrictions On Subcontractor Sales To The Government JUN 2020 52.203-7 Anti-Kickback Procedures JUN 2020 52.203-8 Cancellation, Rescission, and Recovery of Funds for Illegal or MAY 2014 Improper Activity 52.203-10 Price Or Fee Adjustment For Illegal Or Improper Activity MAY 2014 52.203-12 Limitation On Payments To Influence Certain Federal JUN 2020 Transactions 52.203-13 Contractor Code of Business Ethics and Conduct JUN 2020 52.203-17 Contractor Employee Whistleblower Rights and Requirement JUN 2020 To Inform Employees of Whistleblower Rights 52.204-1 Approval of Contract DEC 1989 52.204-4 Printed or Copied Double-Sided on Postconsumer Fiber MAY 2011 Content Paper 52.204-10 Reporting Executive Compensation and First-Tier JUN 2020 Subcontract Awards 52.204-13 System for Award Management Maintenance OCT 2018 52.204-18 Commercial and Government Entity Code Maintenance JUL 2016 52.204-19 Incorporation by Reference of Representations and DEC 2014 Certifications. 52.204-23 Prohibition on Contracting for Hardware, Software, and JUL 2018 Services Developed or Provided by Kaspersky Lab and Other Covered Entities. 52.204-25 Prohibition on Contracting for Certain Telecommunications AUG 2019 and Video Surveillance Services or Equipment. 52.209-6 Protecting the Government's Interest When Subcontracting JUN 2020 With Contractors Debarred, Suspended, or Proposed for Debarment 52.209-10 Prohibition on Contracting With Inverted Domestic NOV 2015 Corporations 52.210-1 Market Research JUN 2020 52.215-2 Audit and Records--Negotiation JUN 2020 52.215-8 Order of Precedence--Uniform Contract Format OCT 1997 52.215-11 Price Reduction for Defective Certified Cost or Pricing Data-- JUN 2020 Modifications 52.215-13 Subcontractor Certified Cost or Pricing Data--Modifications JUN 2020 52.215-14 Integrity of Unit Prices JUN 2020 52.215-15 Pension Adjustments and Asset Reversions OCT 2010 52.215-18 Reversion or Adjustment of Plans for Postretirement Benefits JUL 2005 (PRB) Other than Pensions 52.215-19 Notification of Ownership Changes OCT 1997 52.215-21 Requirements for Certified Cost or Pricing Data and Data JUN 2020 Other Than Certified Cost or Pricing Data -- Modifications 52.217-4 Evaluation Of Options Exercised At The Time Of Contract JUN 1988 Award 52.217-7 Option For Increased Quantity-Separately Priced Line Item MAR 1989 52.217-8 Option To Extend Services NOV 1999 52.219-8 Utilization of Small Business Concerns OCT 2018

W911QY20C0100 Page 46 of 53 52.219-28 Post-Award Small Business Program Rerepresentation MAY 2020 52.222-1 Notice To The Government Of Labor Disputes FEB 1997 52.222-3 Convict Labor JUN 2003 52.222-19 Child Labor -- Cooperation with Authorities and Remedies JAN 2020 52.222-21 Prohibition Of Segregated Facilities APR 2015 52.222-26 Equal Opportunity SEP 2016 52.222-35 Equal Opportunity for Veterans JUN 2020 52.222-36 Equal Opportunity for Workers with Disabilities JUN 2020 52.222-37 Employment Reports on Veterans JUN 2020 52.222-40 Notification of Employee Rights Under the National Labor DEC 2010 Relations Act 52.222-50 Combating Trafficking in Persons JAN 2019 52.222-54 Employment Eligibility Verification OCT 2015 52.223-6 Drug-Free Workplace MAY 2001 52.223-18 Encouraging Contractor Policies To Ban Text Messaging JUN 2020 While Driving 52.225-13 Restrictions on Certain Foreign Purchases JUN 2008 52.227-1 Authorization and Consent JUN 2020 52.227-1 Alt I Authorization And Consent (JUN 2020) - Alternate I APR 1984 52.227-2 Notice And Assistance Regarding Patent And Copyright JUN 2020 Infringement 52.227-11 Patent Rights--Ownership By The Contractor MAY 2014 52.232-9 Limitation On Withholding Of Payments APR 1984 52.232-17 Interest MAY 2014 52.232-23 Assignment Of Claims MAY 2014 52.232-25 Prompt Payment JAN 2017 52.232-33 Payment by Electronic Funds Transfer--System for Award OCT 2018 Management 52.232-39 Unenforceability of Unauthorized Obligations JUN 2013 52.232-40 Providing Accelerated Payments to Small Business DEC 2013 Subcontractors 52.233-1 Disputes MAY 2014 52.233-3 Protest After Award AUG 1996 52.233-4 Applicable Law for Breach of Contract Claim OCT 2004 52.242-13 Bankruptcy JUL 1995 52.243-1 Changes--Fixed Price AUG 1987 52.243-7 Notification Of Changes JAN 2017 52.244-5 Competition In Subcontracting DEC 1996 52.245-9 Use And Charges APR 2012 52.249-2 Termination For Convenience Of The Government (Fixed- APR 2012 Price) 52.249-8 Default (Fixed-Price Supply & Service) APR 1984 52.249-14 Excusable Delays APR 1984 252.203-7000 Requirements Relating to Compensation of Former DoD SEP 2011 Officials 252.203-7002 Requirement to Inform Employees of Whistleblower Rights SEP 2013 252.203-7003 Agency Office of the Inspector General AUG 2019 252.211-7003 Item Unique Identification and Valuation MAR 2016 252.222-7006 Restrictions on the Use of Mandatory Arbitration Agreements DEC 2010 252.225-7048 Export-Controlled Items JUN 2013 252.227-7013 Rights in Technical Data--Noncommercial Items FEB 2014 252.227-7014 Rights in Noncommercial Computer Software and FEB 2014 Noncommercial Computer Software Documentation 252.227-7016 Rights in Bid or Proposal Information JAN 2011

W911QY20C0100 Page 47 of 53 252.227-7017 Identification and Assertion of Use, Release, or Disclosure JAN 2011 Restrictions 252.227-7019 Validation of Asserted Restrictions--Computer Software SEP 2016 252.227-7028 Technical Data or Computer Software Previously Delivered JUN 1995 to the Government 252.227-7030 Technical Data--Withholding Of Payment MAR 2000 252.227-7037 Validation of Restrictive Markings on Technical Data SEP 2016 252.232-7007 Limitation Of Government's Obligation APR 2014 252.244-7000 Subcontracts for Commercial Items JUN 2013 CLAUSES INCORPORATED BY FULL TEXT 52.217-9 OPTION TO EXTEND THE TERM OF THE CONTRACT (MAR 2000) (a) The Government may extend the term of this contract by written notice to the Contractor within 5 days for; provided that the Government gives the Contractor a preliminary written notice of its intent to extend at least 30 days for Options 1 and 2, 60 days for Option 3 and 4 before the contract expires. The preliminary notice does not commit the Government to an extension. (b) If the Government exercises this option, the extended contract shall be considered to include this option clause. (c) The total duration of this contract, including the exercise of any options under this clause, shall not exceed 20 months. (End of clause) 52.232-32 PERFORMANCE-BASED PAYMENTS (APR 2012) (a) Amount of payments and limitations on payments. Subject to such other limitations and conditions as are specified in this contract and this clause, the amount of payments and limitations on payments shall be specified in the contract's description of the basis for payment. (b) Contractor request for performance-based payment. The Contractor may submit requests for payment of performance-based payments not more frequently than monthly, in a form and manner acceptable to the Contracting Officer. Unless otherwise authorized by the Contracting Officer, all performance-based payments in any period for which payment is being requested shall be included in a single request, appropriately itemized and totaled. The Contractor's request shall contain the information and certification detailed in paragraphs (l) and (m) of this clause. (c) Approval and payment of requests. (1) The Contractor shall not be entitled to payment of a request for performance-based payment prior to successful accomplishment of the event or performance criterion for which payment is requested. The Contracting Officer shall determine whether the event or performance criterion for which payment is requested has been successfully accomplished in accordance with the terms of the contract. The Contracting Officer may, at any time, require the Contractor to substantiate the successful performance of any event or performance criterion which has been or is represented as being payable. (2) A payment under this performance-based payment clause is a contract financing payment under the Prompt Payment clause of this contract and not subject to the interest penalty provisions of the Prompt Payment Act. The designated payment office will pay approved requests on the 30th day after receipt of the request for performance- based payment by the designated payment office. However, the designated payment office is not required to provide

W911QY20C0100 Page 48 of 53 payment if the Contracting Officer requires substantiation as provided in paragraph (c)(1) of this clause, or inquiries into the status of an event or performance criterion, or into any of the conditions listed in paragraph (e) of this clause, or into the Contractor certification. The payment period will not begin until the Contracting Officer approves the request. (3) The approval by the Contracting Officer of a request for performance-based payment does not constitute an acceptance by the Government and does not excuse the Contractor from performance of obligations under this contract. (d) Liquidation of performance-based payments. (1) Performance-based finance amounts paid prior to payment for delivery of an item shall be liquidated by deducting a percentage or a designated dollar amount from the delivery payment. If the performance-based finance payments are on a delivery item basis, the liquidation amount for each such line item shall be the percent of that delivery item price that was previously paid under performance-based finance payments or the designated dollar amount. If the performance-based finance payments are on a whole contract basis, liquidation shall be by either predesignated liquidation amounts or a liquidation percentage. (2) If at any time the amount of payments under this contract exceeds any limitation in this contract, the Contractor shall repay to the Government the excess. Unless otherwise determined by the Contracting Officer, such excess shall be credited as a reduction in the unliquidated performance-based payment balance(s), after adjustment of invoice payments and balances for any retroactive price adjustments. (e) Reduction or suspension of performance-based payments. The Contracting Officer may reduce or suspend performance-based payments, liquidate performance-based payments by deduction from any payment under the contract, or take a combination of these actions after finding upon substantial evidence any of the following conditions: (1) The Contractor failed to comply with any material requirement of this contract (which includes paragraphs (h) and (i) of this clause). (2) Performance of this contract is endangered by the Contractor's -- (i) Failure to make progress; or (ii) Unsatisfactory financial condition. (3) The Contractor is delinquent in payment of any subcontractor or supplier under this contract in the ordinary course of business. (f) Title. (1) Title to the property described in this paragraph (f) shall vest in the Government. Vestiture shall be immediately upon the date of the first performance-based payment under this contract, for property acquired or produced before that date. Otherwise, vestiture shall occur when the property is or should have been allocable or properly chargeable to this contract (2) "Property," as used in this clause, includes all of the following described items acquired or produced by the Contractor that are or should be allocable or properly chargeable to this contract under sound and generally accepted accounting principles and practices: (i) Parts, materials, inventories, and work in process; (ii) Special tooling and special test equipment to which the Government is to acquire title;

W911QY20C0100 Page 49 of 53 (iii) Nondurable (i.e., noncapital) tools, jigs, dies, fixtures, molds, patterns, taps, gauges, test equipment and other similar manufacturing aids, title to which would not be obtained as special tooling under subparagraph (f)(2)(ii) of this clause; and (iv) Drawings and technical data, to the extent the Contractor or subcontractors are required to deliver them to the Government by other clauses of this contract. (3) Although title to property is in the Government under this clause, other applicable clauses of this contract (e.g., the termination or clauses) shall determine the handling and disposition of the property. (4) The Contractor may sell any scrap resulting from production under this contract, without requesting the Contracting Officer's approval, provided that any significant reduction in the value of the property to which the Government has title under this clause is reported in writing to the Contracting Officer. (5) In order to acquire for its own use or dispose of property to which title is vested in the Government under this clause, the Contractor shall obtain the Contracting Officer's advance approval of the action and the terms. If approved, the basis for payment (the events or performance criteria) to which the property is related shall be deemed to be not in compliance with the terms of the contract and not payable (if the property is part of or needed for performance), and the Contractor shall refund the related performance-based payments in accordance with paragraph (d) of this clause. (6) When the Contractor completes all of the obligations under this contract, including liquidation of all performance-based payments, title shall vest in the Contractor for all property (or the proceeds thereof) not -- (i) Delivered to, and accepted by, the Government under this contract; or (ii) Incorporated in supplies delivered to, and accepted by, the Government under this contract and to which title is vested in the Government under this clause. (7) The terms of this contract concerning liability for Government-furnished property shall not apply to property to which the Government acquired title solely under this clause. (g) Risk of loss. Before delivery to and acceptance by the Government, the Contractor shall bear the risk of loss for property, the title to which vests in the Government under this clause, except to the extent the Government expressly assumes the risk. If any property is lost (see 45.101), the basis of payment (the events or performance criteria) to which the property is related shall be deemed to be not in compliance with the terms of the contract and not payable (if the property is part of or needed for performance), and the Contractor shall refund the related performance-based payments in accordance with paragraph (d) of this clause. (h) Records and controls. The Contractor shall maintain records and controls adequate for administration of this clause. The Contractor shall have no entitlement to performance-based payments during any time the Contractor's records or controls are determined by the Contracting Officer to be inadequate for administration of this clause. (i) Reports and Government access. The Contractor shall promptly furnish reports, certificates, financial statements, and other pertinent information requested by the Contracting Officer for the administration of this clause and to determine that an event or other criterion prompting a financing payment has been successfully accomplished. The Contractor shall give the Government reasonable opportunity to examine and verify the Contractor's records and to examine and verify the Contractor's performance of this contract for administration of this clause. (j) Special terms regarding default. If this contract is terminated under the Default clause, (1) the Contractor shall, on demand, repay to the Government the amount of unliquidated performance-based payments, and (2) title shall vest in the Contractor, on full liquidation of all performance-based payments, for all property for which

W911QY20C0100 Page 50 of 53 the Government elects not to require delivery under the Default clause of this contract. The Government shall be liable for no payment except as provided by the Default clause. (k) Reservation of rights. (1) No payment or vesting of title under this clause shall -- (i) Excuse the Contractor from performance of obligations under this contract; or (ii) Constitute a waiver of any of the rights or remedies of the parties under the contract. (2) The Government's rights and remedies under this clause -- (i) Shall not be exclusive, but rather shall be in addition to any other rights and remedies provided by law or this contract; and (ii) Shall not be affected by delayed, partial, or omitted exercise of any right, remedy, power, or privilege, nor shall such exercise or any single exercise preclude or impair any further exercise under this clause or the exercise of any other right, power, or privilege of the Government. (l) Content of Contractor's request for performance-based payment. The Contractor's request for performance-based payment shall contain the following: (1) The name and address of the Contractor; (2) The date of the request for performance-based payment; (3) The contract number and/or other identifier of the contract or order under which the request is made; (4) Such information and documentation as is required by the contract's description of the basis for payment; and (5) A certification by a Contractor official authorized to bind the Contractor, as specified in paragraph (m) of this clause. (m) Content of Contractor's certification. As required in paragraph (l)(5) of this clause, the Contractor shall make the following certification in each request for performance-based payment: I certify to the best of my knowledge and belief that -- (1) This request for performance-based payment is true and correct; this request (and attachments) has been prepared from the books and records of the Contractor, in accordance with the contract and the instructions of the Contracting Officer; (2) (Except as reported in writing on ), all payments to subcontractors and suppliers under this contract have been paid, or will be paid, currently, when due in the ordinary course of business; (3) There are no encumbrances (except as reported in writing on ) against the property acquired or produced for, and allocated or properly chargeable to, the contract which would affect or impair the Government's title; (4) There has been no materially adverse change in the financial condition of the Contractor since the submission by the Contractor to the Government of the most recent written information dated ; and (5) After the making of this requested performance-based payment, the amount of all payments for each deliverable item for which performance-based payments have been requested will not exceed any limitation in the contract, and

W911QY20C0100 Page 51 of 53 the amount of all payments under the contract will not exceed any limitation in the contract. (End of Clause) 52.252-2 CLAUSES INCORPORATED BY REFERENCE (FEB 1998) This contract incorporates one or more clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. Also, the full text of a clause may be accessed electronically at this/these address(es): https://www.acquisition.gov/content/regulations (End of clause) 52.252-6 AUTHORIZED DEVIATIONS IN CLAUSES (APR 1984) (a) The use in this solicitation or contract of any Federal Acquisition Regulation (48 CFR Chapter 1) clause with an authorized deviation is indicated by the addition of "(DEVIATION)" after the date of the clause. (b) The use in this solicitation or contract of any Defense Federal Acquisition Regulation Supplement (48 CFR Chapter 2) clause with an authorized deviation is indicated by the addition of "(DEVIATION)" after the name of the regulation. (End of clause)

W911QY20C0100 Page 52 of 53 Section J - List of Documents, Exhibits and Other Attachments Document Type Description Page # Date Exhibit A CDRLs 14 18 July 2020 Attachment 0001 Supply Chain Resiliency Plan for CDRL A010 2 23 July 2020 Attachment 0002 Security Plan 6 23 July 2020 Attachment 0003 Dose Tracking Template Draft Moderna Excel 15 July 2020 Attachment 0004 Data Rights 1 7 August 2020 Attachment 0005 [***] 1 7 August 2020 Attachment 0006 ModernaTx, Inc. Background Intellectual Property 2 6 August 2020 Attachment 0007 Performance Base Payment Milestone Schedule 1 7 August 2020 Attachment 0008 Performance Base Payment Milestone Billing Plan 15 7 August 2020 Exhibit A Contract Data Requirements List (CDRL) Data Item # Title of Data Item Subtitle Date A001 Quality Audit Finding and Response BARDA Audit Findings Report 18-Jul-20 Record (QAFRR) A002 Quality Audit Finding and Response FDA Audit Findings Report 18-Jul-20 Record (QAFRR) A003 Contractor Furnished Material (CFM) Monthly Inventory Report 18-Jul-20 Report A004 Quality Program Plan Quality Program Plan 18-Jul-20 A005 Task Directive Documentation Shipping Documentation - Finished 18-Jul-20 Drag Products (FDP) A006 Task Directive Documentation Expiring Item Report 18-Jul-20 A007 Contractor's Personnel Roster Key Personnel Listing 18-Jul-20 A008 Status Report Monthly Technical Progress Report 18-Jul-20 A009 Contract Summary Report Final Technical Report 18-Jul-20 A010 Supply Chain Risk Management Plan Supply Chain Resiliency Plan (SCRP) 18-Jul-20 A011 Contractor's Risk Management Plan Risk Management Plan (RMP) 18-Jul-20 A012 Research and Development of Vendor Managed Inventory Plan/SOP 18 Jul 20 Medical Products Regulated by the U.S. Food and Drug Administration A013 Internal Contractor Technical Data Manufacturing Reports and Dose 18-Jul-20 Tracking Projections/Actuals A014 Certificate of Compliance (Analysis) Product Acceptance Report 18-Jul-20 A015 N/A - - A016 Accident Incident Report Incident Report 18-Jul-20 A017 Internal Contractor Technical Data FDA Correspondence 18-Jul-20 Report A018 Acquisition Support Documentation Press Releases 18-Jul-20 A019 Contractor's Standard Operating Security Plan 18-Jul-20 Procedures A020 Conference Agenda Conference Agenda 18-Jul-20

W911QY20C0100 Page 53 of 53 A021 Report, Record of Meeting/Minutes Meeting Minutes 18-Jul-20 A022 Presentation Material Presentation Material 18-Jul-20 A023 N/A - - A024 Operations Security (OPSEC) Plan Operational Security (OPSEC) 18 Jul 20 SOP/Plan A025 Research and Development of Manufacturing Development Plan 18 Jul 20 Medical Products Regulated by the U.S. Food & Drug Administration (FDA)

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. Section J Title Description Page Date Exhibit A Contract Data Requirement List (CDRL) 15 18 July 2020 Attachment 0001 Supply Chain Resiliency Plan for CDRL A010 2 23 July 2020 Attachment 0002 Security Plan 6 23 July 2020 Attachment 0003 Dose Tracking Template Draft Moderna Excel 15 July 2020 Attachment 0004 Data Rights 2 7 August 2020 Attachment 0005 [***] 1 7 August 2020 Attachment 0006 ModernaTx, Inc. Background Intellectual 2 6 August 2020 Property Attachment 0007 Performance Based Payment 1 7 August 2020 Milestone Schedule Attachment 0008 Performance Based Payment Milestone 15 7 August 2020 Billing Plan W911QY-20-C-0100 Section J

Contract Data Requirements List (CDRLs) Exhibit A As of 18 July 2020

CONTRACT DATA REQUIREMENTS LIST Form Approved (2 Data Items) OMB No. 0704-0188 The public reporting burden for this collection of information is estimated to average 220 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Department of Defense, Executive Services Directorate (0704-0188). Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. Please do not return your form to the above organization. Send completed form to the Government Issuing Contracting Officer for the Contract/PR No. listed in Block E. A. CONTRACT LINE ITEM NO. B. EXHIBIT C. CATEGORY: 0002 A TDP_____ TM ____ Other General/Admin Data E. CONTRACT/PR NO. F. CONTRACTOR D. SYSTEM/ITEM LARGE SCALE PRODUCTION OF SARS-CoV-2 VACCINE W911QY-20-C-0100 Moderna TX, Inc. 1. DATA ITEM NO. 2. TITLE OF DATA ITEM 3. SUBTITLE 17. Price Group A001 Quality Audit Finding and Response Record (QAFRR) BARDA Audit Findings Report 4. AUTHORITY (Data Acquisition Document No.) 5. CONTRACT REFERENCE 6. REQUIRING OFFICE DI-SESS-81923 C.3.1.2.1, C.3.2.2.1, C.3.3.2.1 ASPR BARDA 12. DATE OF FIRST 18. Estimated 7. DD 250 REQ 10. FREQUENCY SUBMISSION 14. DISTRIBUTION Total Price N/A ASREQ 9. DIST Refer to Block 16 STATEMENT 13. DATE OF b. COPIES REQUIRED 8. APP CODE 11. AS OF DATE SUBSEQUENT C a. ADDRESSEE Final A 0 SUBMISSION Draft Refer to Block 16 Reg Repro 16. REMARKS ASPR BARDA* 1 1 0 4. The Data Item Description (DID) may be obtained from http://quicksearch.dla.mil/. The CCAP-SCN** LT 1 0 contractor shall detail the findings and corrective action(s). 8. The US Government (USG) will respond with comments or approval within 10 calendar days after receipt. 9. Distribution Statement C: Distribution authorized to U.S. Government agencies and their Contractors (Administrative or Operational Use). Determination made July 18, 2020. Distribution guidance is included in DoD Instruction 5230.24. 12. Submit within 10 business days of an Audit. 13. The contractor shall incorporate USG comments and provide a final report to the USG upon completion of corrective action. 14. Submit as an electronic file in Microsoft Office (i.e. Word, Excel, Power Point) via email to the BARDA representative: Marva Taylor ([***]) and the Contracting Officer** (KO), Danny Soto ([***]). LT: Letter of Transmittal (via email). 15. TOTAL → 2. TITLE OF DATA ITEM 1. DATA ITEM NO. 3. SUBTITLE Research and Development of Medical Products 17. Price Group A002 FDA Interactions and Inspections Documents Regulated by the U.S. Food & Drug Administration 4. AUTHORITY (Data Acquisition Document No.) 5. CONTRACT REFERENCE 6. REQUIRING OFFICE DI-TCSP-82040 (Tailored) C.3.1.2.2, C.3.2.2.2, C.3.3.2.2 ASPR BARDA 12. DATE OF FIRST 18. Estimated 7. DD 250 REQ 10. FREQUENCY SUBMISSION 14. DISTRIBUTION Total Price N/A ASREQ 9. DIST Refer to Block 16 STATEMENT 13. DATE OF b. COPIES REQUIRED 8. APP CODE 11. AS OF DATE SUBSEQUENT C a. ADDRESSEE Final A 0 SUBMISSION Draft Refer to Block 16 Reg Repro 16. REMARKS ASPR BARDA* 1 1 0 4. The Data Item Description (DID) may be obtained from http://quicksearch.dla.mil/. The CCAP-SCN** 1 1 0 contractor shall detail the findings and corrective action(s). 8. The US Government (USG) will respond with comments or approval within 10 calendar days after receipt. 9. Distribution Statement C: Distribution authorized to U.S. Government agencies and their Contractors (Administrative or Operational Use). Determination made July 18, 2020. Distribution guidance is included in DoD Instruction 5230.24. 12. Submit within 10 business days of an Audit. 13. The contractor shall incorporate USG comments and provide a final report to the USG upon completion of corrective action. 14. Submit as an electronic file in Microsoft Office (i.e. Word, Excel, Power Point) via email to the BARDA representative: Marva Taylor ([***]) and the Contracting Officer** (KO), Danny Soto ([***]). LT: Letter of Transmittal (via email). 15. TOTAL → 2 2 0 G. PREPARED BY H. DATE I. APPROVED BY J. DATE Pamela Serra July 18, 2020 Marva Taylor July 18, 2020

CONTRACT DATA REQUIREMENTS LIST Form Approved (2 Data Items) OMB No. 0704-0188 The public reporting burden for this collection of information is estimated to average 220 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Department of Defense, Executive Services Directorate (0704-0188). Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. Please do not return your form to the above organization. Send completed form to the Government Issuing Contracting Officer for the Contract/PR No. listed in Block E. A. CONTRACT LINE ITEM NO. B. EXHIBIT C. CATEGORY: 0002 A TDP_____ TM ____ Other General/Admin Data D. SYSTEM/ITEM E. CONTRACT/PR NO. F. CONTRACTOR LARGE SCALE PRODUCTION OF SARS-CoV-2 W911QY-20-C-0100 Moderna TX, Inc. VACCINE 1. DATA ITEM NO. 2. TITLE OF DATA ITEM 3. SUBTITLE 17. Price Group A003 Contractor Furnished Material (CFM) Report Monthly Inventory Report 4. AUTHORITY (Data Acquisition Document No.) 5. CONTRACT REFERENCE 6. REQUIRING OFFICE 18. Estimated DI-MGMT-82049 C.4.1 ASPR BARDA Total Price 7. DD 250 REQ 9. DIST STATEMENT 10. FREQUENCY 12. DATE OF FIRST 14. DISTRIBUTION NO REQUIRED MTHLY SUBMISSION C Refer to Block 16 8. APP CODE 11. AS OF DATE 13. DATE OF b. COPIES NA N SUBSEQUENT a. ADDRESSEE Final SUBMISSION Draft Refer to Block 16 Reg Repro 16. REMARKS ASPR BARDA* 1 1 0 4. The Data Item Description (DID) may be obtained from http://quicksearch.dla.mil/. The CCAP-SCN** 0 LT 0 contractor shall detail the findings and corrective action(s). 8. The US Government (USG) will respond with comments or approval within 10 calendar days after receipt. 9. Distribution Statement C: Distribution authorized to U.S. Government agencies and their Contractors (Administrative or Operational Use). Determination made July 18, 2020. Distribution guidance is included in DoD Instruction 5230.24. 12. Submit within 10 business days of an Audit. 13. The contractor shall incorporate USG comments and provide a final report to the USG upon completion of corrective action. 14. Submit as an electronic file in Microsoft Office (i.e. Word, Excel, Power Point) via email to the BARDA representative: Marva Taylor ([***]) and the Contracting Officer** (KO), Danny Soto ([***]). LT: Letter of Transmittal (via email). 15. TOTAL → 1 1 0 1. DATA ITEM NO. 2. TITLE OF DATA ITEM 3. SUBTITLE 17. Price Group A004 Research and Development of Medical Products Quality Management Plan Regulated by the U.S. Food & Drug Administration 4. AUTHORITY (Data Acquisition Document No.) 5. CONTRACT REFERENCE 6. REQUIRING OFFICE 18. Estimated DI-TCSP-82040 (Tailored) C.4.18 ASPR BARDA Total Price 7. DD 250 REQ 9. DIST STATEMENT 10. FREQUENCY 12. DATE OF FIRST 14. DISTRIBUTION N/A REQUIRED ASREQ SUBMISSION C Refer to Block 16 8. APP CODE 11. AS OF DATE 13. DATE OF b. COPIES A 0 SUBSEQUENT Final a. ADDRESSEE SUBMISSION Draft Re Repro Refer to Block 16 g 16. REMARKS ASPR BARDA* 1 1 0 4. The Data Item Description (DID) may be obtained from http://quicksearch.dla.mil/. Page 10, CCAP-SCN** LT LT 0 paragraph f.(2) applies. 8. The US Government (USG) will respond with comments or approval within 10 calendar days after receipt. 9. Distribution Statement C: Distribution authorized to U.S. Government agencies and their Contractors (Administrative or Operational Use). Determination made July 18, 2020. Distribution guidance is included in DoD Instruction 5230.24. 12. Submit within 30 calendar days after contract award. 13. The contractor shall incorporate USG comments and resubmit within 10 calendar days after receipt. 14. Submit as an electronic file in Microsoft Office (i.e. Word, Excel, Power Point) via email to the BARDA representative: Marva Taylor ([***]) and the Contracting Officer** (KO), Danny Soto ([***]). LT: Letter of Transmittal (via email). 15. TOTAL → 1 1 0 G. PREPARED BY H. DATE I. APPROVED BY J. DATE Pamela Serra July 18, 2020 Marva Taylor July 18, 2020

CONTRACT DATA REQUIREMENTS LIST Form Approved (1 Data Item) OMB No. 0704-0188 The public reporting burden for this collection of information is estimated to average 110 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0701-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. Please DO NOT RETURN your form to the above address. Send completed form to the Government Issuing Contracting Officer for the Contract/PR No. listed in Block E. A. CONTRACT LINE ITEM NO. B. EXHIBIT C. CATEGORY: 0002 A TDP_____ TM ____ Other General/Admin Data D. SYSTEM/ITEM E. CONTRACT/PR NO. F. CONTRACTOR LARGE SCALE PRODUCTION OF SARS-CoV-2 W911QY-20-C-0100 Moderna TX, Inc. VACCINE 1. DATA ITEM NO. 2. TITLE OF DATA ITEM 3. SUBTITLE 17. Price Group A005 Research and Development of Medical Products Regulated by the Shipping Documentation-Finished Drug Product U.S. Food and Drug Administration (FDA) (FDP) 4. AUTHORITY (Data Acquisition Document No.) 5. CONTRACT REFERENCE 6. REQUIRING OFFICE 18. Estimated DI-TCSP-82040 C.4.3 ASPR BARDA Total Price 7. DD 250 REQ 9. DIST STATEMENT 10. FREQUENCY 12. DATE OF FIRST 14. DISTRIBUTION NA REQUIRED ASREQ SUBMISSION C Refer to Block 16 8. APP CODE 11. AS OF DATE 13. DATE OF b. COPIES A 0 SUBSEQUENT a. ADDRESSEE Final SUBMISSION Draft Refer to Block 16 Reg Repro 16. REMARKS ASPR BARDA* 1 1 0 4. The Data Item Description (DID) may be obtained from http://quicksearch.dla.mil/. Provide CCAP-SCN** LT LT 0 shipping document for all FDP transferring from the contractor’s facility to a USG facility. Provide the following information in order to coordinate the movement and delivery of vaccine product from manufacturing locations to USG distribution centers: -Points of Contact information (name, title, phone, email) for manufacturing / supply chain personnel for each manufacturing, CMO, storage and distribution locations: - Head of Manufacturing - Production Planning - Logistics - Distribution - Labeling – Provide vaccine labeling, packaging and distribution information as soon as it becomes available. At a minimum, include the following: a) Primary Container Information; b) Number of doses per primary container; c) Unit of Sale (carton, box, package, other); d) Quantity per Unit of Sale; National Drug Code (NDC) or NDC-like code under EUA; Unit of Sale dimensions (H,W,L); e) Unit of Sale weight; f) Intermediate Package; g) Intermediate Package dimensions; h) Intermediate Package weight; i) Quantity Unit of Sale per pallet; j) Storage Requirements; and k) Stability Information. Packaging List: Include the following DSCSA data elements, TI, TH and TS in packing lists. Include the contract number and CDC’s PO number (which BARDA will provide at the time the bulk order is submitted) on the packing list for all shipments. Include a copy of the MSDS (with QR code) in the packing list envelope with each shipment. Send EDI 856 Advanced Shipment Notice for all products shipped to a USG directed location. CDC will provide EDI mapping specifications that include the CDC generated PO number. Send electronic/scanned copies of all bulk shipment related documents to the COR for three-way matching on the day shipment occurs. 8. Shipping Process Demo: The US Government (USG) will respond within 15 calendar days with comments or approval. Subsequent submission (after USG approval of initial shipping process demo) within 1 calendar day after receipt of the FDP. 9. Distribution Statement C: Distribution authorized to U.S. Government agencies and their Contractors (Administrative or Operational Use). Determination made July 18, 2020. Distribution guidance is included in DoD Instruction 5230.24. 12. 1st Submittal (Demo): 30 calendar days prior to first shipment. Submit concurrent with each FDP delivery. 13. The contractor shall incorporate USG comments and resubmit to the USG within 1 calendar day after receipt. 14. Submit as an electronic file in Microsoft Office (i.e. Word, Excel, Power Point) or Adobe PDF via email to the BARDA representative: Marva Taylor ([***]) and the Contracting Officer** (KO), Danny Soto ([***]). LT: Letter of Transmittal (via email) 15. TOTAL → 1 1 0 G. PREPARED BY H. DATE I. APPROVED BY J. DATE Pamela Serra July 18, 2020 Marva Taylor July 18, 2020

CONTRACT DATA REQUIREMENTS LIST Form Approved (2 Data Items) OMB No. 0704-0188 The public reporting burden for this collection of information is estimated to average 220 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Department of Defense, Executive Services Directorate (0704-0188). Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. Please do not return your form to the above organization. Send completed form to the Government Issuing Contracting Officer for the Contract/PR No. listed in Block E. A. CONTRACT LINE ITEM NO. B. EXHIBIT C. CATEGORY: 0002 A TDP_____ TM ____ Other General/Admin Data D. SYSTEM/ITEM E. CONTRACT/PR NO. F. CONTRACTOR LARGE SCALE PRODUCTION OF SARS-CoV-2 W911QY-20-C-0100 Moderna TX, Inc. VACCINE 1. DATA ITEM NO. 2. TITLE OF DATA ITEM 3. SUBTITLE 17. Price Group A006 Task Directive Documentation Expiring Items Report 4. AUTHORITY (Data Acquisition Document No.) 5. CONTRACT REFERENCE 6. REQUIRING OFFICE 18. Estimated DI-SESS-82206 (Tailored) C.4.3 ASPR BARDA Total Price 7. DD 250 REQ 9. DIST STATEMENT 10. FREQUENCY 12. DATE OF FIRST NA REQUIRED ASREQ SUBMISSION 14. DISTRIBUTION C Refer to Block 16 8. APP CODE 11. AS OF DATE 13. DATE OF b. COPIES NO NA SUBSEQUENT a. ADDRESSEE Final SUBMISSION Draft Refer to Block 16 Reg Repro 16. REMARKS ASPR BARDA* 0 1 0 4. The Data Item Description (DID) may be obtained from http://quicksearch.dla.mil/. Only CCAP-SCN** 0 LT 0 paragraph cc applies. 9. Distribution Statement C: Distribution authorized to U.S. Government agencies and their Contractors (Administrative or Operational Use). Determination made July 18, 2020. Distribution guidance is included in DoD Instruction 5230.24. 12. & 13. Submit 30 calendar days prior to product expiration throughout contract period of performance. 14. Submit as an electronic file in Microsoft Office (i.e. Word, Excel, Power Point) via email to the BARDA representative: Marva Taylor ([***]) and the Contracting Officer** (KO), Danny Soto ([***]). LT: Letter of Transmittal (via email). 15. TOTAL → 0 1 0 1. DATA ITEM NO. 2. TITLE OF DATA ITEM 3. SUBTITLE 17. Price Group A007 Contractor’s Personnel Roster Key Personnel Listing 4. AUTHORITY (Data Acquisition Document No.) 5. CONTRACT REFERENCE 6. REQUIRING OFFICE 18. Estimated DI-MGMT-81834A C.4.5 ASPR BARDA Total Price 7. DD 250 REQ 9. DIST STATEMENT 10. FREQUENCY 12. DATE OF FIRST 14. DISTRIBUTION N/A REQUIRED ASREQ SUBMISSION C Refer to Block 16 8. APP CODE 11. AS OF DATE 13. DATE OF b. COPIES A 0 SUBSEQUENT Final a. ADDRESSEE SUBMISSION Draft Re Repro Refer to Block 16 g 16. REMARKS ASPR BARDA* 1 1 0 4. The Data Item Description (DID) may be obtained from http://quicksearch.dla.mil/. CCAP-SCN** 0 LT 0 8. The US Government (USG) will respond with comments or approval within 10 calendar days after receipt. 9. Distribution Statement C: Distribution authorized to U.S. Government agencies and their Contractors (Administrative or Operational Use). Determination made July 18, 2020. Distribution guidance is included in DoD Instruction 5230.24. 12. Submit with Technical Proposal. 13. The contractor shall incorporate USG comments and resubmit to the USG within 10 calendar days after receipt. Resubmit for any changes to key personnel. 14. Submit as an electronic file in Microsoft Office (i.e. Word, Excel, Power Point) via email to the BARDA representative: Marva Taylor ([***]) and the Contracting Officer** (KO), Danny Soto ([***]). LT: Letter of Transmittal (via email). 15. TOTAL → 1 1 0 G. PREPARED BY H. DATE I. APPROVED BY J. DATE Pamela Serra July 18, 2020 Marva Taylor July 18, 2020

CONTRACT DATA REQUIREMENTS LIST Form Approved (1 Data Item) OMB No. 0704-0188 The public reporting burden for this collection of information is estimated to average 110 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0701-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. Please DO NOT RETURN your form to the above address. Send completed form to the Government Issuing Contracting Officer for the Contract/PR No. listed in Block E. A. CONTRACT LINE ITEM NO. B. EXHIBIT C. CATEGORY: 0002 A TDP_____ TM ____ Other General/Admin Data D. SYSTEM/ITEM E. CONTRACT/PR NO. F. CONTRACTOR LARGE SCALE PRODUCTION OF SARS-CoV-2 W911QY-20-C-0100 Moderna TX, Inc. VACCINE 1. DATA ITEM NO. 2. TITLE OF DATA ITEM 3. SUBTITLE 17. Price Group A008 Status Report Monthly Technical Progress Report 4. AUTHORITY (Data Acquisition Document No.) 5. CONTRACT REFERENCE 6. REQUIRING OFFICE 18. Estimated DI-MGMT-80368A (Tailored) C.4.6 ASPR BARDA Total Price 7. DD 250 REQ 9. DIST STATEMENT 10. FREQUENCY 12. DATE OF FIRST 14. DISTRIBUTION NA REQUIRED MTHLY SUBMISSION C Refer to Block 16 8. APP CODE 11. AS OF DATE 13. DATE OF b. COPIES A 0 SUBSEQUENT a. ADDRESSEE Final SUBMISSION Draft Refer to Block 16 Reg Repro 16. REMARKS ASPR BARDA* 1 1 0 4. The DID may be obtained from http://quicksearch.dla.mil/. The Monthly Progress report shall address each of CCAP-SCN** 1 1 0 the below items and be cross-referenced to the Statement of Work (SOW), Product Delivery Table, and an Integrated Master Schedule (IMS), and detail the following: ● A cover page that includes the contract number and title; the type of report and period that it covers; the Contractor’s name, address, telephone number, fax number, and e-mail address; and the date of submission; ● SECTION I-EXECUTIVE SUMMARY ● SECTION II - PROGRESS ● SECTION II Part A: OVERALL PROGRESS - A description of overall progress. ● SECTION II part B: MANAGEMENT AND ADMINISTRATIVE UPDATE-A description of all meetings, conference calls, etc. that have taken place during the reporting period. Include progress on administration and management issues (e.g., evaluating, and managing subcontractor performance, and personnel changes). ● SECTION II Part C: TECHNICAL PROGRESS - For each activity related to Gantt chart, document the results of work completed and cost incurred during the period covered in relation to proposed progress, effort and budget. The report shall be in sufficient detail to explain comprehensively the results achieved. The description shall include pertinent data and/or graphs in sufficient detail to explain any significant results achieved and preliminary conclusions resulting from analysis and scientific evaluation of data accumulated to date under the contract. The report shall include a description of problems encountered and proposed corrective action; differences between planned and actual progress, why the differences have occurred and what corrective actions are planned; preliminary conclusions resulting from analysis and scientific evaluation of data accumulated to date under the project. ● SECTION II Part D: PROPOSED WORK - A summary of work proposed related to Gantt chart for the next reporting period and preprints/reprints of papers and abstracts. ● SECTION III: Estimated and Actual Expenses. a. This section of the report shall contain a narrative or table detailing whether there is a significant discrepancy (>10%) at this time between the % of work completed and the cumulative costs incurred to date. Monthly and actual expenses should be broken down to the appropriate WBS level. b. This section of the report should also contain estimates for the Subcontractors’ expenses from the previous month if the Subcontractor did not submit a bill in the previous month. If the subcontractor(s) was not working or did not incur any costs in the previous month, then a statement to this effect should be included in this report for those respective subcontractors. Additionally, the report shall detail the following: ● Storage/inventory of ancillary materials (vials, needles, syringes, etc.) ● Shipment and receipt of ancillary materials (vials, needles, syringes, etc.) ● Disposal of ancillary materials (vials, needles, syringes, etc.) ● Bulk drug substance production ● Fill, finish, and release of product ● Storage/inventory of starting materials, bulk substance, or filled/final product or adjuvant ● Stability information of intermediates, bulk substance and/or finished product ● Shipment of bulk substance of final product ● Disposition of bulk substance or final product ● Identify doses accepted by the Government in previous submissions 8. The USG will review the monthly reports with the Contractor and provided feedback with 10 calendar days after receipt. 9. Distribution Statement C: Distribution authorized to U.S. Government agencies and their Contractors (Administrative or Operational Use). Determination made July 18, 2020. Distribution guidance is included in DoD Instruction 5230.24. 12. Submit on the 20th day of the month covering the preceding month. (A Monthly progress report is not due required during the month when the Final Report )final version, not draft) is due (see CDRL A009) 13. The contractor shall incorporate USG comments and resubmit to the USG within 10 calendar days after receipt. Resubmit for any changes to key personnel. 14. Submit as an electronic file in Microsoft Office (i.e. Word, Excel, Power Point) via email to the BARDA representative: Marva Taylor ([***]) and the Contracting Officer** (KO), Danny Soto ([***]). LT: Letter of Transmittal (via email). 15. TOTAL → 2 2 0 G. PREPARED BY H. DATE I. APPROVED BY J. DATE Pamela Serra July 18, 2020 Marva Taylor July 18, 2020

CONTRACT DATA REQUIREMENTS LIST Form Approved (2 Data Items) OMB No. 0704-0188 The public reporting burden for this collection of information is estimated to average 220 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Department of Defense, Executive Services Directorate (0704-0188). Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. Please do not return your form to the above organization. Send completed form to the Government Issuing Contracting Officer for the Contract/PR No. listed in Block E. A. CONTRACT LINE ITEM NO. B. EXHIBIT C. CATEGORY: 0002 A TDP_____ TM ____ Other General/Admin Data D. SYSTEM/ITEM E. CONTRACT/PR NO. F. CONTRACTOR LARGE SCALE PRODUCTION OF SARS-CoV-2 VACCINE W911QY-20-C-0100 Moderna TX, Inc. 1. DATA ITEM NO. 2. TITLE OF DATA ITEM 3. SUBTITLE 17. Price Group A009 Contract Summary Report Final Technical Report 4. AUTHORITY (Data Acquisition Document No.) 5. CONTRACT REFERENCE 6. REQUIRING OFFICE 18. Estimated Total Price DI-ADMN-80447A C.4.7 ASPR BARDA 7. DD 250 REQ 9. DIST 10. FREQUENCY 12. DATE OF FIRST SUBMISSION 14. DISTRIBUTION N/A STATEMENT R/ASR Refer to Block 16 REQUIRED 8. APP CODE 11. AS OF DATE 13. DATE OF SUBSEQUENT b. COPIES C SUBMISSION a. ADDRESSEE Final A 0 Draft Refer to Block 16 Reg Repro 16. REMARKS ASPR BARDA* 1 1 0 4. The Data Item Description (DID) may be obtained from http://quicksearch.dla.mil/. The final report shall be marked as CCAP-SCN** 1 1 0 'Final’. A cover letter with the report shall contain a summary (not to exceed 200 words) of salient results achieved during the performance of the contract and be structured in the following format: Include the following: Identify doses accepted by the Government in previous submissions. a. Cover page to include the contract number, contract title, performance period covered, Contractor's name and address, telephone number, fax number, email address and submission date. b. SECTION I: EXECUTIVE SUMMARY - Summarize the purpose and scope of the contract effort including a summary of the major accomplishments relative to the specific activities set forth in the Statement of Work. c. SECTION II: RESULTS - A detailed description of the work performed related to WBS and Gantt chart, the results obtained, and the impact of the results on the scientific and/or public health community including a listing of all manuscripts (published and in preparation) and abstracts presented during the entire period of performance and a summary of all inventions. 8. The US Government (USG) will respond with comments or approval within 30 calendar days after receipt of first draft report and within 15 calendar days of second submission. 9. Distribution Statement C: Distribution authorized to U.S. Government agencies and their Contractors (Administrative or Operational Use). Determination made July 18, 2020. Distribution guidance is included in DoD Instruction 5230.24. 12. Submit Draft Report 75 calendar days prior to end of contract. Submit Final Report 30 calendar days after contract award. 13. The contractor shall incorporate USG comments and resubmit to the USG within 30 calendar days after receipt for first submission and within 10 calendars days after second submission. 14. Submit as an electronic file in Microsoft Office (i.e. Word, Excel, Power Point) via email to the BARDA representative: Marva Taylor ([***]) and the Contracting Officer** (KO), Danny Soto ([***]). LT: Letter of Transmittal (via email). 15. TOTAL → 2 2 0 1. DATA ITEM NO. 2. TITLE OF DATA ITEM 3. SUBTITLE 17. Price Group A010 Supply Chain Risk Management Plan Supply Chain Resiliency Plan (SCRP) 4. AUTHORITY (Data Acquisition Document No.) 5. CONTRACT REFERENCE 6. REQUIRING OFFICE 18. Estimated Total Price DI-MGMT-82256 C.4.8 ASPR BARDA 7. DD 250 REQ 9. DIST 10. FREQUENCY 12. DATE OF FIRST SUBMISSION 14. DISTRIBUTION N/A STATEMENT ASREQ Refer to Block 16 REQUIRED 8. APP CODE 11. AS OF DATE 13. DATE OF SUBSEQUENT b. COPIES C SUBMISSION a. ADDRESSEE Final A 0 Draft Refer to Block 16 Reg Repro ASPR BARDA* 1 1 0 16. REMARKS CCAP-SCN** LT LT 0 4. The Data Item Description (DID) may be obtained from http://quicksearch.dla.mil/. SPECIFIC CONTENT INSTRUCTIONS ARE PROVIDED AT ATTACHMENT 0001 TO THIS CDRL. 8. The US Government (USG) will respond with comments or approval within 10 calendar days after receipt. 9. Distribution Statement C: Distribution authorized to U.S. Government agencies and their Contractors (Administrative or Operational Use). Determination made July 18, 2020. Distribution guidance is included in DoD Instruction 5230.24. 12. Submit with 30 Calendar days after contract award. 13. The contractor shall incorporate USG comments and resubmit to the USG within 7 calendar days after receipt. Submit any and all proposed revisions to the Plan for USG approval 10 calendar days prior to implementation. 14. Submit as an electronic file in Microsoft Office (i.e. Word, Excel, Power Point) via email to the BARDA representative: Marva Taylor ([***]) and the Contracting Officer** (KO), Danny Soto ([***]). LT: Letter of Transmittal (via email). 15. TOTAL → 1 1 0 G. PREPARED BY H. DATE I. APPROVED BY J. DATE Pamela Serra July 18, 2020 Marva Taylor July 18, 2020

CONTRACT DATA REQUIREMENTS LIST Form Approved (2 Data Items) OMB No. 0704-0188 The public reporting burden for this collection of information is estimated to average 220 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Department of Defense, Executive Services Directorate (0704-0188). Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. Please do not return your form to the above organization. Send completed form to the Government Issuing Contracting Officer for the Contract/PR No. listed in Block E. A. CONTRACT LINE ITEM NO. B. EXHIBIT C. CATEGORY: 0002 A TDP_____ TM ____ Other General/Admin Data D. SYSTEM/ITEM E. CONTRACT/PR NO. F. CONTRACTOR LARGE SCALE PRODUCTION OF SARS-CoV-2 VACCINE W911QY-20-C-0100 Moderna TX, Inc. 1. DATA ITEM NO. 2. TITLE OF DATA ITEM 3. SUBTITLE 17. Price Group A011 Research and Development of Medical Products Risk Management Plan (RMP) Regulated by the U.S. Food and Drug Administration 4. AUTHORITY (Data Acquisition Document No.) 5. CONTRACT REFERENCE 6. REQUIRING OFFICE 18. Estimated Total Price DI-TCSP-82040 (Tailored) C.4.9 ASPR BARDA 7. DD 250 REQ 9. DIST 10. FREQUENCY 12. DATE OF FIRST SUBMISSION 14. DISTRIBUTION N/A STATEMENT R/ASR Refer to Block 16 REQUIRED 8. APP CODE 11. AS OF DATE 13. DATE OF SUBSEQUENT b. COPIES C SUBMISSION a. ADDRESSEE Final A 0 Draft Refer to Block 16 Reg Repro 16. REMARKS ASPR BARDA* 1 1 0 4. The Data Item Description (DID) may be obtained from http://quicksearch.dla.mil/. Page CCAP-SCN** 1 1 0 29, Paragraph (4) applies. 8. The US Government (USG) will respond with comments or approval within 7 calendar days after receipt. 9. Distribution Statement C: Distribution authorized to U.S. Government agencies and their Contractors (Administrative or Operational Use). Determination made July 18, 2020. Distribution guidance is included in DoD Instruction 5230.24. 12. Submit within XX calendar days after contract award. 13. The contractor shall incorporate USG comments and resubmit to the USG within 20 calendar days after receipt. Submit updates to the RMP concurrent with Monthly Progress Report. (CDRL A008). The contractor may choose to notify the USG up to two times every three months if there are no changes from the prior submission, and not submit an update. 14. Submit as an electronic file in Microsoft Office (i.e. Word, Excel, Power Point) via email to the BARDA representative: Marva Taylor ([***]) and the Contracting Officer** (KO), Danny Soto ([***]). LT: Letter of Transmittal (via email). 15. TOTAL → 2 2 0 2. TITLE OF DATA ITEM 17. Price Group 1. DATA ITEM NO. 3. SUBTITLE Research and Development of Medical Products A012 Vendor Managed Inventory Plan/SOP Regulated by the U.S. Food and Drug Administration 4. AUTHORITY (Data Acquisition Document No.) 5. CONTRACT REFERENCE 6. REQUIRING OFFICE 18. Estimated Total Price DI-TCSP-82040 (Tailored) C.7.1 ASPR BARDA 7. DD 250 REQ 9. DIST 10. FREQUENCY 12. DATE OF FIRST SUBMISSION 14. DISTRIBUTION N/A STATEMENT R/ASR Refer to Block 16 REQUIRED 8. APP CODE 11. AS OF DATE 13. DATE OF SUBSEQUENT b. COPIES C SUBMISSION a. ADDRESSEE Final A 0 Draft Refer to Block 16 Reg Repro 16. REMARKS ASPR BARDA* 1 1 0 4. The Data Item Description (DID) may be obtained from http://quicksearch.dla.mil/. CCAP-SCN** 1 1 0 Page 11, paragraph (13) applies and Page 29, Paragraph (4) applies. (Subparagraphs (a) through (c) do not apply.) 8. The US Government (USG) will respond with comments or approval within 7 calendar days after receipt. 9. Distribution Statement C: Distribution authorized to U.S. Government agencies and their Contractors (Administrative or Operational Use). Determination made July 18, 2020. Distribution guidance is included in DoD Instruction 5230.24. 12. Submit within 45 calendar days after contract award. 13. The contractor shall incorporate USG comments and resubmit to the USG within 20 calendar days after receipt. Resubmit for any changes to the USG-approved Plan/SOP. 14. Submit as an electronic file in Microsoft Office (i.e. Word, Excel, Power Point) via email to the BARDA representative: Marva Taylor ([***]) and the Contracting Officer** (KO), Danny Soto ([***]). LT: Letter of Transmittal (via email). 15. TOTAL → 2 2 0 G. PREPARED BY H. DATE I. APPROVED BY J. DATE Pamela Serra July 18, 2020 Marva Taylor July 18, 2020

CONTRACT DATA REQUIREMENTS LIST Form Approved (2 Data Items) OMB No. 0704-0188 The public reporting burden for this collection of information is estimated to average 220 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Department of Defense, Executive Services Directorate (0704-0188). Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. Please do not return your form to the above organization. Send completed form to the Government Issuing Contracting Officer for the Contract/PR No. listed in Block E. A. CONTRACT LINE ITEM NO. B. EXHIBIT C. CATEGORY: 0002 A TDP_____ TM ____ Other General/Admin Data D. SYSTEM/ITEM E. CONTRACT/PR NO. F. CONTRACTOR LARGE SCALE PRODUCTION OF SARS-CoV-2 VACCINE W911QY-20-C-0100 Moderna TX, Inc. 1. DATA ITEM NO. 2. TITLE OF DATA ITEM 3. SUBTITLE 17. Price Group A013 Research and Development of Medical Products Manufacturing Reports and Dose Tracking Regulated by the U.S. Food and Drug Administration Projections/Actuals 4. AUTHORITY (Data Acquisition Document No.) 5. CONTRACT REFERENCE 6. REQUIRING OFFICE 18. Estimated Total Price DI-SESS-81309 C.4.10 ASPR BARDA 7. DD 250 REQ 9. DIST 10. FREQUENCY 12. DATE OF FIRST SUBMISSION 14. DISTRIBUTION N/A STATEMENT ASREQ Refer to Block 16 REQUIRED 8. APP CODE 11. AS OF DATE 13. DATE OF SUBSEQUENT b. COPIES C SUBMISSION a. ADDRESSEE Final A N/A Draft Refer to Block 16 Reg Repro 16. REMARKS ASPR BARDA* 1 1 0 4. The Data Item Description (DID) may be obtained from http://quicksearch.dla.mil/. Pg. 10, CCAP-SCN** 1 LT 0 paragraph e applies. The contractor shall complete the Dose Tracking Template provided at Attachment 0003. 8. The US Government (USG) will respond with comments or approval within 15 business days after receipt. 9. Distribution Statement C: Distribution authorized to U.S. Government agencies and their Contractors (Administrative or Operational Use). Determination made July 18, 2020. Distribution guidance is included in DoD Instruction 5230.24. 12. Submit Manufacturing Reports 15 business days prior to FDA submission. Submit the Dose Tracking Template within 15 calendar days after contract award and daily thereafter. 13. The contractor shall incorporate USG comments and resubmit to the USG within 5 business days after receipt. 14. Submit as an electronic file in Microsoft Excel via email to the BARDA representative: Marva Taylor ([***]) and the Contracting Officer** (KO), Danny Soto ([***]). LT: Letter of Transmittal (via email). 15. TOTAL → 0 1 0 2. TITLE OF DATA ITEM 3. SUBTITLE 17. Price Group 1. DATA ITEM NO. Research and Development of Medical Products Product Acceptance Report and Certificates of A014 Regulated by the U.S. Food and Drug Administration Analyses/Compliance 4. AUTHORITY (Data Acquisition Document No.) 5. CONTRACT REFERENCE 6. REQUIRING OFFICE 18. Estimated Total Price DI-TCSP-82040 C.4.11 ASPR BARDA 7. DD 250 REQ 9. DIST 10. FREQUENCY 12. DATE OF FIRST SUBMISSION 14. DISTRIBUTION N/A STATEMENT ASREQ Refer to Block 16 REQUIRED 8. APP CODE 11. AS OF DATE 13. DATE OF SUBSEQUENT b. COPIES C SUBMISSION a. ADDRESSEE Final A N/A Draft Refer to Block 16 Reg Repro 16. REMARKS ASPR BARDA* 1 1 0 4. The Data Item Description (DID) may be obtained from http://quicksearch.dla.mil/. The CCAP-SCN** LT LT 0 contractor shall provide: pictures of the drug product with lot number, drug product lot tree, list of associated deviations (from drug substance and product), and a Certificate of Analysis/Compliance. 8. The US Government (USG) will respond with comments or approval within 5 calendar days after receipt. 9. Distribution Statement C: Distribution authorized to U.S. Government agencies and their Contractors (Administrative or Operational Use). Determination made July 18, 2020. Distribution guidance is included in DoD Instruction 5230.24. 12. Submit for each lot of FDP delivered. 13. The contractor shall incorporate USG comments and resubmit to the USG within 3 calendar days after receipt. 14. Submit as an electronic file in Microsoft Office (i.e. Word, Excel, Power Point) via email to the BARDA representative: Marva Taylor ([***]) and the Contracting Officer** (KO), Danny Soto ([***]). LT: Letter of Transmittal (via email). 15. TOTAL → 1 1 0 G. PREPARED BY H. DATE I. APPROVED BY J. DATE Pamela Serra July 18, 2020 Marva Taylor July 18, 2020

CONTRACT DATA REQUIREMENTS LIST Form Approved (2 Data Items) OMB No. 0704-0188 The public reporting burden for this collection of information is estimated to average 220 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Department of Defense, Executive Services Directorate (0704-0188). Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. Please do not return your form to the above organization. Send completed form to the Government Issuing Contracting Officer for the Contract/PR No. listed in Block E. A. CONTRACT LINE ITEM NO. B. EXHIBIT C. CATEGORY: 0002 A TDP_____ TM ____ Other General/Admin Data D. SYSTEM/ITEM E. CONTRACT/PR NO. F. CONTRACTOR LARGE SCALE PRODUCTION OF SARS-CoV-2 VACCINE W911QY-20-C-0100 Moderna TX, Inc. 1. DATA ITEM NO. 2. TITLE OF DATA ITEM 3. SUBTITLE 17. Price Group A017 Research and Development of Medical Products FDA Correspondence Regulated by the U.S. Food and Drug Administration 4. AUTHORITY (Data Acquisition Document No.) 5. CONTRACT REFERENCE 6. REQUIRING OFFICE 18. Estimated Total Price DI-TCSP-82040 (Tailored) C.4.13 ASPR BARDA 7. DD 250 REQ 9. DIST 10. FREQUENCY 12. DATE OF FIRST SUBMISSION 14. DISTRIBUTION N/A STATEMENT ASREQ Refer to Block 16 REQUIRED 8. APP CODE 11. AS OF DATE 13. DATE OF SUBSEQUENT b. COPIES C SUBMISSION a. ADDRESSEE Final A 0 Draft Refer to Block 16 Reg Repro 16. REMARKS ASPR BARDA* 0 1 0 4. The Data Item Description (DID) may be obtained from http://quicksearch.dla.mil/. CCAP-SCN** 0 LT 0 8. The US Government (USG) will respond with comments or approval within 10 business days after receipt. 9. Distribution Statement C: Distribution authorized to U.S. Government agencies and their Contractors (Administrative or Operational Use). Determination made July 18, 2020. Distribution guidance is included in DoD Instruction 5230.24. 12. Submit within 2 business days of receipt of FDA correspondence. 13. The contractor shall incorporate USG comments and resubmit concurrent with FDA submission or no later than 1 calendar day of its submission to FDA. 14. Submit as an electronic file in Microsoft Office (i.e. Word, Excel, Power Point) via email to the BARDA representative: Marva Taylor ([***]) and the Contracting Officer** (KO), Danny Soto ([***]). LT: Letter of Transmittal (via email). 15. TOTAL → 0 1 0 1. DATA ITEM NO. 2. TITLE OF DATA ITEM 3. SUBTITLE 17. Price Group A018 Acquisition Support Documentation Press Releases 4. AUTHORITY (Data Acquisition Document No.) 5. CONTRACT REFERENCE 6. REQUIRING OFFICE 18. Estimated Total Price DI-MGMT-81607 C.4.14 ASPR BARDA 7. DD 250 REQ 9. DIST 10. FREQUENCY 12. DATE OF FIRST SUBMISSION 14. DISTRIBUTION N/A STATEMENT ASREQ Refer to Block 16 REQUIRED 8. APP CODE 11. AS OF DATE 13. DATE OF SUBSEQUENT b. COPIES C SUBMISSION a. ADDRESSEE Final A 0 Draft Refer to Block 16 Reg Repro 16. REMARKS ASPR BARDA* 1 1 0 4. The Data Item Description (DID) may be obtained from http://quicksearch.dla.mil/. Only CCAP-SCN** LT LT 0 paragraphs 3.e, 3.f and 3.g apply. 9. Distribution Statement C: Distribution authorized to U.S. Government agencies and their Contractors (Administrative or Operational Use). Determination made July 18, 2020. Distribution guidance is included in DoD Instruction 5230.24. 12. Submit no less than 5 business days prior to the issuance of the press release. 13. Submit any final press releases no later than one (1) calendar day prior to its release. 14. Submit as an electronic file in Microsoft Office (i.e. Word, Excel, Power Point) via email to the BARDA representative: Marva Taylor ([***]) and the Contracting Officer** (KO), Danny Soto ([***]). LT: Letter of Transmittal (via email). 15. TOTAL → 1 1 0 G. PREPARED BY H. DATE I. APPROVED BY J. DATE Pamela Serra July 18, 2020 Marva Taylor July 18, 2020

CONTRACT DATA REQUIREMENTS LIST Form Approved (2 Data Items) OMB No. 0704-0188 The public reporting burden for this collection of information is estimated to average 220 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Department of Defense, Executive Services Directorate (0704-0188). Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. Please do not return your form to the above organization. Send completed form to the Government Issuing Contracting Officer for the Contract/PR No. listed in Block E. A. CONTRACT LINE ITEM NO. B. EXHIBIT C. CATEGORY: 0002 A TDP_____ TM ____ Other General/Admin Data D. SYSTEM/ITEM E. CONTRACT/PR NO. F. CONTRACTOR LARGE SCALE PRODUCTION OF SARS-CoV-2 VACCINE W911QY-20-C-0100 Moderna TX, Inc. 1. DATA ITEM NO. 2. TITLE OF DATA ITEM 3. SUBTITLE 17. Price Group A019 Contractor's Standard Operating Procedures Security Plan 4. AUTHORITY (Data Acquisition Document No.) 5. CONTRACT REFERENCE 6. REQUIRING OFFICE 18. Estimated Total Price DI-MGMT-81580 C.6 ASPR BARDA 7. DD 250 REQ 9. DIST 10. FREQUENCY 12. DATE OF FIRST SUBMISSION 14. DISTRIBUTION N/A STATEMENT R/ASR Refer to Block 16 REQUIRED 8. APP CODE 11. AS OF DATE 13. DATE OF SUBSEQUENT b. COPIES C SUBMISSION a. ADDRESSEE Final A N/A Draft Refer to Block 16 Reg Repro 16. REMARKS ASPR BARDA* 1 1 0 4. The Data Item Description (DID) may be obtained from http://quicksearch.dla.mil/. CCAP-SCN** 1 1 0 8. The US Government (USG) will respond with comments or approval within 15 calendar days after receipt. 9. Distribution Statement C: Distribution authorized to U.S. Government agencies and their Contractors (Administrative or Operational Use). Determination made July 18, 2020. Distribution guidance is included in DoD Instruction 5230.24. 12. Submit within 45 calendar days after contract award. 13. The contractor shall incorporate USG comments and resubmit to the USG within 10 calendar days after receipt. Resubmit for any and all revisions for USG approval. 14. Submit as an electronic file in Microsoft Office (i.e. Word, Excel, Power Point) via email to the BARDA representative: Marva Taylor ([***]) and the Contracting Officer** (KO), Danny Soto ([***]). LT: Letter of Transmittal (via email). 15. TOTAL → 2 2 2 1. DATA ITEM NO. 2. TITLE OF DATA ITEM 3. SUBTITLE 17. Price Group A020 Conference Agenda Agenda 4. AUTHORITY (Data Acquisition Document No.) 5. CONTRACT REFERENCE 6. REQUIRING OFFICE 18. Estimated Total Price DI-ADMN-81249B C.5.11, C.5.4 ASPR BARDA 7. DD 250 REQ 9. DIST 10. FREQUENCY 12. DATE OF FIRST SUBMISSION 14. DISTRIBUTION N/A STATEMENT ASREQ Refer to Block 16 REQUIRED 8. APP CODE 11. AS OF DATE 13. DATE OF SUBSEQUENT b. COPIES C SUBMISSION a. ADDRESSEE Final A 0 Draft Refer to Block 16 Reg Repro 16. REMARKS ASPR BARDA* 1 1 0 4. The Data Item Description (DID) may be obtained from http://quicksearch.dla.mil/. CCAP-SCN** LT LT 0 8. Post Award Teleconference: The USG will respond with comments or approval within 1 calendar days after receipt. Kickoff Meeting: The USG will respond with comments or approval within 3 calendar days after receipt. 9. Distribution Statement C: Distribution authorized to U.S. Government agencies and their Contractors (Administrative or Operational Use). Determination made July 18, 2020. Distribution guidance is included in DoD Instruction 5230.24. 12. Post Award Teleconference: Submit at least 3 business days prior to conduct of meeting and establish a teleconference number, unless otherwise provided by the USG. Kickoff Meeting: Submit at least 5 business days prior to conduct of meeting. 13. The contractor shall incorporate USG comments and distribute agenda at least 2 business days prior to meeting. 14. Submit as an electronic file in Microsoft Office (i.e. Word, Excel, Power Point) via email to the BARDA representative: Marva Taylor ([***]) and the Contracting Officer** (KO), Danny Soto ([***]). LT: Letter of Transmittal (via email). 15. TOTAL → 1 2 0 G. PREPARED BY H. DATE I. APPROVED BY J. DATE Pamela Serra July 18, 2020 Marva Taylor July 18, 2020

CONTRACT DATA REQUIREMENTS LIST Form Approved (2 Data Items) OMB No. 0704-0188 The public reporting burden for this collection of information is estimated to average 220 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Department of Defense, Executive Services Directorate (0704-0188). Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. Please do not return your form to the above organization. Send completed form to the Government Issuing Contracting Officer for the Contract/PR No. listed in Block E. A. CONTRACT LINE ITEM NO. B. EXHIBIT C. CATEGORY: 0002 A TDP_____ TM ____ Other General/Admin Data D. SYSTEM/ITEM E. CONTRACT/PR NO. F. CONTRACTOR LARGE SCALE PRODUCTION OF SARS-CoV-2 VACCINE W911QY-20-C-0100 Moderna TX, Inc. 1. DATA ITEM NO. 2. TITLE OF DATA ITEM 3. SUBTITLE 17. Price Group A021 Report, Record of Meeting/Minutes Meeting Minutes 4. AUTHORITY (Data Acquisition Document No.) 5. CONTRACT REFERENCE 6. REQUIRING OFFICE 18. Estimated Total Price DI-ADMN-81505 C.4.12, C.5.4 ASPR BARDA 7. DD 250 REQ 9. DIST 10. FREQUENCY 12. DATE OF FIRST SUBMISSION 14. DISTRIBUTION N/A STATEMENT ASREQ Refer to Block 16 REQUIRED 8. APP CODE 11. AS OF DATE 13. DATE OF SUBSEQUENT b. COPIES C SUBMISSION a. ADDRESSEE Final A 0 Draft Refer to Block 16 Reg Repro 16. REMARKS ASPR BARDA* 1 1 0 4. The Data Item Description (DID) may be obtained from http://quicksearch.dla.mil/. CCAP-SCN** LT 1 0 8. The US Government (USG) will respond with comments or approval within 10 calendar days after receipt. 9. Distribution Statement C: Distribution authorized to U.S. Government agencies and their Contractors (Administrative or Operational Use). Determination made July 18, 2020. Distribution guidance is included in DoD Instruction 5230.24. 12. Submit within 3 calendar days after conduct of meeting. 13. Post Award Teleconference: The contractor shall incorporate USG comments and resubmit to the USG within 3 business day after receipt and within 10 business days for Kickoff Meeting. 14. Submit as an electronic file in Microsoft Office (i.e. Word, Excel, Power Point) via email to the BARDA representative: Marva Taylor ([***]) and the Contracting Officer** (KO), Danny Soto ([***]). LT: Letter of Transmittal (via email). 15. TOTAL → 2 2 0 1. DATA ITEM NO. 2. TITLE OF DATA ITEM 3. SUBTITLE 17. Price Group A022 Presentation Material Presentation Material 4. AUTHORITY (Data Acquisition Document No.) 5. CONTRACT REFERENCE 6. REQUIRING OFFICE 18. Estimated Total Price DI-ADMN-81373 C.5.4 ASPR BARDA 7. DD 250 REQ 9. DIST 10. FREQUENCY 12. DATE OF FIRST SUBMISSION 14. DISTRIBUTION N/A STATEMENT ASREQ Refer to Block 16 REQUIRED 8. APP CODE 11. AS OF DATE 13. DATE OF SUBSEQUENT b. COPIES C SUBMISSION a. ADDRESSEE Final A N/A Draft Refer to Block 16 Reg Repro 16. REMARKS ASPR BARDA* 1 1 0 4. The Data Item Description (DID) may be obtained from http://quicksearch.dla.mil/. CCAP-SCN** 1 1 0 8. The US Government (USG) will respond with comments or approval within 5 calendar days after receipt. 9. Distribution Statement C: Distribution authorized to U.S. Government agencies and their Contractors (Administrative or Operational Use). Determination made July 18, 2020. Distribution guidance is included in DoD Instruction 5230.24. 12. Submit concurrent with Agenda (CDRL A020). 13. The contractor shall incorporate USG comments and resubmit to the USG within 5 calendar days after receipt. 14. Submit as an electronic file in Microsoft Office (i.e. Word, Excel, Power Point) via email to the BARDA representative: Marva Taylor ([***]) and the Contracting Officer** (KO), Danny Soto ([***]). LT: Letter of Transmittal (via email). 15. TOTAL → 2 2 0 G. PREPARED BY H. DATE I. APPROVED BY J. DATE Pamela Serra July 18, 2020 Marva Taylor July 18, 2020

15. TOTAL → 2 2 0 G. PREPARED BY H. DATE I. APPROVED BY J. DATE Pamela Serra July 18, 2020 Marva Taylor July 18, 2020 INSTRUCTIONS FOR COMPLETING DD FORM 1423 (See DoD 5010.12-M for detailed instructions.) FOR GOVERNMENT PERSONNEL FOR THE CONTRACTOR Item A. Self-explanatory. Item 17. Specify appropriate price group from one of the following groups of effort in developing estimated prices for each data item listed on the DD Item B. Self-explanatory. Form 1423. Item C. Mark (X) appropriate category: TDP - Technical Data Package; TM - a. Group I. Definition - Data which is not otherwise essential to the Technical Manual; Other - other category of data, such as “Provisioning," contractor's performance of the primary contracted effort "Configuration Management," etc. (production, development, testing, and administration) but which is required by DD Form 1423. Item D. Enter name of system/item being acquired that data will support. Item E. Self-explanatory (to be filled in after contract award). Estimated Price - Costs to be included under Group I are those applicable to preparing and assembling the data item in conformance with Item F. Self-explanatory (to be filled in after contract award). Government requirements, and the administration and other expenses Item G. Signature of preparer of CDRL. related to reproducing and delivering such data items to the Government. Item H. Date CDRL was prepared. b. Group II. Definition - Data which is essential to the performance of the primary contracted effort but the contractor is required to Item I. Signature of CDRL approval authority. perform additional work to conform to Government requirements Item J. Date CDRL was approved. with regard to depth of content, format, frequency of submittal, preparation, control, or quality of the data item. Item 1. See DoD FAR Supplement Subpart 4.71 for proper numbering. Item 2. Enter title as it appears on data acquisition document cited in Item Estimated Price - Costs to be included under Group II are those 4. incurred over and above the cost of the essential data item without conforming to Government requirements, and the administrative and Item 3. Enter subtitle of data item for further definition of data item other expenses related to reproducing and delivering such data item to the (optional entry). Government. Enter Data Item Description (DID) number, military specification Item 4. c. Group III. Definition - Data which the contractor must develop for number, or military standard number listed in DoD 5010.12-L (AMSDL), or his internal use in performance of the primary contracted effort one-time DID number, that defines data content and format requirements. and does not require any substantial change to conform to Item 5. Enter reference to tasking in contract that generates requirement Government requirements with regard to depth of content, for the data item (e.g., Statement of Work paragraph number). format, frequency of submittal, preparation, control, and quality of the data item. Item 6. Enter technical office responsible for ensuring adequacy of the data item. Estimated Price - Costs to be included under Group III are the administrative and other expenses related to reproducing and delivering Item 7. Specify requirement for inspection/acceptance of the data item by such data item to the Government. the Government. Item 8. Specify requirement for approval of a draft before preparation of d. Group IV. Definition - Data which is developed by the contractor as the final data item. part of his normal operating procedures and his effort in supplying these data to the Government is minimal. Item 9. For technical data, specify requirement for contractor to mark the appropriate distribution statement on the data (ref. DoDD 5230.24). Estimated Price - Group IV items should normally be shown on the Item 10. Specify number of times data items are to be delivered. DD Form 1423 at no cost. Item 11. Specify as-of date of data item, when applicable. Item 12. Specify when first submittal is required. Item 18. For each data item, enter an amount equal to that portion of the total price which is estimated to be attributable to the production or Item 13. Specify when subsequent submittals are required, when applicable. development for the Government of that item of data. These estimated data prices shall be developed only from those costs which will be incurred Item 14. Enter addressees and number of draft/final copies to be delivered as a direct result of the requirement to supply the data, over and above

to each addressee. Explain reproducible copies in Item 16. those costs which would otherwise be incurred in performance of the contract if no data were required. The estimated data prices shall not Item 15. Enter total number of draft/final copies to be delivered. include any amount for rights in data. The Government's right to use the Item 16. Use for additional/clarifying information for Items 1 through 15. data shall be governed by the pertinent provisions of the contract. Examples are: Tailoring of documents cited in Item 4; Clarification of submittal dates in Items 12 and 13; Explanation of reproducible copies in Item 14.; Desired medium for delivery of the data item.

Supply Chain Resiliency Plan for CDRL A010 Attachment 0001 As of 23 July 2020 W911QY-20-C-0100 Supply Chain Resiliency Plan Attachment 0001 Page 1 of 3

ATTACHMENT 0001 TO CONTRACT DATA REQUIREMENTS LIST A010 Supply Chain Resiliency Plan The contractor shall provide a comprehensive Supply Chain Resiliency Plan that provides for identification and reporting of critical components associated with the secure supply of drug substance, drug product, and work-in- process through to finished goods. 1. A critical component is defined as any material that is essential to the product or the manufacturing process associated with that product. Included in the definition are consumables and disposables associated with manufacturing. NOT included in the definition are facility and capital equipment. Consideration of critical components includes the evaluation and potential impact of raw materials, excipients, active ingredients, substances, pieces, parts, software, firmware, labeling, assembly, testing, analytical and environmental componentry, reagents, or utility materials which are used in the manufacturing of a drug, cell banks, seed stocks, devices and key processing components and equipment. A clear example of a critical component is one where a sole supplier is utilized. 2. The contractor shall identify key equipment suppliers, their locations, local resources, and the associated control processes at the time of award. This document shall address planning and scheduling for active pharmaceutical ingredients, upstream, downstream, component assembly, finished drug product and delivery events as necessary for the delivery of product. a) Communication for these requirements shall be updated as part of an annual review, or as necessary, as part of regular contractual communications. b) For upstream and downstream processing, both single-use and re-usable in-place processing equipment, and manufacturing disposables also shall be addressed. For finished goods, the inspection, labeling, packaging, and associated machinery shall be addressed taking into account capacity capabilities. c) The focus on the aspects of resiliency shall be on critical components and aspects of complying with the contractual delivery schedule. Delivery methods shall be addressed, inclusive of items that are foreign- sourced, both high and low volume, which would significantly affect throughput and adherence to the contractually agreed deliveries. 3. The contractor shall articulate in the plan, the methodology for inventory control, production planning, scheduling processes and ordering mechanisms, as part of those agreed deliveries. a) Production rates and lead times shall be understood and communicated to the HHS/ASPR/BARDA Contracting Officer or the Contracting Officer's Representative as necessary. b) Production throughput critical constraints should be well understood by activity and by design, and communicated to contractual personnel. As necessary, communication should focus on identification, exploitation, elevation, and secondary constraints of throughput, as appropriate. 4. Reports for critical items should include the following information: a) Critical Material b) Primary vendor and secondary vendor, if applicable c) Supplier, Manufacturing / Distribution Location d) Supplier Lead Time e) Shelf Life f) Transportation / Shipping restrictions W911QY-20-C-0100 Supply Chain Resiliency Plan Attachment 0001 Page 2 of 3

g) Comparability studies, if applicable h) Amount of material (dose equivalent) in inventory W911QY-20-C-0100 Supply Chain Resiliency Plan Attachment 0001 Page 3 of 3

Security Plan Attachment 0002 As of 23 July 2020 W911QY-20-C-0100 Security Plan Attachment 0002 Page 1 of 7

ATTACHMENT 0002 CONTRACT DATA REQUIREMENTS LIST A019 BARDA SECURITY REQUIREMENTS The contractor shall provide a Security Plan which shall address the following: [***] W911QY-20-C-0100 Security Plan Attachment 0002 Page 2 of 7

Data Rights Attachment 0004 As of 7 August 2020 Data Rights Attachment 0004 Page 1 of 3

Data Rights Restrictions Limited Rights Data The following are Modern’s technical data assertions required by DFAR 252.227-7017 (“Identification and assertion of use, release, or disclosure restrictions”). Notwithstanding any contrary representation by the Contractor on the System for Award Management or any contrary provision in the contract, the following categories of information developed exclusively at private expense will, if provided to the Government, be considered limited rights data subject to the restrictions specified in DFAR 227.7013. These restrictions apply to any component of information covered by this provision, regardless of whether a component is included in a contract deliverable. The Government will, as applicable, retain government purpose rights or unlimited rights in technical data generated in performance or included in a deliverable as required by DFARS 252.227-7013 or another applicable data rights clause to the extent that any component of such technical data (i) was developed in whole or in part with Government funds, (ii) pertains to an item developed in whole in part with Government funds, or (iii) was first produced in performance of a Government contract subject to FAR 52.227-14. Nothing in this Contract or this Attachment affects any data rights that the Government may already have under prior agreements between Moderna and the Government, including with respect to Agreement Nos. [***] The Government will not reverse engineer or otherwise evaluate materials provided under this Contract to reproduce the type of information described below without Moderna’s prior written consent. [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] W911QY-20-C-0100 Data Rights August 7, 2020 Attachment 0004 Page 2 of 3

[***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] August 7, 2020 W911QYData-20-C Rights-0100 Attachment 0004 Page 3 of 3

[***] Attachment 0005 As of 7 August 2020 W911QY-20-C-0100 [***] Attachment 0005 Page 1 of 2

[***] August 7, 2020 W911QY-20-C-0100 [***] Attachment 0005 Page 2 of 2

Moderna Tx, Inc. Background Intellectual Property Attachment 0006 As of 6 August 2020 W911QY-20-C-0100 ModernaTx, Inc. Background Intellectual Property Attachment 0006 Page 1 of 3

Description of Moderna, Inc. Representative Intellectual Property [***] W911QY-20-C-0100 ModernaTx, Inc. Background Intellectual Property Attachment 0006 Page 2 of 3

Description of Moderna, Inc. Representative Intellectual Property [***] W911QY-20-C-0100 ModernaTx, Inc. Background Intellectual Property Attachment 0006 Page 3 of 3

Performance Based Payment (PBP) Milestone Schedule Attachment 0007 As of 7 August W911QY-20-C-0100 PBP Milestone Schedule Attachment 0007 Page 1 of 2

Severable/ Milestone Price Milestone Completion Verification Method CLIN Cumulative Moderna shall provide: 1) written confirmation from the CMO network that sufficient capacity has Capacity been reserved; and, 2) written confirmation of and Raw Severable $601,400,000 reservation of sufficient raw materials along with a 001 Material manufacturing schedule. Reservation [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] W911QY-20-C-0100 PBP Milestone Schedule Attachment 0007

Page 2 of 2

Performance Base Payment (PBP) Milestone Billing Plan Attachment 0008 As of 7 August 2020 W911QY-20-C-0100 PBP Milestone Billing Plan Attachment 0008

Page 1 of 16

Page 2 of 16 [***] W911QY-20-C-0100 PBP Milestone Billing Plan Attachment 0008

[***] W911QY-20-C-0100 PBP Milestone Billing Plan Attachment 0008 Page 3 of 16

[***] W911QY-20-C-0100 PBP Milestone Billing Plan Attachment 0008 Page 4 of 16

[***] W911QY-20-C-0100 PBP Milestone Billing Plan Attachment 0008 Page 5 of 16

[***] W911QY-20-C-0100 PBP Milestone Billing Plan Attachment 0008 Page 6 of 16

[***]

[***] W911QY-20-C-0100 PBP Milestone Billing Plan Attachment 0008 Page 7 of 16

[***] W911QY-20-C-0100 PBP Milestone Billing Plan Attachment 0008 ACTIVE/105609918.3

Page 8 of 16

[***] W911QY-20-C-0100 PBP Milestone Billing Plan Attachment 0008 Page 9 of 16 ACTIVE/105609918.3

[***] W911QY-20-C-0100 PBP Milestone Billing Plan Attachment 0008 Page 10 of 16

[***] W911QY-20-C-0100 PBP Milestone Billing Plan Attachment 0008 Page 11 of 16

[***] W911QY-20-C-0100 PBP Milestone Billing Plan Attachment 0008 Page 12 of 16

[***] W911QY-20-C-0100 PBP Milestone Billing Plan Attachment 0008 Page 13 of 16

[***] W911QY-20-C-0100 PBP Milestone Billing Plan Attachment 0008 Page 14 of 16

[***] W911QY-20-C-0100 PBP Milestone Billing Plan Attachment 0008 Page 15 of 16

[***] W911QY-20-C-0100 PBP Milestone Billing Plan Attachment 0008 Page 16 of 16

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. 1. CONTRACT ID CODE PAGE OF PAGES AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1 16 2. AMENDMENT/MODIFICATION NO. 3. EFFECTIVE DATE 4. REQUISITION/PURCHASE REQ. NO. 5. PROJECT NO.(If applicable) 0011534693 6. ISSUED BY CODE W911QY 7. ADMINISTERED BY (If other than item 6) CODE S2206A DEFENSE CONTRACT MANAGEMENT AGENCY W6QK ACC-APG NATICK DIVISION DCMA BOSTON BLDG 1 GENERAL GREENE AVENUE 495 SUMMER STREET NATICK MA 01760-5011 BOSTON MA 02210-2138 8. NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code) 9A. AMENDMENT OF SOLICIT AT ION NO. MODERNA US INC [***] 9B. DATED (SEE ITEM 11) 200 TECHNOLOGY SQ CAMBRIDGE MA 02139-3578 10A. MOD. OF CONTRACT/ORDER NO. X W911QY20C0100 10B. DATED (SEE ITEM 13) CODE 8PTM0 FACILITY CODE X 09-Aug-2020 11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offer is extended, is not extended. Offer must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended by one of the following methods: (a) By completing Items 8 and 15, and returning copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegramor letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified. 12. ACCOUNT ING AND APPROPRIATION DATA (If required) 13. THIS ITEM APPLIES ONLY TO MODIFICAT IONS OF CONTRACT S/ORDERS. IT MODIFIES THE CONT RACT /ORDER NO. AS DESCRIBED IN ITEM 14. A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A. B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B). X C. THIS SUPPLEMENT AL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF: Mutual Agreement of the parties, FAR 43.103(a)(3) & H.14, Novation D. OTHER (Specify type of modification and authority) E. IMPORTANT: Contractor is not, X is required to sign this document and return 1 copies to the issuing office. 14. DESCRIPTION OF AMENDMENT /MODIFICATION (Organized by UCF section headings, including solicitat ion/contract subject matter where feasible.) Modification Control Number: dsoto202575 The purpose of this modification is to 1. Novation Change from Moderna TX to Moderna US 2. Section C make administrative revisions to correct type-o and update company name 3. Section G update company name, correct type-o in subCLINs, and revise WAWF Clause inspect by from S2206A to W911QY 4. Section I add FAR 52.204-25 and update information in FAR 252.232-7007 5. Section J revised page number on Exhibits and Attachments The total obligated amount and contract price remains the unchanged. Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect. 15A. NAME AND TITLE OF SIGNER (Type or print) 16A. NAME AND TITLE OF CONT RACTING OFFICER (Type or print) CAMILLE B. CONNELL-MAGAW [***] Stephane Bancel, CEO TEL: [***] EMAIL: (Signature of 15C. DATE SIGNED 16B. UNITED 15B. CONTRACTOR/OFFEROR person STATES OF /s/ Stephane Bancel authorized to 9/4/2020 sign) AMERICA BY

/s/ Camille B. Connell-Magaw 16C. DATE SIGNED (Signature of Contracting Officer) 9/08/2020 EXCEPTION TO SF 30 30-105-04 STANDARD FORM 30 (Rev. 10-83) APPROVED BY OIRM 11-84 Prescribed by GSA FAR (48 CFR) 53.243

W911QY20C0100 (dsoto202575) Page 2 of 16 SECTION SF 30 BLOCK 14 CONTINUATION PAGE SUMMARY OF CHANGES SECTION C - DESCRIPTIONS AND SPECIFICATIONS The following have been modified: STATEMENT OF WORK LARGE SCALE PRODUCTION OF SARS-CoV-2 VACCINE C.1 SCOPE. The Department of Defense and Health and Human Services (HHS) require large scale manufacturing of vaccine doses in support of the national emergency response to the Coronavirus Disease 2019 (COVID-19) for the United States Government (USG) and the US population. C.1.1 Background. In December 2019, a novel coronavirus now known as SARS-CoV-2 was first detected in Wuhan, Hubei Province, People’s Republic of China, causing outbreaks of the coronavirus disease COVID-19 that has now spread globally. The Secretary of Health and Human Service declared a public health emergency on January 31, 2020, under section 319 of the Public Health Service Act (42 U.S.C. 247d), in response to COVID-19. On March 1, 2020, the President of the United States, pursuant to sections 01 and 301 of the National Emergencies Act (50 U.S.C. 1601 et seq.) and consistent with section 1135 of the Social Security Act (SSA), as amended (42 U.S.C. 1320b-5), proclaimed that the COVID-19 outbreak in the United States constitutes a national emergency. C.1.1.1 Under Operation Warp Speed (OWS), the Department of Defense and HHS are leading a whole of nation effort to ensure development of promising vaccine, diagnostic and therapeutic candidates and ensure that these medical countermeasures are available in the quantities required to reduce SARS-CoV-2 transmission, identify prior and/or current infection, and improve patient care, thereby mitigating the impact of COVID-19 on the nation and its people. The DoD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRD) is providing expertise and contracting support to HHS, in compliance with PL 115-92 Authorization Letter for DoD Medical Priorities, through an Interagency Agreement, signed April 23, 2020. As OWS products progress to clinical trials to evaluate the safety and efficacy of vaccines and therapeutics, it is critical that, in parallel, the USG supports large scale manufacturing so that vaccine doses or therapeutic treatment courses are immediately available for nationwide access as soon as a positive efficacy signal is obtained and the medical countermeasures are authorized for widespread use. C.1.2 Objective: The objective of this effort is to obtain the following: a. Base Period: Large scale manufacturing of 100 million vaccine doses b. Option Period 1: Large scale manufacturing of 100 million vaccine doses c. Option Period 2: Large scale manufacturing of 100 million vaccine doses d. Option Period 3: Large scale manufacturing of 100 million vaccine doses e. Option Period 4: Large scale manufacturing of 100 million vaccine doses The Base Period is 9 months, with overlapping options for a total of 20 months if all options are exercised. C.2 APPLICABLE DOCUMENTS. C.2.1 Federal Documents: C.2.1.1 Title 21 Code of Federal Regulations (CFR), Food and Drugs: Part 210, Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs; General; and, Part 211, Current Good Manufacturing Practice In Manufacturing, Processing, Packing, or Holding of Drugs; General.

W911QY20C0100 (dsoto202575) Page 3 of 16 (https://www.ecfr.gov/cgi-bin/text- idx?SID=a95cab20f443897a400bb7e44a27cf4c&mc=true&tpl=/ecfrbrowse/Title21/21cfrv4_02.tpl#0) C.3 REQUIREMENTS. Independently, and not as an agent of the USG, in accordance with the Proposal submitted by Moderna US, Inc. in response to Solicitation Number W911QY20R0043, Titled, “Advanced Procurement of mRNA-1273 Vaccine for Prevention of SARS-CoV-2 Coronavirus (COVID-19)”), dated July 10, 2020 (and any subsequent USG-approved revisions thereto), the contractor shall provide all necessary services, qualified personnel, material, equipment and facilities (not otherwise provided by the USG under the terms of this contract) to perform the specific tasks set forth below. C.3.1 Contract Line Item Number (CLIN) 0001 - Base Period: Large Scale Manufacturing of 100 Million Vaccine Doses. C.3.1.1 The contractor shall complete all scope required for the production, release and delivery use of 100 million Final Drug Product (FDP) doses of a SARS-CoV-2 mRNA-1273 vaccine. This shall include, the following tasks and other activities reasonably contemplated by such task: C.3.1.1.1 Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations. Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of 12 months. (Based on FDP stability data that supports a 12-month shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC. Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation. C.3.1.1.2 cGMP manufacturing of 100 million doses fully compliant with 21 CFR 210 and 211. C.3.1.1.3 Ensuring that vial labeling and packaging is consistent with FDA guidance for use in target populations and that labeling is updated as appropriate. C.3.1.1.4 Coordinating with FDA to establish an approved commercial vial label, carton and packaging insert (printed or electronic). C.3.1.1.5 Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements, subject to any exceptions established by or the enforcement discretion of the FDA, including “Exemption from Certain Product Tracing and Product Identification Requirements Under Section 582 of the FD&C Act” (April 2020). C.3.1.1.6 In coordination with the USG, the contractor shall conduct a demonstration of the vaccine shipping process prior to the first delivery of FDP doses at a time mutually agreed to by the contractor and the USG. Moderna shall provide specifications and details associated with the shipping process and containers (IAW CDRL A005) to enable the USG to adequately plan and prepare for potential distribution of the vaccine. C.3.1.1.7 Following release of product the contractor shall, promptly deliver product to the designated delivery site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below. In the unforeseen event that a designated delivery site cannot receive product and the contractor provides storage beyond 20 days of product release, the contract will be subject to modification for acceptance purposes. C.3.1.2 Site Visits and Audits. The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract. C.3.1.2.1 BARDA Audits. If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.

W911QY20C0100 (dsoto202575) Page 4 of 16 C.3.1.2.2 FDA Audits. The Contractor shall notify the Contracting Officer and Contracting Officer’s Representative (COR) within [***] of a scheduled FDA audit or within [***] of an ad hoc site visit or audit if the FDA does not provide advance notice. The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within [***] of receiving correspondence from the FDA or third party in accordance with CDRL A002. The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within [***] of submittal of the audit report in accordance with CDRL A002. C.3.1.2.3 FDA Interactions. The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologics for the following, but not limited to: FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002. C.3.2 CLIN 1001 - Option Period 1: Large Scale Manufacturing of 100 Million Vaccine Doses. C.3.2.1 The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine. This shall include the following tasks and other activities reasonably contemplated by such tasks: C.3.2.1.1 Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations. Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of 12 months. (Based on FDP stability data that supports a 12-month shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC. Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation. C.3.2.1.2 cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA. C.3.2.1.3 Ensuring that vial labeling and packaging is consistent with FDA guidance for use in target populations and that labeling is updated. C.3.2.1.4 Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements subject to any exceptions established by or the enforcement discretion of the FDA. C.3.2.1.5 Following release of the product the contractor shall deliver the product to the designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below. To the extent a natural disaster or other emergency affecting a designated delivery site restricts such site’s ability to receive product, the Contractor and the USG will promptly agree on an alternate USG delivery location, or storage as Vendor Managed Inventory (VMI) at the contractor site. C.3.2.2 Site Visits and Audits. The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract. C.3.2.2.1 BARDA Audits. If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001. C.3.2.2.2 FDA Audits. The Contractor shall notify the Contracting Officer and COR within [***] of a scheduled FDA audit or within [***] of an ad hoc site visit or audit if the FDA does not provide advance notice. The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within [***] of receiving correspondence from the FDA or third party in

W911QY20C0100 (dsoto202575) Page 5 of 16 accordance with CDRL A015. The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within [***] of submittal of the audit report in accordance with CDRL A002. C.3.2.2.3 FDA Interactions. The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologics for the following, but not limited to: FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002. C.3.3 CLIN 2001 - Option Period 2: Large Scale Manufacturing of 100 Million Vaccine Doses. C.3.3.1 The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine. This shall include the following tasks and other activities reasonably contemplated by such tasks: C.3.3.1.1 Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations. Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of 12 months. (Based on FDP stability data that supports a 12-month shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC. Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation. C.3.3.1.2 cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA. C.3.3.1.3 Ensuring that vial labeling and packaging is consistent with FDA guidance for use in target populations and that labeling is updated as appropriate. C.3.3.1.4 Ensuring that the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581- 585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements, subject to any exceptions established by or the enforcement discretion of the FDA. C.3.3.1.5 Following release the contractor shall deliver product to the nearest designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below. To the extent a natural disaster or other emergency affecting a designated delivery site restricts such site’s ability to receive product, the Contractor and the USG will promptly agree on an alternate USG delivery location, or storage as Vendor Managed Inventory (VMI) at the contractor site. C.3.3.2 Site Visits and Audits. The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract. C.3.3.2.1 BARDA Audits. If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001. C.3.3.2.2 FDA Audits. The Contractor shall notify the Contracting Officer and COR within [***] of a scheduled FDA audit or within [***] of an ad hoc site visit or audit if the FDA does not provide advance notice. The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within [***] of receiving correspondence from the FDA or third party in accordance with CDRL A002. The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within [***] of submittal of the audit report in accordance with CDRL A002.

W911QY20C0100 (dsoto202575) Page 6 of 16 C.3.3.2.3 FDA Interactions. The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologics for the following, but not limited to: FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002. C.3.4 CLIN 3001 - Option Period 3: Large Scale Manufacturing of 100 Million Vaccine Doses. C.3.4.1 The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine. This shall include the following tasks and other activities reasonably contemplated by such tasks: C.3.4.1.1 Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations. Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of 12 months. (Based on FDP stability data that supports a 12-month shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC. Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation. C.3.4.1.2 cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA. C.3.4.1.3 Ensuring that vial labeling and packaging is consistent with FDA guidance for use in target populations and that labeling is updated. C.3.4.1.4 Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements subject to any exceptions established by or the enforcement discretion of the FDA. C.3.4.1.5 Following release of the product the contractor shall deliver the product to the designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below. To the extent a natural disaster or other emergency affecting a designated delivery site restricts such site’s ability to receive product, the Contractor and the USG will promptly agree on an alternate USG delivery location, or storage as Vendor Managed Inventory (VMI) at the contractor site. C.3.4.2 Site Visits and Audits. The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract. C.3.4.2.1 BARDA Audits. If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001. C.3.4.2.2 FDA Audits. The Contractor shall notify the Contracting Officer and COR within [***] of a scheduled FDA audit or within [***] of an ad hoc site visit or audit if the FDA does not provide advance notice. The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within [***] of receiving correspondence from the FDA or third party in accordance with CDRL A015. The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within [***] of submittal of the audit report in accordance with CDRL A002. C.3.4.2.3 FDA Interactions. The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding mRNA-1273 for the following, but not limited to: FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.

W911QY20C0100 (dsoto202575) Page 7 of 16 C.3.5 CLIN 4001 - Option Period 4: Large Scale Manufacturing of 100 Million Vaccine Doses. C.3.5.1 The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine. This shall include the following tasks and other activities reasonably contemplated by such tasks: C.3.5.1.1 Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations. Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of 12 months. (Based on FDP stability data that supports a 12-month shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC. Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation. C.3.5.1.2 cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA. C.3.5.1.3 Ensuring that vial labeling and packaging is consistent with FDA guidance for use in target populations and that labeling is updated. C.3.5.1.4 Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements subject to any exceptions established by or the enforcement discretion of the FDA. C.3.5.1.5 Following release of the product the contractor shall deliver the product to the designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below. To the extent a natural disaster or other emergency affecting a designated delivery site restricts such site’s ability to receive product, the Contractor and the USG will promptly agree on an alternate USG delivery location, or storage as Vendor Managed Inventory (VMI) at the contractor site. C.3.5.2 Site Visits and Audits. The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract. C.3.5.2.1 BARDA Audits. If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001. C.3.5.2.2 FDA Audits. The Contractor shall notify the Contracting Officer and COR within [***] of a scheduled FDA audit or within [***] of an ad hoc site visit or audit if the FDA does not provide advance notice. The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within [***] of receiving correspondence from the FDA or third party in accordance with CDRL A015. The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within [***] of submittal of the audit report in accordance with CDRL A002. C.3.5.2.3 FDA Interactions. The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologics for the following, but not limited to: FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002. C.4 CLIN 0002: Data Deliverables. The contractor shall provide the following in accordance with the Contract Data Requirements List (CDRL), DD Forms 1423, provided at Appendix A. C.4.1 Monthly Inventory Report (CDRL A003), detailing at a minimum, raw materials, Bulk mRNA, formulated LNPs, and the fill, finish, and released product.

W911QY20C0100 (dsoto202575) Page 8 of 16 C.4.2 Quality Management Plan. The contractor shall provide a Quality Management Plan, in accordance with CDRL A004, describing the quality policy and objectives, management review, competencies and training, process document control, feedback, evaluation, corrective action and preventive action, process improvement, measurement, and data analysis processes. The framework is normally divided into infrastructure, senior management responsibility, resource management, lifecycle management, and quality management system evaluation. C.4.3 Shipping Documentation (CDRL A005) for all Finished Drug Product (FDP) transferring from the contractor’s fill/finish facility to a USG facility. The contractor shall obtain concurrence on planned shipment protocols prior to transport. C.4.4 Expiring Items Report (CDRL A006) for all FDP in the USG’s possession. C.4.5 Key Personnel Listing (CDRL A007). C.4.6 Monthly Technical Progress Report (CDRL A008), to include an Integrated Master Schedule, identifying key activities and contract status. C.4.7 Final Technical Report (CDRL A009), documenting the work performed and results obtained for the entire contract period of performance. C.4.8 Supply Chain Resiliency Plan (SCRP). The contractor shall provide, in accordance with CDRL A010 and CDRL Attachment 0001, a comprehensive SCRP that provides for identification and reporting of critical components associated with the secure supply of drug substance, drug product, and work-in-process through to finished goods, and key equipment suppliers and their locations, including addresses, points of contact, and work performed per location, to include subcontractors. C.4.9 Risk Management Plan (RMP). The Contractor shall provide an RMP in accordance with CDRL A011 that outlines the impacts of each risk in relation to the cost, schedule, and performance objectives. The plan shall include risk mitigation strategies. Each risk mitigation strategy shall capture how the corrective action will reduce impacts on cost, schedule and performance. C.4.10 Manufacturing Reports and Dose Tracking. The Contractor shall provide, in accordance with CDRL A013, manufacturing reports and manufacturing dose tracking projections and actuals utilizing the USG-provided “COVID-19 Dose Tracking Template” (CDRL Attachment 0003). C.4.11 Product Acceptance Report (for each lot of Drug Product). The contractor shall provide, in accordance with CDRL A014, pictures of the drug product with lot number, drug product lot tree, list of associated deviations (from drug substance and product), and a Certificate of Analysis. C.4.12 Incident Report. The contractor shall communicate to BARDA and document all critical programmatic concerns, issues, or probable risks that have or are likely to significantly impact project schedule and/or cost and/or performance in accordance with CDRL A016. “Significant” is frequently defined as a 10% or greater cost or schedule variance within a control account, but should be confirmed in consultation with the COR. Incidents that present liability to the project even without cost/schedule impact, such as breach of GCP during a clinical study, shall also be reported. C.4.13 FDA Correspondence. The contractor shall provide any correspondence between Contractor and FDA relevant to the scope of this contract and submit in accordance with CDRL A017. C.4.14 Press Releases. The contractor shall accurately and factually represent the work conducted under this contract in all press releases. The contractor shall provide an advance copy of any press release in accordance with CDRL A018.

W911QY20C0100 (dsoto202575) Page 9 of 16 C.4.15 Manufacturing Development Plan. The contractor shall provide a Manufacturing Development Plan, in accordance with CDRL A025, describing the manufacturing process for the drug/biologic product to ensure conformity with §501(a)(2)(B) of the Food, Drug, and Cosmetics Act (FD&C Act, Title 21 United States Code (USC) §351 (a)(2)(B)), regarding good manufacturing practices (GMP). C.5 Administration. C.5.1 Post Award Teleconference. The contractor shall host a Post Award Teleconference within 15 7 calendar days after contract award. C.5.1.1 The contractor shall provide an Agenda, IAW CDRL A020, detailing the planned activities for the subsequent 30 calendar days and shall discuss agenda items for the Post Award Kickoff Meeting. C.5.1.2 The contractor shall provide Meeting Minutes IAW CDRL A021. C.5.2 Post Award Kickoff Meeting. The contracting officer may request the contractor host a contract Kick-Off Meeting within 30 calendar days after contract award via teleconference. The contracting officer shall establish the date and time of the conference and prepare the agenda to include discussion on contract activities and schedule. C.5.3 Bi-Weekly Teleconference. The contractor shall participate in bi-weekly teleconferences (or more frequent meetings required by the USG if warranted based on contract activities) to discuss performance on the contract. C.5.4 The contractor shall provide an Agenda, IAW CDRL A020; Meeting Minutes in accordance with CDRL A021; and, Presentation Material in accordance with CDRL A022 for each of the aforementioned teleconferences or meetings throughout the contract period of performance. C.5.5 Daily “Check-In”. The contractor shall participate in a daily “check-in” (via teleconference or email) to address key cost, schedule and technical updates. Daily updates may be shared with senior USG leaders during the COVID- 19 response and should be provided on a non-confidential basis, unless the update includes confidential information in which case, the contractor shall provide the update in both confidential and non-confidential formats. Daily check-ins may occur on weekdays, excluding federal holidays. Upon request of the USG, check-ins may also occur on weekends and on federal holidays, provided at least 24 hours’ notice. C.6 Security. C.6.1 Access and General Protection/Security Policy and Procedures. The contractor shall provide all information required for background checks necessary to access critical information related to OWS, and to meet USG installation access requirements to be accomplished by the installation Director of Emergency Services or Security Office. The contractor employees shall comply with all personnel identity verification requirements as directed by the USG and/or local policy. In addition to the changes otherwise authorized by the changes clause of this contract, should the security status of OWS change the USG may require changes in the contractor’s security matters or processes. In addition to the industry standards for employment background checks, the contractor shall be willing to have key individuals, in exceptionally sensitive positions, identified for additional vetting by the United States USG. C.6.2 Security Program and Plan. The contractor shall implement a comprehensive security program that provides overall protection of personnel, information, data, and facilities associated with fulfilling the USG’s requirement. The contractor’s security practices and procedures shall be detailed in a Security Plan, in accordance with CDRL A019, and shall demonstrate how the contractor shall meet and adhere to the security requirements outlined in CDRL Attachment 0002. This plan shall be delivered to the USG within 45 days of award, and the USG will review in detail and submit comments within ten (10) business days to the Contracting Officer (CO) to be forwarded to the Contractor. The Contractor shall review the Security Plan comments, and, submit a final Security Plan to the U.S. USG within thirty (30) calendar days after receipt of the comments. The Security Plan shall include a timeline for compliance of all the required security measures outlined in CDRL Attachment 0002.

W911QY20C0100 (dsoto202575) Page 10 of 16 C.6.3 Operational Security (OPSEC). The contractor shall develop and submit an OPSEC Standard Operating Procedure (SOP)/Plan IAW CDRL A024. The contractor shall identify in the SOP/Plan critical information related to this contract, why it needs to be protected, where it is located, who is responsible for it, and how to protect it. C.7 CLIN 0002 Vendor Managed Inventory (VMI). The Contractor shall provide the capability to store the vaccine for up to 52 weeks, up to 100M doses of mRNA-1273 vaccine, in accordance with product labeling. The contractor shall, in accordance with paragraph C.3.1.1.6, ensure the product storage of FDP doses for up to 12 months prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations . [***] The contractor shall store the product to insure product quality with audible alarms and contacting. The contractor shall notify the USG within [***] of detection of an incident with the potential to impact product quality, and implement corrective actions to mitigate the incident. . BARDA/JPEO- CBRND personnel may conduct Quality Audits of the storage facility, when deemed necessary. The contractor shall notify the USG of Corrective/Preventive actions within [***] of detection of an incident with potential to impacts product quality. BARDA/JPEO-CBRND personnel may conduct Quality Audits of the storage facility, when deemed necessary. C.7.1 The USG will provide the contractor advance notice of the required delivery locations for the vaccine. The contractor shall ship mRNA-1273 vaccines to designated locations in up to [***] in the United States. The contractor shall be responsible for shipment of all vaccine product whether acceptance is conducted at origin or destination. [***] C.7.2 The vaccine product shall be shipped and tracked by the distribution vendor’s shipping tracking number, to the USG-designated sites within the continental United States. C.7.3 [***] Implementation of a Vendor Managed Inventory Plan/SOP (CDRL A012) shall be provided to the USG. [***] Notwithstanding either of the foregoing sentences, the contractor shall not be liable for loss of or damage to supplies caused by the negligence of officers, agents, or employees of the USG acting within the scope of their employment. SECTION G - CONTRACT ADMINISTRATION DATA The following have been modified: G.1 GOVERNMENT CONTRACT ADMINISTRATION In no event shall any understanding or agreement, contract modification, change order, or other matter in deviation from the terms of this contract between the Contractor and a person other than the Contracting Officer be effective or binding upon the Government. All such actions must be formalized by a proper contractual document executed by the Contracting Officer. Procuring Contracting Officer: Camille Connell-Magaw / [***] / [***] [***] [***]

W911QY20C0100 (dsoto202575) Page 11 of 16 Contract Specialist: Danny Soto / [***] / [***] [***] [***] G.2 GOVERNMENT TECHNICAL POINT OF CONTACT Marva Taylor / [***] / [***] Biologist/Project Officer [***] [***] G.3 CONTRACTOR’S CONTRACT ADMINISTRATION [***] ModernaTX, Inc. 200 Technology SQ. Cambridge, MA 02139-3578 G.4 PLACES OF PERFORMANCE Moderna US, Inc. 200 Technology SQ. Cambridge, MA 02139-3578 G.5 NOTIFICATION OF REVISIONS AND CHANGE Notification of revision or changes to names or email addresses will be provided by official correspondence from the PCO/ACO or office of the PCO/ACO in lieu of a contract modification. This does not apply to any such revisions or changes in the event this contract includes a key personnel clause. G.6 PERFORMANCE BASED PAYMENT Performance-based payments (PBP) are authorized under this contract in accordance with FAR 52.232-32. The contractor shall bill for the PBP upon achievement of the completion criteria identified in Attachment 0007, Performance-based Payment Milestone Table. Upon achievement of the completion criteria, the contractor shall bill for the PBP for the base and each option IAW the following schedule: CLIN PERIOD AMOUNT 0001AA BASE $ 90,210,000 0001AB BASE $ 132,308,000 0001AC BASE $ 180,420,000 0001AD BASE $ 198,462,000 TOTAL $ 601,400,000 [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]

W911QY20C0100 (dsoto202575) Page 12 of 16 [***] [***] [***] [***] [***] [***] [***] [***] Delivery Invoicing: PBPs are a type of contract financing and are recouped by the Government through deductions of payments otherwise due to the contractor for the partial or complete delivery of contract items. The deductions are made by applying a liquidation rate to the price of delivered contract items. Attachment 0008, Performance- based Payment Milestone Billing Plan, identifies the contractor invoicing schedule for liquidation. The contractor shall submit all invoices IAW Attachment 0008. 252.232-7006 WIDE AREA WORKFLOW PAYMENT INSTRUCTIONS (DEC 2018) (a) Definitions. As used in this clause-- “Department of Defense Activity Address Code (DoDAAC)” is a six position code that uniquely identifies a unit, activity, or organization. “Document type” means the type of payment request or receiving report available for creation in Wide Area WorkFlow (WAWF). “Local processing office (LPO)” is the office responsible for payment certification when payment certification is done external to the entitlement system. “Payment request” and “receiving report” are defined in the clause at 252.232-7003, Electronic Submission of Payment Requests and Receiving Reports. (b) Electronic invoicing. The WAWF system provides the method to electronically process vendor payment requests and receiving reports, as authorized by Defense Federal Acquisition Regulation Supplement (DFARS) 252.232- 7003, Electronic Submission of Payment Requests and Receiving Reports. (c) WAWF access. To access WAWF, the Contractor shall— (1) Have a designated electronic business point of contact in the System for Award Management at https://www.sam.gov; and (2) Be registered to use WAWF at https://wawf.eb.mil/ following the step-by-step procedures for self-registration available at this web site. (d) WAWF training. The Contractor should follow the training instructions of the WAWF Web-Based Training Course and use the Practice Training Site before submitting payment requests through WAWF. Both can be accessed by selecting the “Web Based Training” link on the WAWF home page at https://wawf.eb.mil/. (e) WAWF methods of document submission. Document submissions may be via web entry, Electronic Data Interchange, or File Transfer Protocol. (f) WAWF payment instructions. The Contractor shall use the following information when submitting payment requests and receiving reports in WAWF for this contract or task or delivery order: (1) Document type. The Contractor shall submit payment requests using the following document type(s): COMBO

W911QY20C0100 (dsoto202575) Page 13 of 16 (ii) For fixed price line items— (A) That require shipment of a deliverable, submit the invoice and receiving report specified by the Contracting Officer. Invoice and receiving report document type (B) For services that do not require shipment of a deliverable, submit either the Invoice 2in1, which meets the requirements for the invoice and receiving report, or the applicable invoice and receiving report, as specified by the Contracting Officer. N/A (iii) For customary progress payments based on costs incurred, submit a progress payment request. (iv) For performance based payments, submit a performance based payment request. (v) For commercial item financing, submit a commercial item financing request. (2) Fast Pay requests are only permitted when Federal Acquisition Regulation (FAR) 52.213-1 is included in the contract. (3) Document routing. The Contractor shall use the information in the Routing Data Table below only to fill in applicable fields in WAWF when creating payment requests and receiving reports in the system. Routing Data Table Field Name in WAWF Data to be entered in WAWF Pay Official DoDAAC HQ0337 Issue By DoDAAC W911QY Admin DoDAAC** S2206A Inspect By DoDAAC W911QY / BARDA Acceptor W911QY Ship To TDB (4) Payment request. The Contractor shall ensure a payment request includes documentation appropriate to the type of payment request in accordance with the payment clause, contract financing clause, or Federal Acquisition Regulation 52.216-7, Allowable Cost and Payment, as applicable. (5) Receiving report. The Contractor shall ensure a receiving report meets the requirements of DFARS Appendix F. (g) WAWF point of contact. (1) The Contractor may obtain clarification regarding invoicing in WAWF from the following contracting activity’s WAWF point of contact. Orlando Ortiz / DCMA Boston-AFAW, Administrative Contracting Officer / [***]

W911QY20C0100 (dsoto202575) Page 14 of 16 (2) Contact the WAWF helpdesk at 866-618-5988, if assistance is needed. (End of clause) FOR REFERANCE: DFARS PGI 204.7108 Payment Instructions Table https://www.acq.osd.mil/dpap/dars/pgi/pgi_htm/current/PGI204_71.htm#payment_instructions SECTION I - CONTRACT CLAUSES The following have been added by reference: 52.204-25 Prohibition on Contracting for AUG 2020 Certain Telecommunications and Video Surveillance Services or Equipment. The following have been modified: 252.232 7007 LIMITATION OF GOVERNMENT'S OBLIGATION (APR 2014) (a) Contract line item 0003 is incrementally funded. For this item, the sum of $0.00 of the total price is presently available for payment and allotted to this contract. An allotment schedule is set forth in paragraph (j) of this clause. (b) For items(s) identified in paragraph (a) of this clause, the Contractor agrees to perform up to the point at which the total amount payable by the Government, including reimbursement in the event of termination of those item(s) for the Government's convenience, approximates the total amount currently allotted to the contract. The Contractor is not authorized to continue work on those item(s) beyond that point. The Government will not be obligated in any event to reimburse the Contractor in excess of the amount allotted to the contract for those item(s) regardless of anything to the contrary in the clause entitled "TERMINATION FOR THE CONVENIENCE OF THE GOVERNMENT." As used in this clause, the total amount payable by the Government in the event of termination of applicable contract line item(s) for convenience includes costs, profit and estimated termination settlement costs for those item(s).

W911QY20C0100 (dsoto202575) Page 15 of 16 (c) Notwithstanding the dates specified in the allotment schedule in paragraph (j) of this clause, the Contractor will notify the Contracting Officer in writing at least ninety days prior to the date when, in the Contractor's best judgment, the work will reach the point at which the total amount payable by the Government, including any cost for termination for convenience, will approximate 85 percent of the total amount then allotted to the contract for performance of the applicable item(s). The notification will state (1) the estimated date when that point will be reached and (2) an estimate of additional funding, if any, needed to continue performance of applicable line items up to the next scheduled date for allotment of funds identified in paragraph (j) of this clause, or to a mutually agreed upon substitute date. The notification will also advise the Contracting Officer of the estimated amount of additional funds that will be required for the timely performance of the item(s) funded pursuant to this clause, for subsequent period as may be specified in the allotment schedule in paragraph (j) of this clause, or otherwise agreed to by the parties. If after such notification additional funds are not allotted by the date identified in the Contractor's notification, or by an agreed substitute date, the Contracting Officer will terminate any item(s) for which additional funds have not been allotted, pursuant to the clause of this contract entitled "TERMINATION FOR THE CONVENIENCE OF THE GOVERNMENT". (d) When additional funds are allotted for continued performance of the contract line item(s) identified in paragraph (a) of this clause, the parties will agree as to the period of contract performance which will be covered by the funds. The provisions of paragraph (b) through (d) of this clause will apply in like manner to the additional allotted funds and agreed substitute date, and the contract will be modified accordingly. (e) If, solely by reason of failure of the Government to allot additional funds, by the dates indicated below, in amounts sufficient for timely performance of the contract line item(s) identified in paragraph (a) of this clause, the Contractor incurs additional costs or is delayed in the performance of the work under this contract and if additional funds are allotted, an equitable adjustment will be made in the price or prices (including appropriate target, billing, and ceiling prices where applicable) of the item(s), or in the time of delivery, or both. Failure to agree to any such equitable adjustment hereunder will be a dispute concerning a question of fact within the meaning of the clause entitled "disputes." (f) The Government may at any time prior to termination allot additional funds for the performance of the contract line item(s) identified in paragraph (a) of this clause. (g) The termination provisions of this clause do not limit the rights of the Government under the clause entitled "DEFAULT." The provisions of this clause are limited to work and allotment of funds for the contract line item(s) set forth in paragraph (a) of this clause. This clause no longer applies once the contract if fully funded except with regard to the rights or obligations of the parties concerning equitable adjustments negotiated under paragraphs (d) or (e) of this clause. (h) Nothing in this clause affects the right of the Government to this contract pursuant to the clause of this contract entitled "TERMINATION FOR CONVENIENCE OF THE GOVERNMENT." (i) Nothing in this clause shall be construed as authorization of voluntary services whose acceptance is otherwise prohibited under 31 U.S.C. 1342.

W911QY20C0100 (dsoto202575) Page 16 of 16 (j) The parties contemplate that the Government will allot funds to this contract in accordance with the following schedule: On execution of contract $0.00 Upon successful completion of CLIN 0003 $300,000,000 (End of clause) SECTION J - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS The following have been modified: Document Type Description Page # Date Exhibit A CDRLs 15 18 July 2020 Attachment 0001 Supply Chain Resiliency Plan for CDRL A010 3 23 July 2020 Attachment 0002 Security Plan 7 23 July 2020 Attachment 0003 Dose Tracking Template Draft Moderna Excel 15 July 2020 Attachment 0004 Data Rights 3 7 August 2020 Attachment 0005 [***] 2 7 August 2020 Attachment 0006 ModernaTx, Inc. Background Intellectual Property 3 6 August 2020 Attachment 0007 Performance Base Payment Milestone Schedule 2 7 August 2020 Attachment 0008 Performance Base Payment Milestone Billing Plan 16 7 August 2020 (End of Summary of Changes)

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. 1. CONTRACT ID CODE PAGE OF PAGES AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1 3 2. AMENDMENT/MODIFICATION NO. EFFECTIVE 4. REQUISITION/PURCHASE REQ. NO. 5. PROJECT NO.(If applicable) DATE 0011534693 11-Sep-2020 6. ISSUED BY CODE W911QY 7. ADMINISTERED BY (If other than item 6) CODE S2206A DEFENSE CONTRACT MANAGEMENT AGENCY W6QK ACC-APG NATICK DIVISION DCMA BOSTON BLDG 1 GENERAL GREENE AVENUE 495 SUMMER STREET NATICK MA 01760-5011 BOSTON MA 02210-2138 8. NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code) 9A. AMENDMENT OF SOLICITATION NO. MODERNA US, INC. [***] 9B. DATED (SEE ITEM 11) 200 TECHNOLOGY SQ CAMBRIDGE MA 02139-3578 10A. MOD. OF CONTRACT/ORDER NO. X W911QY20C0100 10B. DATED (SEE ITEM 13) CODE 8PTM0 FACILITY CODE X 09-Aug-2020 11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offer is extended, is not extended. Offer must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended by one of the following methods: (a) By completing Items 8 and 15, and returning copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegramor letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified. 12. ACCOUNT ING AND APPROPRIAT ION DATA (If required) 13. THIS ITEM APPLIES ONLY TO MODIFICAT IONS OF CONTRACT S/ORDERS. IT MODIFIES THE CONT RACT /ORDER NO. AS DESCRIBED IN ITEM 14. A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A. B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B). X C. THIS SUPPLEMENT AL AGREEMENT IS ENTERED INTO PURSUANT TO AUT HORIT Y OF: 45 CFR part 101, Health Resources and Priorities Allocations System (HRPAS) D. OTHER (Specify type of modification and authority) E. IMPORTANT: Contractor is not, X is required to sign this document and return 1 copies to the issuing office. 14. DESCRIPTION OF AMENDMENT /MODIFICAT ION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.) Modification Control Number: tscott202802 OBLIGATION AMOUNT: $0.00 See Block 14 continuation page Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect. 15A. NAME AND TITLE OF SIGNER (Type or print) 16A. NAME AND TITLE OF CONT RACTING OFFICER (Type or print) [***] Stephane BANCEL, CEO Christine F. Sordillo TEL: [***] EMAIL: 15B. CONTRACTOR/OFFEROR 15C. DATE SIGNED 16B. UNIT ED STATES OF AMERICA 16C. DATE SIGNED /s/ Stephane Bancel 9/10/2020 BY /s/ Christine F. Sordillo 11 Sept 2020 (Signature of person authorized to sign) (Signature of Contracting Officer) EXCEPTION TO SF 30 30-105-04 STANDARD FORM 30 (Rev. 10-83) APPROVED BY OIRM 11-84 Prescribed by GSA FAR (48 CFR) 53.243

W911QY20C0100 (tscott202802) Page 2 of 3 SECTION SF 30 BLOCK 14 CONTINUATION PAGE SUMMARY OF CHANGES SECTION SF 30 - BLOCK 14 CONTINUATION PAGE The following have been added by full text: The purpose of this modification is to: 1. Add a Health Resources Priorities and Allocations System (HRPAS) priority rating of DO-HR to this contract: This is a DO rated contract for the purpose of emergency preparedness and the Contractor shall follow all the provisions of the Health Resources Priorities and Allocations System regulation (45 CFR Part 101). If the contractor needs to utilize industrial resources to fulfill this rated order for a health resource, it is authorized pursuant to 45 CFR §101.36(b) to place the same priority rating and program identification symbol for health resources on its orders for industrial resources with its suppliers. 2. Add a Defense Priorites and Allocation System (DPAS) priority rating of DO-C9 to this contract to act as the equivalent to the HRPAS priority rating of DO-HR. 3. Add FAR 52.211-15, Defense Priority and Allocation Requirements This is a rated order certified for national defense, emergency preparedness, and energy program use, and the Contractor shall follow all the requirements of the Defense Priorities and Allocations System regulation (15 CFR 700). 4. Add Attachment 0009 - HRPAS Moderna Letter to Section J The total funded amount and total contract price remain unchanged. SECTION A - SOLICITATION/CONTRACT FORM The DPAS code DO-C9 has been added. The contractor organization has changed from MODERNATX, INC. [***] 200 TECHNOLOGY SQ CAMBRIDGE MA 02139-3578 to MODERNA US, INC. [***] 200 TECHNOLOGY SQ CAMBRIDGE MA 02139-3578 SECTION I - CONTRACT CLAUSES

W911QY20C0100 (tscott202802) Page 3 of 3 The following have been added by full text: 52.211-15 DEFENSE PRIORITY AND ALLOCATION REQUIREMENTS (APR 2008) This is a rated order certified for national defense, emergency preparedness, and energy program use, and the Contractor shall follow all the requirements of the Defense Priorities and Allocations System regulation (15 CFR 700). (End of clause) SECTION J - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS The following have been modified: Document Type Description Page # Date Exhibit A CDRLs 15 18 July 2020 Attachment 0001 Supply Chain Resiliency Plan for CDRL A010 3 23 July 2020 Attachment 0002 Security Plan 7 23 July 2020 Attachment 0003 Dose Tracking Template Draft Moderna Excel 15 July 2020 Attachment 0004 Data Rights 3 7 August 2020 Attachment 0005 [***] 2 7 August 2020 Attachment 0006 ModernaTx, Inc. Background Intellectual Property 3 6 August 2020 Attachment 0007 Performance Base Payment Milestone Schedule 2 7 August 2020 Attachment 0008 Performance Base Payment Milestone Billing Plan 16 7 August 2020 Attachment 0009 HRPAS Moderna Letter 1 3 September 2020 (End of Summary of Changes)


Delaware		81-3467528
(State or Other Jurisdiction of Incorporation or Organization)		(IRS Employer Identification No.)

200 Technology Square
Cambridge,	Massachusetts	02139
(Address of Principal Executive Offices)		(Zip Code)


Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common stock, par value $0.0001 per share	MRNA	The NASDAQ Stock Market LLC


	September 30,		December 31,
	2020		2019
Assets
Current assets:
Cash and cash equivalents	$	1,505,581	$	235,876
Investments	1,770,721		867,124
Accounts receivable	190,501		5,369
Prepaid expenses and other current assets	109,376		19,403
Restricted cash	1,032		1,032
Total current assets	3,577,211		1,128,804
Investments, non-current	691,969		159,987
Property and equipment, net	276,909		201,495
Right-of-use assets, operating leases	91,684		86,414
Restricted cash, non-current	11,053		10,791
Other non-current assets	2,047		1,931
Total assets	$	4,650,873	$	1,589,422
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	20,521	$	7,090
Accrued liabilities	208,832		67,652
Deferred revenue	1,234,506		63,310
Other current liabilities	9,702		5,063
Total current liabilities	1,473,561		143,115
Deferred revenue, non-current	207,768		138,995
Operating lease liabilities, non-current	98,954		93,675
Financing lease liabilities, non-current	108,609		38,689
Other non-current liabilities	2,183		138
Total liabilities	1,891,075		414,612
Commitments and contingencies (Note 9)
Stockholders’ equity:
Preferred stock, par value $0.0001; 162,000,000 shares authorized as of September 30, 2020 and December 31, 2019; no shares issued or outstanding at September 30, 2020 and December 31, 2019	—		—
Common stock, par value $0.0001; 1,600,000,000 shares authorized as of September 30, 2020 and December 31, 2019; 395,390,672 and 336,536,985 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively	40		34
Additional paid-in capital	4,726,007		2,669,426
Accumulated other comprehensive income	4,784		1,804
Accumulated deficit	(1,971,033)		(1,496,454)
Total stockholders’ equity	2,759,798		1,174,810
Total liabilities and stockholders’ equity	$	4,650,873	$	1,589,422


	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019 (1)		2020		2019 (1)
Revenue:
Grant revenue	$	145,694	$	3,708	$	187,535	$	8,671
Collaboration revenue	12,216		13,338		45,115		37,483
Total revenue	157,910		17,046		232,650		46,154
Operating expenses:
Research and development	344,486		119,637		611,479		378,355
General and administrative	48,541		28,173		109,277		83,913
Total operating expenses	393,027		147,810		720,756		462,268
Loss from operations	(235,117)		(130,764)		(488,106)		(416,114)
Interest income	5,571		9,252		20,515		30,546
Other expense, net	(3,226)		(1,881)		(5,910)		(5,689)
Loss before income taxes	(232,772)		(123,393)		(473,501)		(391,257)
Provision for (benefit from) income taxes	864		(178)		1,078		(526)
Net loss	$	(233,636)	$	(123,215)	$	(474,579)	$	(390,731)
Net loss per share, basic and diluted	$	(0.59)	$	(0.37)	$	(1.26)	$	(1.19)
Weighted average common shares used in net loss per share, basic and diluted	394,682,744		330,769,341		376,174,283		329,592,322


	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019 (1)		2020		2019 (1)
Net loss	$	(233,636)	$	(123,215)	$	(474,579)	$	(390,731)
Other comprehensive income:
Unrealized (loss) gain on available-for-sale debt securities, net of tax of $0 and $25, for the three months ended September 30, 2020 and 2019, respectively, and net of tax of $0 and $1,173 for the nine months ended September 30, 2020 and 2019, respectively	(3,683)		168		1,878		4,243
Less: amounts recognized for net realized loss (gain) included in net loss	211		(79)		1,102		(93)
Total other comprehensive (loss) income	(3,472)		89		2,980		4,150
Comprehensive loss	$	(237,108)	$	(123,126)	$	(471,599)	$	(386,581)


PART I.		Page
Item 1.	Financial Statements (Unaudited)	6
	Condensed Consolidated Balance Sheets as of Se ptember 30 , 2020 and December 31, 2019	6
	Condensed Consolidated Statements of Operations for the three months and nine months ended S epte mber 30 , 2020 and 2019	7
	Condensed Consolidated Statements of Comprehensive Loss for the three months and nine months ended Se ptember 30 , 2020 and 2019	8
	Condensed Consolidated Statements of Stockholders' Equity for the three months and nine months ended Septe mber 30 , 2020 and 2019	9
	Condensed Consolidated Statements of Cash Flows for the nine months ended Se ptember 30 , 2020 and 2019	11
	Notes to Condensed Consolidated Financial Statements	12
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	43
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	62
Item 4.	Controls and Procedures	63
PART II.
Item 1.	Legal Proceedings	64
Item 1A.	Risk Factors	64
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	121
Item 5.	Other Information	121
Item 6.	Exhibits	121
SIGNATURES		123


	Common Stock			Additional Paid-In Capital		Accumulated Other Comprehensive Income		Accumulated Deficit		Total Stockholders’ Equity
	Shares	Amount

Balance at June 30, 2020	393,277,267	$	39	$	4,675,987	$	8,256	$	(1,737,397)	$	2,946,885
Vesting of restricted common stock units	43,374	—		—		—		—		—
Exercise of options to purchase common stock, net	2,070,031	1		26,814		—		—		26,815

Stock-based compensation	—	—		23,206		—		—		23,206
Unrealized loss on marketable securities	—	—		—		(3,472)		—		(3,472)
Net loss	—	—		—		—		(233,636)		(233,636)
Balance at September 30, 2020	395,390,672	$	40	$	4,726,007	$	4,784	$	(1,971,033)	$	2,759,798


	Common Stock			Additional Paid-In Capital		Accumulated Other Comprehensive Income		Accumulated Deficit (1)		Total Stockholders’ Equity (1)
	Shares	Amount

Balance at June 30, 2019	329,958,172	$	33	$	2,582,134	$	2,741	$	(1,249,948)	$	1,334,960

Vesting of restricted common stock	33,678	—		—		—		—		—
Exercise of options to purchase common stock, net	2,502,927	—		15,554		—		—		15,554
Stock-based compensation	—	—		20,804		—		—		20,804
Unrealized gain on marketable securities	—	—		—		89		—		89
Net loss	—	—		—		—		(123,215)		(123,215)
Balance at September 30, 2019	332,494,777	$	33	$	2,618,492	$	2,830	$	(1,373,163)	$	1,248,192


	Three Months Ended September 30, 2019						Nine Months Ended September 30, 2019
			ASC 842						ASC 842
	Previously reported		Adjustments		As adjusted		Previously reported		Adjustments		As adjusted
Operating expenses:
Research and development	$	119,715	$	(78)	$	119,637	$	378,786	$	(431)	$	378,355
General and administrative	28,188		(15)		28,173		83,994		(81)		83,913
Total operating expenses	147,903		(93)		147,810		462,780		(512)		462,268
Loss from operations	(130,857)		93		(130,764)		(416,626)		512		(416,114)
Other expense, net	(1,767)		(114)		(1,881)		(5,351)		(338)		(5,689)
Loss before benefit from income taxes	(123,372)		(21)		(123,393)		(391,431)		174		(391,257)
Net loss	(123,194)		(21)		(123,215)		(390,905)		174		(390,731)
Net loss per share attributable to common stockholders, basic and diluted	(0.37)		—		(0.37)		(1.19)		—		(1.19)


	Nine Months Ended September 30, 2019
	Previously reported		ASC 842 Adjustment during the period		As adjusted
Operating activities
Net loss	$	(390,905)	$	174	$	(390,731)
Depreciation and amortization	22,082		(36)		22,046
Prepaid expenses and other assets	(1,407)		3,220		1,813
Right-of-use assets, operating leases	—		(7,970)		(7,970)
Deferred lease obligation	3,844		(3,844)		—
Operating lease liabilities	—		13,475		13,475
Other liabilities	1,617		(1,770)		(153)
Net cash used in operating activities	(363,195)		3,249		(359,946)
Financing activities
Reimbursement of assets under lease financing obligation	3,678		(3,678)		—
Charges to financing lease obligation	—		741		741
Payments on financing lease obligation	312		(312)		—
Net cash provided by financing activities	23,531		(3,249)		20,282


	Unrealized (Loss) Gain on Available-for-Sale Debt Securities
Accumulated other comprehensive income, balance at December 31, 2019	$	1,804
Other comprehensive loss	(7,931)
Accumulated other comprehensive loss, balance at March 31, 2020	(6,127)
Other comprehensive income	14,383
Accumulated other comprehensive income, balance at June 30, 2020	8,256
Other comprehensive loss	(3,472)
Accumulated other comprehensive income, balance at September 30, 2020	$	4,784


	Three Months Ended September 30,				Nine Months Ended September 30,
Collaboration Revenue by Strategic Collaborator:	2020		2019		2020		2019
AstraZeneca	$	48	$	3,724	$	17,202	$	4,726
Merck	6,718		9,110		18,060		28,456
Vertex	5,450		504		9,698		4,301
Other	—		—		155		—
Total collaboration revenue	$	12,216	$	13,338	$	45,115	$	37,483


	December 31, 2019		Additions		Deductions		September 30, 2020
Contract Assets:
Accounts receivable	$	1,972	$	115,037	$	(85,354)	$	31,655
Contract Liabilities:
Deferred revenue	$	199,528	$	117,002	$	(50,320)	$	266,210


Revenue recognized in the period from:	Three Months Ended September 30, 2020		Nine Months Ended September 30, 2020
Amounts included in contract liabilities at the beginning of the period (1)	$	13,263	$	50,320
Performance obligations satisfied (or partially satisfied) in previous reporting periods (2)	—		1,262


	Transaction Price
	September 30,		December 31,
Combined 2018 AZ Agreements:	2020		2019
Upfront payments	$	240,000	$	240,000
Sublicense reimbursement	1,000		1,000
Toxicity milestone payment	60,000		60,000
Competition milestone payment	60,000		60,000
Estimated reimbursement for IL-12 manufacturing obligations	38,089		40,782
Total	$	399,089	$	401,782


FORM			10-Q


	September 30, 2020		December 31, 2019
Combined AZ Agreements	$	72,266	$	73,669


	Transaction Price
	September 30, 2020
2016 VEGF Exercise combined performance obligation	$	60,312
Remaining unsatisfied performance obligation	41,877


	September 30, 2020		December 31, 2019
2016 VEGF Exercise	$	29,335	$	41,266


	Transaction Price
	September 30, 2020
2015 Merck Agreement	$	54,222
Remaining unsatisfied performance obligation	—


	Transaction Price
PCV/SAV Agreement:	September 30, 2020
PCV performance obligation	$	206,356
KRAS performance obligation	7,004
Total	$	213,360
Remaining unsatisfied performance obligation	$	60,548


	September 30, 2020		December 31, 2019
PCV/SAV Agreement	$	60,548	$	83,799


	Transaction Price
Vertex Agreement - First Extended Research Term:	September 30, 2020
Upfront payment	$	4,000
Research and development	46,410
Total	$	50,410


	Transaction Price
	September 30, 2020
First Extended Research Term transaction price	$	50,410
Remaining unsatisfied performance obligation	42,766


	September 30, 2020		December 31, 2019
Vertex Agreement1	$	4,061	$	793


	Transaction Price
Chiesi Agreement:	September 30, 2020
Upfront payment	$	25,000
Estimated reimbursement for research and development	17,656
Total	$	42,656


	September 30, 2020
	Amortized Cost		Unrealized Gains		Unrealized Losses		Estimated Fair Value		Cash and Cash Equivalents		Current Marketable Securities		Non- Current Marketable Securities
Cash and cash equivalents	$	1,505,579	$	2	$	—	$	1,505,581	$	1,505,581	$	—	$	—
Available-for-sale:
Level 2:
Certificates of deposit	161,097		46		(1)		161,142		—		152,649		8,493
U.S. treasury securities	130,495		385		(1)		130,879		—		81,607		49,272
Debt securities of U.S. government agencies and corporate entities	2,165,133		6,043		(507)		2,170,669		—		1,536,465		634,204
	$	3,962,304	$	6,476	$	(509)	$	3,968,271	$	1,505,581	$	1,770,721	$	691,969

	December 31, 2019
	Amortized Cost		Unrealized Gains		Unrealized Losses		Estimated Fair Value		Cash and Cash Equivalents		Current Marketable Securities		Non- Current Marketable Securities
Cash and cash equivalents	$	225,874	$	—	$	—	$	225,874	$	225,874	$	—	$	—
Available-for-sale:
Level 2:
Certificates of deposit	82,028		79		(6)		82,101		10,002		69,197		2,902
U.S. treasury securities	117,891		260		(2)		118,149		—		110,186		7,963
Debt securities of U.S. government agencies and corporate entities	834,187		2,708		(32)		836,863		—		687,741		149,122
	$	1,259,980	$	3,047	$	(40)	$	1,262,987	$	235,876	$	867,124	$	159,987


	September 30, 2020
	Amortized Cost		Estimated Fair Value
Due in one year or less	$	1,766,834	$	1,770,721
Due after one year through five years	689,891		691,969
Total	$	2,456,725	$	2,462,690


	Less than 12 months				12 months or more				Total
	Gross Unrealized Losses		Estimated Fair Value		Gross Unrealized Losses		Estimated Fair Value		Gross Unrealized Losses		Estimated Fair Value
As of September 30, 2020:
Certificates of deposit	$	(1)	$	14,893	$	—	$	—	$	(1)	$	14,893
U.S. treasury securities	(1)		15,341		—		—		(1)		15,341
Debt securities of U.S. government agencies and corporate entities	(507)		729,249		—		—		(507)		729,249
Total	$	(509)	$	759,483	$	—	$	—	$	(509)	$	759,483

As of December 31, 2019:
Certificates of deposit	$	(6)	$	12,822	$	—	$	—	$	(6)	$	12,822
U.S. treasury securities	(2)		9,979		—		—		(2)		9,979
Debt securities of U.S. government agencies and corporate entities	(32)		62,360		—		—		(32)		62,360
Total	$	(40)	$	85,161	$	—	$	—	$	(40)	$	85,161


	Deferred Revenue
Balance at December 31, 2019	$	202,305
Additions	1,293,370
Deductions	(53,401)
Balance at September 30, 2020	$	1,442,274


Fiscal Year		Operating Leases (1)		Financing Leases (1)
2020	(remainder of the year)	$	2,770	$	1,858
2021		15,492		11,634
2022		15,913		11,848
2023		16,008		12,054
2024		16,168		12,279
Thereafter		110,167		440,552
Total minimum lease payments		176,518		490,225
Less amounts representing interest or imputed interest		(72,833)		(381,616)		(2)
Present value of lease liabilities		$	103,685	$	108,609


	Number of Options	Weighted- Average Exercise Price per Share		Weighted- Average Grant Date Fair Value per Share		Weighted- Average Remaining Contractual Term	Aggregate Intrinsic Value (1) (in thousands)
Outstanding at Outstanding at December 31, 2019	45,536,915	$	13.82	$	7.35	7.2 years	$	286,310
Granted	4,809,336	33.79		18.10
Exercised	(10,613,303)	12.57		6.32
Canceled/forfeited	(2,471,131)	17.78		10.39
Outstanding at September 30, 2020	37,261,817	16.49		8.82		7.0 years	2,022,154
Exercisable at September 30, 2020	18,348,695	10.96		5.61		5.6 years	1,097,117
Expected to vest at September 30, 2020	18,913,122	21.86		11.94		8.3 years	926,598


	Units	Weighted-Average Fair Value per Unit
Outstanding, non-vested at December 31, 2019	1,177,249	$	19.01
Issued	1,386,066	34.29
Vested	(203,488)	20.46
Canceled/forfeited	(187,650)	22.69
Outstanding, non-vested at September 30, 2020	2,172,177	28.37


	Weighted Average
	Nine Months Ended September 30,
	2020			2019
Options:
Risk-free interest rate	0.85		%	2.39		%
Expected term	6.11 years			6.07 years
Expected volatility	57.82		%	62		%
Expected dividends	—		%	—		%
Weighted average fair value per share	$	18.10		$	11.71

ESPP:
Risk-free interest rate	0.18		%	2.31		%
Expected term	0.50 years			0.50 years
Expected volatility	65		%	50		%
Expected dividends	—		%	—		%
Weighted average fair value per share	$	20.64		$	19.85


	Three Months Ended September 30,				Change 2020 vs. 2019
	2020		2019		$		%
Revenue:
Grant revenue	$	145,694	$	3,708	$	141,986	3829%
Collaborative revenue	12,216		13,338		(1,122)		(8)%
Total revenue	157,910		17,046		140,864		826%
Operating Expenses:
Research and development	344,486		119,637		224,849		188%
General and administrative	48,541		28,173		20,368		72%
Total operating expenses	393,027		147,810		245,217		166%
Loss from operations	(235,117)		(130,764)		(104,353)		80%
Interest income	5,571		9,252		(3,681)		(40)%
Other expense, net	(3,226)		(1,881)		(1,345)		72%
Loss before income taxes	(232,772)		(123,393)		(109,379)		89%
Provision for (benefit from) income taxes	864		(178)		1,042		(585)%
Net loss	$	(233,636)	$	(123,215)	$	(110,421)	90%


Exhibit No.						Exhibit Index

10.1*†						Agreement No. HHSO100201600029C, by and between the Company and the Biomedical Advanced Research and Development Authority, dated as of April 16, 2020, as amended on May 24, 2020, June 16, 2020, July 25, 2020, August 31, 2020 and September 15, 2020
10.2*†						Global Long Term Agreement, by and among ModernaTX Inc., Lonza Sales Ltd., and Lonza Ltd., dated September 4, 2020
10.3*†						Award Contract No. W911QY20C0100, by and between Moderna US Inc. and the Army Contracting Command of the U.S. Department of Defense, dated August 9, 2020, as amended September 8, 2020 and September 11, 2020
31.1*						Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*						Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1+						Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*						XBRL Instance Document
101.SCH*						XBRL Taxonomy Extension Schema Document
101.CAL*						XBRL Taxonomy Extension Calculation Document
101.DEF*						XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*						XBRL Taxonomy Extension Label Linkbase Document
101.PRE*						XBRL Taxonomy Extension Presentation Link Document
104*						Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101.*)